

HORIZON PHARMA, INC.
Form PRER14A
July 28, 2014
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. 1)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
- Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))**
- Definitive Proxy Statement
- Definitive Additional Materials
- Soliciting Material Pursuant to §240.14a-12

Horizon Pharma, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box)

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

1. Title of each class of securities to which transaction applies:

2. Aggregate number of securities to which transaction applies:

3. Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

4. Proposed maximum aggregate value of transaction:

\$1,875,653,447.62

5. Total fee paid:

\$241,584.16

Fee paid previously with preliminary materials.

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

1. Amount Previously Paid:

\$241,584.16

2. Form, Schedule or Registration Statement No.:

Form S-4, 333-197052

3. Filing Party:

Vidara Therapeutics International Limited

4. Date Filed:

June 26, 2014

Table of Contents

The information in this proxy statement/prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This proxy statement/prospectus is not an offer to sell these securities and it is not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.

PRELIMINARY COPY

SUBJECT TO COMPLETION, DATED JULY 25, 2014

PROXY STATEMENT/PROSPECTUS

Dear Fellow Stockholder:

You are cordially invited to attend the Special Meeting of Stockholders on _____, _____, 2014. The Special Meeting will begin at 8:00 a.m., Central Time, at Horizon's corporate office, located at 520 Lake Cook Road, Suite 520, Deerfield, IL 60015.

The attached Notice of Special Meeting and proxy statement/prospectus describes how Horizon's Board of Directors operates, provides biographical information on Horizon's director nominees, gives information for the voting matters to be acted upon at the Special Meeting and explains the proxy voting process.

Horizon's Board of Directors urges you to read the accompanying proxy statement/prospectus and recommends that you vote FOR the adoption of the Merger Agreement and the approval of the Merger, FOR the approval, on an advisory basis, of certain compensatory arrangements between Horizon and its named executive officers relating to the Merger contemplated by the Merger Agreement, FOR the approval of the Horizon Pharma Public Limited Company 2014 Equity Incentive Plan, FOR the approval of the Horizon Pharma Public Limited Company 2014 Non-Employee Equity Plan, FOR the approval of the Horizon Pharma Public Limited Company 2014 Employee Stock Purchase Plan and FOR the approval of the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to adopt the Merger Agreement and approve the Merger.

Whether or not you plan to attend the Special Meeting, it is important that your shares be represented and voted. Please take a moment now to vote your shares by internet, toll-free telephone call or by signing and dating the enclosed proxy card and returning it in the pre-addressed, postage-paid envelope provided.

Horizon looks forward to seeing you on _____, 2014, and urges you to vote as soon as possible.

Sincerely,

Timothy P. Walbert

Chairman of the Board, President and

Chief Executive Officer

This proxy statement/prospectus refers to important business and financial information about Horizon that is not included in or delivered with this proxy statement/prospectus. Such information is available without charge to Horizon stockholders upon written or oral request at the following address: Horizon Pharma, Inc., Attn: Investor Relations, 520 Lake Cook Road, Suite 520, Deerfield, IL 60015, or by telephone at (224) 383-3000. **To obtain timely delivery, Horizon stockholders must request the information no later than five business days before the date of the Horizon special meeting, or no later than _____, 2014.**

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this proxy statement/prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

For the avoidance of doubt, this proxy statement/prospectus is not intended to be and is not a prospectus for the purposes of the Investment Funds, Companies and Miscellaneous Provisions Act 2005 of Ireland (the 2005 Act), the Prospectus (Directive 2003/71/EC) Regulations 2005 of Ireland or the Prospectus Rules issued under the 2005 Act, and the Central Bank of Ireland has not approved this document.

This proxy statement/prospectus is dated _____, 2014, and is first being mailed to the Horizon stockholders on or about _____, 2014.

Table of Contents

HORIZON PHARMA, INC.

520 Lake Cook Road, Suite 520

Deerfield, Illinois 60015

NOTICE OF SPECIAL MEETING OF STOCKHOLDERS

TO BE HELD ON _____, 2014

Dear Stockholder:

Horizon will be holding the Special Meeting of Stockholders of Horizon Pharma, Inc., on _____, 2014, beginning promptly at 8:00 a.m., Central Time, at Horizon's corporate office, located at 520 Lake Cook Road, Suite 520, Deerfield, IL 60015. You are being asked to vote on the following matters:

1. To adopt the Merger Agreement and approve the Merger.
2. To approve, on an advisory basis, certain compensatory arrangements between Horizon and its named executive officers relating to the Merger contemplated by the Merger Agreement.
3. To approve the Horizon Pharma Public Limited Company 2014 Equity Incentive Plan.
4. To approve the Horizon Pharma Public Limited Company 2014 Non-Employee Equity Plan.
5. To approve the Horizon Pharma Public Limited Company 2014 Employee Stock Purchase Plan.
6. To approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to adopt the Merger Agreement and approve the Merger.
7. To conduct any other business properly brought before the meeting.

Only stockholders of record at the close of business on July 30, 2014, the record date for the Special Meeting, are entitled to notice of the Special Meeting and to vote at the Special Meeting or any adjournment or postponement thereof. On or about _____, 2014, Horizon will mail proxy materials to our common stockholders. Horizon asks that you review the proxy statement/prospectus carefully and complete, sign, date and return the enclosed proxy card in the envelope provided or vote over the internet or by telephone as instructed in these materials, as promptly as possible in order to ensure your representation at the meeting. A return envelope (which is postage prepaid if mailed in the United States) will be provided for your convenience. Even if you have voted by proxy, you may still vote in person if you attend the meeting. Please note, however, that if your shares are held of record by a broker, bank or other nominee and you wish to vote at the meeting, you must obtain a proxy issued in your name from that record holder.

**Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting to Be Held on
, 2014, at 8:00 a.m., Central Time, at 520 Lake Cook Road, Suite 520, Deerfield, IL
60015.**

The Proxy Statement/Prospectus and Annual Report to stockholders
are available at www.envisionreports.com/hznp.

By Order of the Board of Directors

Robert J. De Vaere

Secretary

Deerfield, Illinois

, 2014

Table of Contents

TABLE OF CONTENTS

	Page
<u>QUESTIONS AND ANSWERS ABOUT THE PROPOSED TRANSACTIONS AND THE HORIZON SPECIAL MEETING OF STOCKHOLDERS AND VOTING</u>	1
<u>SUMMARY</u>	13
<u>The Companies</u>	13
<u>The Reorganization and the Merger</u>	14
<u>Post-Merger Management of New Horizon</u>	14
<u>Horizon's Reasons for the Merger</u>	14
<u>Recommendations of Horizon's Board of Directors</u>	15
<u>Opinion of Horizon's Financial Advisor</u>	15
<u>The Special Meeting of Horizon Stockholders</u>	16
<u>Interests of Certain Persons in the Merger</u>	17
<u>Certain U.S. Federal Tax Consequences of the Merger to U.S. Stockholders</u>	18
<u>No Appraisal Rights</u>	18
<u>Regulatory Approvals Required</u>	18
<u>Listing of New Horizon Ordinary Shares on NASDAQ</u>	19
<u>Conditions to the Completion of the Merger</u>	19
<u>Termination of the Merger Agreement</u>	19
<u>Accounting Treatment of the Merger</u>	19
<u>Restrictions on Resales</u>	19
<u>Comparison of the Rights of Holders of Horizon Common Stock and New Horizon Ordinary Shares</u>	19
<u>RISK FACTORS</u>	20
<u>Risks Related to the Proposed Transactions</u>	20
<u>Risks Related to the Businesses of New Horizon</u>	24
<u>Risks Related to the Financial Condition of New Horizon</u>	30
<u>Risks Related to the New Horizon Ordinary Shares</u>	32
<u>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</u>	36
<u>THE REORGANIZATION AND THE MERGER</u>	37
<u>The Reorganization of Vidara</u>	37
<u>The Merger</u>	37
<u>Background of the Transaction</u>	38
<u>Horizon's Reasons for the Merger and Recommendation of Horizon's Board of Directors</u>	45
<u>Vidara and Horizon Unaudited Prospective Financial Information</u>	47
<u>Horizon's Vidara Projections</u>	49

<u>Horizon Projections</u>	50
<u>Opinion of Horizon's Financial Advisor</u>	50
<u>Interests of Certain Persons in the Merger</u>	58
<u>Security Ownership of Certain Beneficial Owners and Management</u>	66
<u>Principal Shareholders Following the Merger</u>	69
<u>Regulatory Approvals Required</u>	71

Table of Contents

	Page
<u>Accounting Treatment of the Merger</u>	72
<u>Restrictions on Resales</u>	72
<u>CERTAIN TAX CONSEQUENCES OF THE MERGER</u>	73
<u>U.S. Federal Income Tax Considerations</u>	73
<u>Tax Consequences of the Merger to Horizon and New Horizon</u>	74
<u>Tax Consequences of the Merger to U.S. Holders</u>	75
<u>Tax Consequences to U.S. Holders of Holding New Horizon Ordinary Shares or Convertible Notes</u>	76
<u>Gain or Loss on Dispositions of New Horizon Ordinary Shares or Convertible Notes by U.S. Holders</u>	77
<u>Medicare Tax</u>	78
<u>Information Reporting and Backup Withholding</u>	78
<u>Irish Tax Considerations</u>	79
<u>NO APPRAISAL RIGHTS</u>	87
<u>LISTING OF NEW HORIZON ORDINARY SHARES ON NASDAQ</u>	87
<u>VOTE REQUIRED TO ADOPT THE MERGER AGREEMENT; BOARD RECOMMENDATION</u>	87
<u>THE COMPANIES</u>	88
<u>Horizon Pharma, Inc.</u>	88
<u>Vidara Therapeutics International Limited</u>	88
<u>Hamilton Holdings (USA), Inc.</u>	89
<u>Hamilton Merger Sub, Inc.</u>	89
<u>TRANSACTION AGREEMENT AND PLAN OF MERGER</u>	90
<u>The Reorganization of Vidara</u>	90
<u>The Merger; Closing of the Merger</u>	90
<u>Merger Consideration to Horizon Stockholders</u>	91
<u>Merger Sub Capital Stock</u>	91
<u>Payment of Estimated Cash Consideration</u>	91
<u>Treatment of Horizon Stock Options and Other Equity-Based Awards</u>	91
<u>Treatment of Horizon Warrants</u>	92
<u>Governing Documents Following the Merger</u>	92
<u>Exchange of Stock Certificates Following the Merger</u>	92
<u>Representations and Warranties</u>	93
<u>Material Adverse Effect</u>	95
<u>Covenants</u>	96
<u>Employee Benefits</u>	105
<u>Officers and Directors upon Completion of the Merger</u>	106
<u>Conditions to the Completion of the Merger</u>	106
<u>No Survival of Representations and Warranties or Post-Closing Indemnification</u>	109

<u>Termination of the Merger Agreement</u>	109
<u>Obligations in Event of Termination</u>	110
<u>Expenses and Termination Fees</u>	110

Table of Contents

	Page
<u>Amendment and Waiver</u>	111
<u>OTHER RELATED AGREEMENTS</u>	112
<u>The Voting Agreements</u>	112
<u>Temporary Escrow Agreement</u>	113
<u>Registration Rights Agreement</u>	113
<u>Commitment Letter</u>	114
<u>STOCKHOLDER ADVISORY VOTE ON CERTAIN COMPENSATORY ARRANGEMENTS</u>	117
<u>Background; Stockholder Resolution</u>	117
<u>Required Vote; Board Recommendation</u>	117
<u>APPROVAL OF 2014 EQUITY INCENTIVE PLAN</u>	118
<u>Reasons to Approve the 2014 Plan</u>	119
<u>Overhang</u>	120
<u>Burn Rate</u>	120
<u>Forecasted Utilization Rates</u>	121
<u>Forecasted Overhang and Burn Rate</u>	122
<u>Note Regarding Forecasts and Forward-Looking Statements</u>	122
<u>The 2014 Plan Combines Compensation and Governance Best Practices</u>	123
<u>Description of the 2014 Plan</u>	123
<u>U.S. Federal Income Tax Information</u>	131
<u>New Plan Benefits</u>	133
<u>Required Vote and Board Recommendation</u>	134
<u>APPROVAL OF 2014 NON-EMPLOYEE EQUITY PLAN</u>	135
<u>Reasons to Approve the Non-Employee Plan</u>	135
<u>Historical Information Regarding Prior Places, Overhang, Total Ordinary Shares Outstanding at the Merger Effective Time, Burn Rate and Forecasted Burn Rate</u>	136
<u>Forecasted Utilization Rates</u>	136
<u>Note Regarding Forecasts and Forward-Looking Statements</u>	136
<u>The Non-Employee Plan Combines Compensation and Governance Best Practices</u>	137
<u>Description of the Non-Employee Plan</u>	138
<u>U.S. Federal Income Tax Information</u>	144
<u>New Plan Benefits</u>	145
<u>Required Vote and Board Recommendation</u>	145
<u>APPROVAL OF THE 2014 EMPLOYEE STOCK PURCHASE PLAN</u>	146
<u>Reasons to Approve the 2014 ESPP</u>	146
<u>Stock Subject to the 2014 ESPP and Total New Horizon Ordinary Shares Outstanding at the Effective Time</u>	147
<u>Forecasted Utilization Rates</u>	147
<u>Note Regarding Forecasts and Forward-Looking Statements</u>	147

<u>Description of the 2014 ESPP</u>	148
<u>U.S. Federal Income Tax Information</u>	151
<u>New Plan Benefits</u>	152

Table of Contents

	Page
<u>Plan Benefits</u>	153
<u>Required Vote and Board Recommendation</u>	153
<u>POSSIBLE ADJOURNMENT OF THE HORIZON SPECIAL MEETING</u>	154
<u>SELECTED HISTORICAL FINANCIAL DATA OF HORIZON</u>	155
<u>SELECTED HISTORICAL FINANCIAL DATA OF VIDARA AND THE ACTIMMUNE BUSINESS OF INTERMUNE</u>	156
<u>MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OF VIDARA</u>	158
<u>Overview</u>	158
<u>Principal Revenue and Expense Items</u>	159
<u>Critical Accounting Policies and Significant Estimates</u>	160
<u>Results of Operations</u>	163
<u>Liquidity and Capital Resources</u>	166
<u>Contractual Obligations</u>	169
<u>Off-Balance Sheet Arrangements</u>	169
<u>Provisions</u>	170
<u>Quantitative and Qualitative Disclosures about Market Risk</u>	170
<u>UNAUDITED PRO FORMA COMBINED FINANCIAL INFORMATION</u>	171
<u>COMPARATIVE HISTORICAL AND UNAUDITED PRO FORMA PER SHARE DATA</u>	188
<u>THE BUSINESS OF HORIZON</u>	189
<u>THE BUSINESS OF VIDARA</u>	190
<u>Overview</u>	190
<u>History of Vidara and Acquisition and Growth of ACTIMMUNE</u>	190
<u>Sales and Marketing</u>	192
<u>Customers and Distribution</u>	192
<u>Competition</u>	193
<u>Manufacturing</u>	193
<u>Research and Development</u>	194
<u>Government Regulation</u>	195
<u>Reimbursement</u>	198
<u>Compliance</u>	199
<u>Patents and Proprietary Rights</u>	199
<u>Employees</u>	200
<u>Properties</u>	200
<u>Legal Proceedings</u>	200
<u>MANAGEMENT AND OTHER INFORMATION OF NEW HORIZON</u>	201
<u>Directors of New Horizon</u>	201

<u>Director Independence</u>	203
<u>Board Committees</u>	203
<u>Senior Management of New Horizon</u>	204

Table of Contents

	Page
<u>EXECUTIVE COMPENSATION</u>	207
<u>Compensation Discussion and Analysis</u>	207
<u>2013 Performance Highlights and Executive Summary</u>	207
<u>Non-Employee Director Compensation</u>	223
<u>Limitation of Liability and Indemnification</u>	223
<u>Certain Relationships and Related Transactions</u>	224
<u>Compensation Committee Interlocks and Insider Participation</u>	227
<u>Compensation Committee Report</u>	227
<u>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS</u>	228
<u>Policy and Procedures for Review of Related Party Transactions of New Horizon</u>	228
<u>Certain Transactions With or Involving Horizon's Related Persons</u>	228
<u>Certain Transactions With or Involving Vidara's Related Persons</u>	228
<u>DESCRIPTION OF NEW HORIZON WARRANTS</u>	229
<u>DESCRIPTION OF NEW HORIZON ORDINARY SHARES</u>	232
<u>Capital Structure</u>	232
<u>Preemption Rights, Share Warrants and Share Options</u>	233
<u>Dividends</u>	234
<u>Share Repurchases, Redemptions and Conversions</u>	235
<u>Lien on Shares, Calls on Shares and Forfeiture of Shares</u>	236
<u>Consolidation and Division; Subdivision</u>	236
<u>Reduction of Share Capital</u>	236
<u>Annual Meetings of Shareholders</u>	236
<u>Extraordinary General Meetings of Shareholders</u>	237
<u>Quorum for General Meetings</u>	237
<u>Voting</u>	237
<u>Variation of Rights Attaching to a Class or Series of Shares</u>	238
<u>Inspection of Books and Records</u>	238
<u>Acquisitions</u>	239
<u>Appraisal Rights</u>	239
<u>Disclosure of Interests in Shares</u>	239
<u>Anti-Takeover Provisions</u>	240
<u>Corporate Governance</u>	242
<u>Legal Name; Formation; Fiscal Year; Registered Office</u>	244
<u>Duration; Dissolution; Rights upon Liquidation</u>	244
<u>Uncertificated Shares</u>	244
<u>Stock Exchange Listing</u>	244

<u>No Sinking Fund</u>	244
<u>No Liability for Further Calls or Assessments</u>	244
<u>Transfer and Registration of Shares</u>	245

Table of Contents

	Page
<u>COMPARISON OF THE RIGHTS OF HOLDERS OF HORIZON COMMON STOCK AND NEW HORIZON ORDINARY SHARES</u>	246
<u>LEGAL MATTERS</u>	258
<u>EXPERTS</u>	259
<u>ENFORCEABILITY OF CIVIL LIABILITIES</u>	260
<u>SECTION 16(A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</u>	261
<u>HOUSEHOLDING OF PROXY STATEMENT/PROSPECTUS</u>	261
<u>OTHER MATTERS</u>	262
<u>WHERE YOU CAN FIND MORE INFORMATION</u>	263
<u>INDEX TO COMBINED FINANCIAL STATEMENTS OF VIDARA THERAPEUTICS INTERNATIONAL LIMITED AND SUBSIDIARIES AND VIDARA THERAPEUTICS, INC.</u>	F-1
<u>INDEX TO FINANCIAL STATEMENTS OF THE ACTIMMUNE® PRODUCT LINE OF INTERMUNE, INC.</u>	F-31
ANNEXES	
<u>Annex A</u>	A-1
<u>Annex A-1</u>	A-1-1
<u>Annex B</u>	B-1
<u>Annex C</u>	C-1
<u>Annex D</u>	D-1
<u>Annex E</u>	E-1
<u>Annex F</u>	F-1

We incorporate by reference important information into this proxy statement/prospectus. You may obtain the information incorporated by reference without charge by following the instructions under Where You Can Find Additional Information. You should carefully read this proxy statement/prospectus as well as additional information described under Incorporation of Certain Information by Reference, before deciding to invest in shares of our common stock.

You should rely only on the information contained in this proxy statement/prospectus and the information incorporated by reference in this proxy statement/prospectus. We have not authorized anyone to provide you with information that is different. This proxy statement/prospectus may only be used where it is legal to sell these securities. The information in this proxy statement/prospectus is only accurate on the date of this proxy statement/prospectus, regardless of the time of delivery of this proxy statement/prospectus or any sale of shares of our common stock.

Table of Contents

QUESTIONS AND ANSWERS ABOUT THE PROPOSED TRANSACTIONS AND THE HORIZON SPECIAL MEETING OF STOCKHOLDERS AND VOTING

The following are answers to some of the questions you may have as a stockholder of Horizon. These questions and answers only highlight some of the information contained in this proxy statement/prospectus. They may not contain all the information that is important to you. You should carefully read this entire proxy statement/prospectus, including the Annexes and the documents incorporated by reference into this proxy statement/prospectus, to understand fully the proposed transactions and the voting procedures for the Horizon Special Meeting of stockholders. All references in this proxy statement/prospectus to:

Horizon refer to Horizon Pharma, Inc., a Delaware corporation;

Vidara Holdings refer to Vidara Therapeutics Holdings LLC, a Delaware limited liability company;

Vidara refer to Vidara Therapeutics International Limited, a private limited company formed under the laws of Ireland that will be re-registered as a public limited company, a wholly-owned subsidiary of Vidara Holdings;

Vidara U.S. refer to Vidara Therapeutics, Inc., a Delaware corporation and a wholly-owned subsidiary of Vidara Holdings;

Vidara Group refer to Vidara and its subsidiaries and Vidara U.S.;

New Horizon refer to Vidara following the completion of the reorganization described in this proxy statement/prospectus at which time Vidara will change its name to Horizon Pharma plc;

New Horizon ordinary shares refer to the ordinary shares of Vidara following the completion of the reorganization described in this proxy statement/prospectus;

U.S. HoldCo refer to Hamilton Holdings (USA), Inc., a Delaware corporation and indirect wholly-owned subsidiary of Vidara;

Merger Sub refer to Hamilton Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of U.S. HoldCo;

the Merger Agreement refer to the Transaction Agreement and Plan of Merger, dated as of March 18, 2014, by and among Horizon, Vidara Holdings, Vidara, U.S. HoldCo and Merger Sub, a copy of which is included

as Annex A to this proxy statement/prospectus, as amended by the First Amendment to Transaction Agreement and Plan of Merger, dated as of June 12, 2014, by and between Horizon and Vidara Holdings, a copy of which is included as Annex A-1 to this proxy statement/prospectus;

the Merger refer to the merger between Merger Sub and Horizon, with Horizon as the surviving corporation that will occur pursuant to the Merger Agreement;

the closing refer to the closing of the Merger, and the date on which the closing occurs is referred to as the closing date ; and

the effective time refer to effective time of the consummation of the Merger, which will occur when the certificate of merger is filed with the Secretary of State of the State of Delaware (or at such later time as may be agreed by the parties and specified in the certificate of merger) immediately following the closing.

Unless otherwise indicated, all references to dollars or \$ in this proxy statement/prospectus are references to U.S. dollars, and all references to euro or in this proxy statement/prospectus are references to the legal currency of those members of the European Union that have adopted the euro as their national currency.

1.

Table of Contents

Q: Why am I receiving this proxy statement/prospectus?

A: This proxy statement/prospectus is being provided to Horizon stockholders as part of a solicitation of proxies by the Horizon board of directors for use at the Special Meeting of Horizon stockholders, which is referred to in this proxy statement/prospectus as the Special Meeting, and at any adjournments or postponements of such meeting. In addition, this proxy statement/prospectus constitutes a prospectus for New Horizon in connection with the issuance by New Horizon of ordinary shares and the assumption and conversion of Horizon warrants in connection with the Merger. This proxy statement/prospectus also provides Horizon stockholders with information they need to be able to vote or instruct their vote to be cast at the Special Meeting.

Q: Where and when will the Special Meeting be held?

A: The Special Meeting will be held on _____, _____, 2014, at 8:00 a.m. Central Time, at the offices of Horizon located at 520 Lake Cook Road, Suite 520, Deerfield, IL 60015. Directions to the Horizon Special Meeting may be found at www.horizonpharma.com. Information on how to vote in person at the Horizon Special Meeting is discussed below.

Q: What are the proposals on which I am being asked to vote?

A: There are six matters scheduled for a vote at the Horizon Special Meeting:

Proposal to adopt the Merger Agreement and approve the Merger (Proposal 1);

Proposal to approve, on an advisory basis, certain compensatory arrangements between Horizon and its named executive officers relating to the Merger contemplated by the Merger Agreement (Proposal 2);

Proposal to approve the Horizon Pharma Public Limited Company 2014 Equity Incentive Plan (Proposal 3);

Proposal to approve the Horizon Pharma Public Limited Company 2014 Non-Employee Equity Plan (Proposal 4);

Proposal to approve the Horizon Pharma Public Limited Company 2014 Employee Stock Purchase Plan (Proposal 5); and

Proposal to approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to adopt the Merger Agreement and approve the Merger (Proposal 6).

Q: What if another matter is properly brought before the meeting?

A: The Board of Directors of Horizon knows of no other matters that will be presented for consideration at the Horizon Special Meeting. If any other matters are properly brought before the meeting, it is the intention of the persons named in the accompanying proxy to vote on those matters in accordance with their best judgment.

Q: What is the reorganization?

A: Prior to the effective time of the Merger, Vidara will carry out a reorganization of its capital structure (the reorganization). The reorganization consists of a series of corporate actions as a result of which: (i) Vidara has formed a new non-resident Irish company that is a tax resident in Bermuda referred to as Newco, (ii) Vidara has assigned all of its contracts and has sold and transferred all of its intellectual property to Newco in exchange for a promissory note with an original principal amount equal to the fair market value of such assets, which will be repaid in consideration for the issuance of two promissory notes of the same

2.

Table of Contents

aggregate original principal amount, one of which will be repaid in cash on the closing date, (iii) Vidara has moved its tax residence from Bermuda to Ireland, (iv) Vidara has created a new class of ordinary shares denominated in US dollars (as well as created additional euro-denominated share capital up to a par value of 40,000) such that the aggregate number of US dollar-denominated ordinary shares is sufficient to cover the ordinary shares to be issued in exchange for the outstanding shares of Horizon common stock and shares of Horizon common stock reserved for issuance under outstanding Horizon equity awards and warrants and Horizon's outstanding convertible notes, and ordinary shares and bonus shares equal to 31,350,000 shares representing Vidara Holdings' agreed shareholdings in New Horizon following the closing and a bonus issue of shares to be held by Vidara Holdings and redeemed by Vidara from distributable reserves for cash as of the closing, (v) Vidara will be re-registered as a public limited company in Ireland, (vi) Vidara will redeem the bonus issue of shares for cash in the amount of \$200,000,000 plus cash on hand at Vidara on the closing date, less Vidara's unpaid indebtedness and unpaid transaction expenses, and plus or minus an adjustment to the extent that Vidara working capital as of the closing is more or less than target working capital of \$123,000 and (vii) Vidara will be renamed Horizon Pharma plc.

Q: What is the Merger?

A: Following the completion of the reorganization and assuming the satisfaction (or waiver, to the extent permissible) of the closing conditions, Merger Sub will merge with and into Horizon, with Horizon as the surviving corporation becoming a wholly-owned subsidiary of U.S. HoldCo and an indirect wholly-owned subsidiary of New Horizon. At the effective time, among other things, (i) each share of Horizon common stock then issued and outstanding will be canceled and automatically converted into and become the right to receive one ordinary share of New Horizon and (ii) each outstanding warrant to acquire Horizon's common stock will be converted into a warrant to acquire, on substantially the same terms and conditions as were applicable under such warrant before the effective time, the number of New Horizon ordinary shares equal to the number of shares of Horizon common stock otherwise purchasable pursuant to such warrant. Upon consummation of the merger, the stockholders of Horizon are expected to own approximately 74% of New Horizon on a fully diluted basis.

Q: What are Horizon's reasons for the Merger?

A: Horizon believes that the Merger is likely to result in significant strategic and financial benefits to New Horizon, which would accrue to the Horizon stockholders as stockholders of New Horizon, including that New Horizon would broaden its portfolio of marketed pharmaceutical products with the addition of Vidara's ACTIMMUN® therapy for the treatment of *chronic granulomatous disease* and *severe, malignant osteopetrosis*. Horizon also believes New Horizon will have a strong overall financial position, with expected pro forma combined full year revenues in 2014 of over \$250 million and an efficient corporate structure based in Ireland. See *The Reorganization and the Merger: Horizon's Reasons for the Merger and Recommendations of Horizon's Board of Directors*.

Q: Why am I being asked to approve new benefit plans?

A:

The Horizon board of directors is recommending that Horizon stockholders approve the Horizon Pharma Public Limited Company 2014 Equity Incentive Plan, the Horizon Pharma Public Limited Company 2014 Non-Employee Equity Plan and the Horizon Pharma Public Limited Company 2014 Employee Stock Purchase Plan. The Horizon board of directors believes approving the 2014 Equity Incentive Plan, the 2014 Non-Employee Equity Plan and the 2014 Employee Stock Purchase Plan is necessary for purposes of compliance with the requirements of applicable Irish laws, to permit grants of equity awards to employees, non-employee directors and consultants of New Horizon and its subsidiaries following the Merger and to permit the grant of purchase rights under offerings of New Horizon and its subsidiaries following the Merger.

3.

Table of Contents

Q: What are the voting recommendations of the Horizon board of directors?

A: After careful consideration, the Horizon board of directors has approved and declared advisable the Merger Agreement and Merger, and has determined that the Merger Agreement and the Merger are fair to and in the best interests of Horizon and its stockholders. The Horizon board of directors recommends that you vote your shares:

For approval of the adoption of the Merger Agreement and approval of the Merger (Proposal 1);

For approval, on an advisory basis, of certain compensatory arrangements between Horizon and its named executive officers relating to the Merger contemplated by the Merger Agreement (Proposal 2);

For approval of the Horizon Pharma Public Limited Company 2014 Equity Incentive Plan (Proposal 3);

For approval of the Horizon Pharma Public Limited Company 2014 Non-Employee Equity Plan (Proposal 4);

For approval of the Horizon Pharma Public Limited Company 2014 Employee Stock Purchase Plan (Proposal 5); and

For adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to adopt the Merger Agreement and approve the Merger (Proposal 6).

Q: How many shares will Horizon's executive officers and directors be entitled to vote at the Special Meeting? Have they entered into voting agreements?

A: As of the record date, Horizon's executive officers and directors, together with the stockholders with which certain of Horizon's directors and former directors are affiliated or associated, had the right to vote approximately _____ shares of Horizon common stock, representing approximately _____% of the Horizon common stock then outstanding and entitled to vote at the Special Meeting. Horizon expects that its executive officers and directors, and the stockholders with which certain of Horizon's directors and former directors are affiliated or associated, will vote For each of the proposals described in the question above.

In addition, Horizon's executive officers, directors and certain of the stockholders with which certain of Horizon's directors or former Horizon directors are affiliated or associated entered into voting agreements with Horizon and Vidara pursuant to which these stockholders agreed, among other things, to vote their shares of Horizon common stock in favor of the adoption of the Merger Agreement and approval of the Merger (Proposal 1), and in favor of any proposal to adjourn or postpone the Special Meeting to a later date if there are not sufficient votes in favor of the adoption of the Merger Agreement (Proposal 6). These stockholders also granted Vidara irrevocable proxies to vote their shares of Horizon common stock in favor of, among other things, the adoption of the Merger Agreement and

approval of the Merger, and any proposal to adjourn or postpone the Special Meeting to a later date if there are not sufficient votes in favor of the adoption of the Merger Agreement and approval of the Merger. Approximately _____ shares of Horizon common stock, which represent approximately _____ % of the outstanding shares of Horizon common stock as of the record date, are subject to these voting agreements and irrevocable proxies. For more information regarding the voting agreements, see the section entitled *Other Related Agreements The Voting Agreements*.

Q: What will the Horizon stockholders receive as consideration in the Merger?

A: If the Merger is consummated, each share of Horizon common stock issued and outstanding immediately prior to the effective time will be canceled and automatically converted into and become the right to receive one ordinary share of New Horizon. The one-for-one conversion ratio, which is referred to in this proxy statement/prospectus as the exchange ratio, is fixed. The exchange ratio will not fluctuate up or down

4.

Table of Contents

based on the market price of a share of Horizon common stock prior to the Merger. Following the Merger, Horizon common stock will be delisted from The NASDAQ Global Market, which is referred to in this proxy statement/prospectus as NASDAQ. There are no plans to publicly list the warrants to purchase New Horizon ordinary shares into which outstanding warrants to purchase Horizon common stock will be converted in the Merger. The New Horizon ordinary shares to be issued to the Horizon stockholders will be registered with the U.S. Securities and Exchange Commission, which is referred to in this proxy statement/prospectus as the SEC, and are expected to be listed and traded on NASDAQ under the symbol HZNP, the same NASDAQ trading symbol currently used for Horizon common stock.

Q: What percentage of New Horizon ordinary shares will the Horizon security holders and Vidara shareholders own following the proposed transactions?

A: Immediately following the Merger, the former security holders of Horizon are expected to own approximately 74% of New Horizon on a fully diluted basis excluding any shares that may be issued upon the conversion of the convertible notes, and Vidara Holdings, the sole historical shareholder of Vidara, is expected to own approximately 26% of New Horizon on a fully diluted basis.

Q: Is the sole shareholder of Vidara receiving any other consideration in connection with the proposed transactions?

A: Yes. At the closing of the Merger, Vidara Holdings will receive a cash payment equal to \$200 million, plus the cash of Vidara and its subsidiaries as of closing, less the indebtedness of Vidara and its subsidiaries and less transaction expenses of Vidara and its subsidiaries paid by New Horizon at or following the closing, plus or minus an adjustment to the extent that Vidara's working capital (exclusive of cash) as of the closing exceeds or is less than target working capital of \$123,000.

Q: Does Horizon have to complete a financing to fund the cash consideration being paid to the Vidara Holdings?

A: Yes, Horizon does not have \$200 million in available cash to fund the cash consideration and has entered into a credit agreement with a group of lenders to provide Horizon with \$300.0 million in financing through a five year senior secured term loan facility. Although completion of the term loan facility is not a condition to closing under the Merger Agreement, Horizon will need to close the term loan facility or an alternative financing in order to consummate the Merger and the transactions contemplated by the Merger Agreement.

Q: How are Horizon stock options treated in the Merger?

A: At the effective time, each outstanding option under the Horizon equity incentive plans will be converted into an option to acquire, on substantially the same terms and conditions as were applicable under such option immediately prior to the Merger, the number of New Horizon ordinary shares equal to the number of shares of

Horizon common stock subject to such option immediately prior to the effective time, at an exercise price per New Horizon ordinary share equal to the exercise price per share of Horizon common stock otherwise purchasable pursuant to such option.

Q: How are other Horizon equity awards treated in the Merger?

A: At the effective time, each other equity award that is outstanding under the Horizon equity incentive plans will be converted into a right to receive, on substantially the same terms and conditions as were applicable under such equity award immediately prior to the effective time, the number of New Horizon ordinary shares equal to the number of shares of Horizon common stock subject to such equity award immediately prior to the effective time. The other equity awards expected to be outstanding as of the effective time are purchase rights under ongoing offerings under the Horizon 2011 Employee Stock Purchase Plan and rights to receive shares upon vesting of outstanding restricted share units.

5.

Table of Contents

Q: How are Horizon warrants treated in the Merger?

A: At the effective time, each outstanding warrant to acquire Horizon common stock will be converted into a warrant to acquire, on substantially the same terms and conditions as were applicable under such warrant immediately prior the effective time, the number of New Horizon ordinary shares equal to the number of shares of Horizon common stock subject to such warrant immediately prior to the effective time, at an exercise price per New Horizon ordinary share equal to the exercise price per share of Horizon common stock otherwise purchasable pursuant to such warrant. Certain outstanding warrants to acquire Horizon common stock expire as of the closing if not exercised prior to the closing.

Q: What is required to complete the proposed transactions?

A: The obligation of Horizon and the Vidara parties to consummate the Merger and the transactions contemplated by the Merger Agreement is subject to certain conditions, including conditions with respect to the receipt of approval of the Merger Agreement by Horizon stockholders; accuracy of representations and warranties of the other party to the applicable standard provided by the Merger Agreement; compliance by the other party with its covenants in the Merger Agreement in all material respects; absence of a material adverse effect on the other party's business, assets, financial condition or results of operations (subject to certain exceptions) since the date of the Merger Agreement; satisfaction or early termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, which is referred to in this proxy statement/prospectus as the HSR Act (early termination of the waiting period under the HSR Act was granted effective April 11, 2014); approval for listing of the New Horizon ordinary shares to be issued in the Merger and the New Horizon ordinary shares held by the sole historical shareholder of Vidara as of the effective time; delivery of all closing deliverables; absence of any temporary restraining order, preliminary or permanent injunction or other order preventing the Merger or other transactions contemplated by the Merger Agreement; and the effectiveness of the registration statement of which this proxy statement/prospectus forms a part, as well as other customary closing conditions. In addition, Horizon's obligation to consummate the Merger is subject to completion of the reorganization and general releases being entered into by Vidara Holdings and certain employees of Vidara for the benefit of Vidara and its subsidiaries. Please see *Agreement and Plan of Merger and Reorganization Conditions to the Completion of the Merger*.

Q: Will appraisal rights be available for dissenting Horizon stockholders?

A: Appraisal rights are not available to Horizon stockholders in connection with the Merger.

Q: When are the Merger and reorganization expected to be completed?

A: As of the date of this proxy statement/prospectus, the Merger and reorganization are expected to be completed in the third quarter of 2014. However, no assurance can be provided as to when or if the Merger and reorganization will occur. The required vote of Horizon stockholders to adopt the Merger Agreement at the Special Meeting, as well as the necessary regulatory consents and approvals, must first be obtained and certain other conditions

specified in the Merger Agreement must be satisfied or, to the extent permissible, waived.

Q: What will be the relationship between Horizon and New Horizon after the proposed transactions?

A: Following completion of the proposed transactions, Horizon will be an indirect wholly-owned subsidiary of New Horizon. Horizon will be treated as the accounting acquirer following completion of the Merger and its financial statements issued after the completion of the Merger will include the operations of New Horizon beginning on the effective date of the Merger. Please see *The Reorganization and the Merger Accounting Treatment of the Merger*.

6.

Table of Contents

Q: What are the material U.S. federal income tax consequences of the Merger to U.S. stockholders of Horizon?

A: Generally, a U.S. stockholder of Horizon should recognize gain or loss, if any, on the receipt of New Horizon ordinary shares in exchange for shares of Horizon common stock pursuant to the Merger. The amount of gain or loss recognized should equal the difference between the fair market value of the New Horizon ordinary shares received in the Merger and the U.S. stockholder's adjusted tax basis in the shares of Horizon common stock surrendered. Horizon recommends that U.S. holders consult their own tax advisers as to the particular tax consequences of the Merger, including the effect of U.S. federal, state and local tax laws or foreign tax laws. Please see *Certain Tax Consequences of the Merger* for a more detailed description of the U.S. federal income tax consequences of the Merger.

Q: Will transfers of New Horizon ordinary shares be subject to the Irish stamp duty?

A: Transfers of New Horizon ordinary shares could be subject to Irish stamp duty. However, transfers of New Horizon ordinary shares effected by means of the transfer of book entry interests in The Depository Trust Company, which is referred to in this proxy statement/prospectus as DTC, will not be subject to Irish stamp duty. If you hold your New Horizon ordinary shares directly (i.e. you are a registered shareholder), any transfer of your New Horizon ordinary shares could be subject to Irish stamp duty (currently at the rate of 1% of the higher of the price paid or the market value of the shares acquired). Payment of Irish stamp duty is generally a legal obligation of the transferee.

Due to the potential Irish stamp duty charge on transfers of New Horizon ordinary shares, it is strongly recommended that those shareholders who do not hold their shares through DTC (or through a broker who in turn holds such shares through DTC) should arrange for the transfer of their Horizon shares into DTC as soon as possible and before the transactions are consummated. It is also strongly recommended that any person who wishes to acquire New Horizon ordinary shares after the effective time of the transactions acquire such shares through DTC (or through a broker who in turn holds such shares through DTC).

The imposition of Irish stamp duty charges could adversely affect the price of your shares and/or your ability to trade your shares.

See *Certain Tax Consequences of the Merger Irish Tax Considerations Stamp Duty* beginning on page 84.

Q: How many votes are needed to approve each proposal?

A: Proposal 1, the adoption of the Merger Agreement and the approval of the Merger, will be approved if it receives For votes from the holders of a majority of shares outstanding on the record date. If you Abstain from voting, it will have the same effect as an Against vote. Broker non-votes will have the same effect as an Against vote.

Proposal 2, the approval, on an advisory basis, of certain compensatory arrangements between Horizon and its named executive officers relating to the Merger contemplated by the Merger Agreement, will be approved if it receives For votes from the holders of a majority of shares present in person or by proxy and entitled to vote. If you Abstain from voting, it will have the same effect as an Against vote. Broker non-votes will have no effect.

Proposal 3, the approval of the Horizon Pharma Public Limited Company 2014 Equity Incentive Plan, will be approved if it receives For votes from the holders of a majority of shares present in person or by proxy and entitled to vote. If you Abstain from voting, it will have the same effect as an Against vote. Broker non-votes will have no effect.

7.

Table of Contents

Proposal 4, the approval of the Horizon Pharma Public Limited Company 2014 Non-Employee Equity Plan, will be approved if it receives For votes from the holders of a majority of shares present in person or by proxy and entitled to vote. If you Abstain from voting, it will have the same effect as an Against vote. Broker non-votes will have no effect.

Proposal 5, the approval of the Horizon Pharma Public Limited Company 2014 Employee Stock Purchase Plan, will be approved if it receives For votes from the holders of a majority of shares present in person or by proxy and entitled to vote. If you Abstain from voting, it will have the same effect as an Against vote. Broker non-votes will have no effect.

Proposal 6, the approval of the adjournment of the Horizon Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Horizon Special Meeting to adopt the Merger Agreement and approve the Merger, will be approved if it receives For votes from the holders of a majority of shares present in person or by proxy and entitled to vote. If you Abstain from voting, it will have the same effect as an Against vote. Broker non-votes will have no effect.

Q: Who can vote at the Horizon Special Meeting?

A: Only stockholders of record of Horizon at the close of business on July 30, 2014 will be entitled to vote at the Special Meeting. If on July 30, 2014 your shares were registered directly in your name with Horizon's transfer agent, Computershare Trust Company, then you are a stockholder of record. As a stockholder of record, you may vote in person at the Special Meeting or vote by proxy. Whether or not you plan to attend the Special Meeting, Horizon urges you to vote by proxy over the telephone or on the internet as instructed below, or fill out and return a proxy card.

If on July 30, 2014 your shares were held not in your name, but rather in an account at a brokerage firm, bank, dealer, or other similar organization, then you are the beneficial owner of shares held in street name and this proxy statement/prospectus is being sent to you by that organization. The organization holding your account is considered to be the stockholder of record for purposes of voting at the Special Meeting. As a beneficial owner, you have the right to direct your broker or other agent regarding how to vote the shares in your account by following the instructions that the broker, bank or other nominee provides you along with this proxy statement/prospectus. You are also invited to attend the Special Meeting. However, since you are not the stockholder of record, you may not vote your shares in person at the Special Meeting unless you request and obtain a valid proxy from your broker or other agent.

Q: What is the quorum requirement?

A: A quorum of stockholders is necessary to hold a valid meeting. A quorum will be present if stockholders holding at least a majority of the outstanding shares entitled to vote are present at the meeting in person or represented by proxy. On the record date, there were _____ shares outstanding and entitled to vote. Thus, the holders of _____ shares must be present in person or represented by proxy at the meeting to have a quorum.

Your shares will be counted towards the quorum only if you submit a valid proxy (or one is submitted on your behalf by your broker, bank or other nominee) or if you vote in person at the meeting. Abstentions and broker non-votes will

be counted towards the quorum requirement. If there is no quorum, the holders of a majority of shares present at the meeting in person or represented by proxy may adjourn the meeting to another date.

8.

Table of Contents

Q: How do I vote?

A: For each of the matters to be voted on, you may vote For or Against or abstain from voting. The procedures for voting are fairly simple:

Stockholder of Record: Shares Registered in Your Name

If you are a stockholder of record, you may vote in person at the Horizon Special Meeting, vote by proxy using the enclosed proxy card, vote by proxy over the telephone, or vote by proxy through the internet. Whether or not you plan to attend the meeting, Horizon urges you to vote by proxy to ensure your vote is counted. You may still attend the meeting and vote in person even if you have already voted by proxy.

To vote in person, come to the Horizon Special Meeting and Horizon will give you a ballot when you arrive.

To vote using the proxy card, simply complete, sign and date the enclosed proxy card and return it promptly in the envelope provided. If you return your signed proxy card to Horizon before the Horizon Special Meeting, Horizon will vote your shares as you direct.

To vote over the telephone, dial toll-free 1-800-652-VOTE (8683) using a touch-tone phone and follow the recorded instructions. You will be asked to provide the company number and control number from the enclosed proxy card. Your vote must be received by 11:59 p.m., Eastern Time on _____, 2014, to be counted.

To vote through the internet, go to <http://www.envisionreports.com/hznp> to complete an electronic proxy card. You will be asked to provide the company number and control number from the enclosed proxy card. Your vote must be received by 11:59 p.m. Eastern Time on _____, 2014, to be counted.

Beneficial Owner: Shares Registered in the Name of Broker or Bank

If you are a beneficial owner of shares registered in the name of your broker, bank or other agent, you should have received a voting instruction form with these proxy materials from that organization rather than from Horizon. Simply complete and mail the voting instruction form to ensure that your vote is counted. Alternatively, you may vote by telephone or through the internet as instructed by your broker or bank. To vote in person at the Horizon Special Meeting, you must obtain a valid proxy from your broker, bank or other agent. Follow the instructions from your broker or bank included with these proxy materials, or contact your broker or bank to request a proxy form.

Internet proxy voting is being provided to allow you to vote your shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers

and telephone companies.

Q: If my shares are held in street name by my bank, broker or other agent, will my bank, broker or other agent vote my shares for me?

A: Only if you provide your bank, broker or other agent with instructions on how to vote your shares. If you do not provide the organization that holds your shares with specific instructions, under the rules of various national and regional securities exchanges, the organization that holds your shares may generally vote on routine matters but cannot vote on non-routine matters. If the organization that holds your shares does not receive instructions from you on how to vote your shares on a non-routine matter, the organization that holds your shares will inform the inspector of elections for the Special Meeting that it does not have the authority to vote on this matter with respect to your shares. This is generally referred to as a broker non-vote. When Horizon's inspector of elections tabulates the votes for any particular matter, broker non-votes

Table of Contents

will be counted for purposes of determining whether a quorum is present, but will not be counted toward the vote total for any proposal other than Proposal 1. On Proposal 1, a broker non-vote will have the effect as a vote against the adoption of the Merger Agreement and approval of the Merger. Horizon expects that each of the proposals presented at the Special Meeting will be considered non-routine matters, so Horizon encourages you to provide voting instructions to the organization that holds your shares to ensure that your vote is counted on all eleven proposals.

Q: How many votes do I have?

A: On each matter to be voted upon, you have one vote for each share of Horizon common stock you own as of July 30, 2014.

Q: What happens if I do not vote?

A: *Stockholder of Record: Shares Registered in Your Name*

If you are a stockholder of record and do not vote by completing your proxy card, by telephone, through the internet or in person at the Horizon Special Meeting, your shares will not be voted.

Beneficial Owner: Shares Registered in the Name of Broker or Bank

If you are a beneficial owner and do not instruct your broker, bank, or other agent how to vote your shares, the question of whether your broker or nominee will still be able to vote your shares depends on whether the New York Stock Exchange (NYSE) deems the particular proposal to be a routine matter. Brokers and nominees can use their discretion to vote uninstructed shares with respect to matters that are considered to be routine, but not with respect to non-routine matters. Under the rules and interpretations of the NYSE, non-routine matters are matters that may substantially affect the rights or privileges of stockholders, such as mergers, stockholder proposals, elections of directors (even if not contested), executive compensation (including any advisory stockholder votes on executive compensation) and certain corporate governance proposals, even if management-supported. Accordingly, your broker or nominee may not vote your shares on any of the proposals without your instructions.

Q: What if I return a proxy card or otherwise vote but do not make specific choices?

A: If you return a signed and dated proxy card or otherwise vote without marking voting selections, your shares will be voted, as applicable, FOR the adoption of the Merger Agreement and the approval of the Merger, FOR the approval, on an advisory basis, of certain compensatory arrangements between Horizon and its named executive officers relating to the Merger contemplated by the Merger Agreement, FOR the approval of the Horizon Pharma Public Limited Company 2014 Equity Incentive Plan, FOR the approval of the Horizon Pharma Public Limited Company 2014 Non-Employee Equity Plan, FOR the approval of the Horizon Pharma Public Limited Company 2014 Employee Stock Purchase Plan and FOR the approval of the adjournment of the Horizon Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Horizon Special Meeting to adopt the Merger Agreement and approve the Merger. If any other matter is properly presented at the

meeting, your proxy holder (one of the individuals named on your proxy card) will vote your shares using his or her best judgment.

Q: Should I send in my stock certificates now?

A: No. Horizon stockholders should keep their existing stock certificates at this time. After the proposed Merger and reorganization are completed, you will receive written instructions for exchanging your Horizon stock certificates for New Horizon ordinary shares. Because of the potential Irish stamp duty on transfer of New Horizon ordinary shares, Horizon strongly recommends that all directly registered Horizon stockholders open broker accounts so they can transfer their shares of Horizon common stock into DTC prior to their exchange for New Horizon ordinary shares.

10.

Table of Contents

Q: What do I need to do now?

A: After carefully reading and considering the information contained in this proxy statement/prospectus, including the Annexes and the documents incorporated by reference, please vote your shares of Horizon common stock as described in *Questions and Answers About the Proposed Transactions and the Horizon Special Meeting of Stockholders and Voting How do I vote?* Whether or not you plan to attend the Special Meeting, Horizon urges you to vote by proxy to ensure your vote is counted.

Q: Can I change my vote after submitting my proxy?

A: *Stockholder of Record: Shares Registered in Your Name*

Yes. You can revoke your proxy at any time before the final vote at the meeting. If you are the record holder of your shares, you may revoke your proxy in any one of the following ways:

You may submit another properly completed proxy card with a later date.

You may grant a subsequent proxy by telephone or through the internet.

You may send a timely written notice that you are revoking your proxy to Horizon's Secretary at 520 Lake Cook Road, Suite 520, Deerfield, IL 60015.

You may attend the Horizon Special Meeting and vote in person. Simply attending the meeting will not, by itself, revoke your proxy.

Your most current proxy card or telephone or internet proxy is the one that is counted.

Beneficial Owner: Shares Registered in the Name of Broker or Bank

If your shares are held by your broker or bank as a nominee or agent, you should follow the instructions provided by your broker or bank.

Q: How are votes counted?

A: Votes will be counted by the inspector of election appointed for the meeting, who will separately count, with respect to the proposal to elect directors, votes For, Withhold and broker non-votes, and with respect to other proposals, votes For and Against, abstentions and broker non-votes. Abstentions will be counted for purposes of determining the presence of a quorum at the meeting but will not be voted at the meeting and will have the same effect as Against votes for all proposals. Horizon does not believe that brokers have authority to vote on any of

the proposals. Broker non-votes on Proposal 1 will have the effect of a vote Against Proposal 1. Broker non-votes will have no effect on the outcome of Proposals 2 through 6.

Q: What are broker non-votes ?

A: As discussed above, when a beneficial owner of shares held in street name does not give instructions to the broker or nominee holding the shares as to how to vote on matters deemed by the NYSE to be non-routine, the broker or nominee cannot vote the shares. These un-voted shares are counted as broker non-votes.

Q: What happens if I sell my shares of Horizon common stock after the record date but before the Special Meeting?

A: If you transfer your Horizon common stock after the record date but before the date of the Special Meeting, you will retain your right to vote at the Special Meeting. However, you will not have the right to receive any New Horizon ordinary shares in exchange for your former shares of Horizon common stock if and when the Merger is completed. In order to receive New Horizon ordinary shares in exchange for your shares of Horizon common stock, you must hold your Horizon common stock through the completion of the Merger.

Table of Contents

Q: Who is paying for this proxy solicitation?

A: Horizon has retained MacKenzie Partners, Inc. (MacKenzie), a proxy solicitation firm, to solicit proxies in connection with the Horizon Special Meeting at a cost of approximately \$35,000 plus expenses. The cost of soliciting proxies incurred by Horizon and MacKenzie, including the preparation, assembly and mailing of the proxies and soliciting material, as well as the cost of forwarding such material to beneficial owners of Horizon's common stock, will be borne by Horizon. Directors, officers and regular employees of Horizon may, without compensation other than their regular remuneration, solicit proxies personally or by telephone.

Q: What does it mean if I receive more than one set of proxy materials?

A: If you receive more than one set of proxy materials, your shares may be registered in more than one name or in different accounts. Please follow the voting instructions on the proxy cards in the proxy materials to ensure that all of your shares are voted.

Q: How can I find out the results of the voting at the Horizon Special Meeting?

A: Preliminary voting results will be announced at the Horizon Special Meeting. In addition, final voting results will be published in a current report on Form 8-K that Horizon expects to file within four business days after the Horizon Special Meeting. If final voting results are not available to Horizon in time to file a Form 8-K within four business days after the meeting, Horizon intends to file a Form 8-K to publish preliminary results and, within four business days after the final results are known to Horizon, file an additional Form 8-K to publish the final results.

Q: What proxy materials are available on the internet?

A: The proxy statement/prospectus and the Horizon Annual Report on Form 10-K are available at www.envisionreports.com/hznp.

Q: Who can help answer my questions?

A: If you have any questions about the proposed transactions, need assistance in voting your shares, or if you need additional copies of this proxy statement/prospectus or the enclosed proxy card, you should contact Horizon or its proxy solicitor, MacKenzie, as follows:

Horizon Pharma, Inc.

MacKenzie Partners, Inc.

Attn: Investor Relations

105 Madison Avenue

520 Lake Cook Road, Suite 520

New York, NY 10016

Deerfield, IL 60015

(212) 929-5500

(224) 383-3000

Q: Where can I find more information about Horizon?

A: You can find more information about Horizon from the various sources described under *Where You Can Find More Information*.

12.

Table of Contents

SUMMARY

This summary highlights selected information contained in this proxy statement/prospectus and may not contain all of the information that is important to you. You should read carefully this entire proxy statement/prospectus, including the Annexes and the documents incorporated by reference, to fully understand the proposed transactions and the voting procedures for the Special Meeting. See also the section entitled "Where You Can Find More Information" beginning on page 263 of this proxy statement/prospectus. The page references have been included in this summary to direct you to a more complete description of the topics presented below.

The Companies (Page 88)

Horizon Pharma, Inc.

520 Lake Cook Road, Suite 520

Deerfield, IL 60015

(224) 383-3000

Horizon Pharma, Inc. is a commercial stage, specialty pharmaceutical company that markets DUEXIS[®], VIMOVO[®] and RAYOS[®]/LODOTRA[®], which target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The Company's strategy is to develop, acquire or in-license additional innovative medicines where it can execute a targeted commercial approach among specific target physicians such as primary care physicians, orthopedic surgeons and rheumatologists, while taking advantage of its commercial strengths and the infrastructure the Company has put in place. For more information, please visit www.horizonpharma.com.

Vidara Therapeutics Holdings LLC

c/o DFW Capital Partners

300 Frank W. Burr Blvd., Suite 5

Teaneck, NJ 07666

Vidara Therapeutics Holdings LLC is a Delaware limited liability company and is the parent company of Vidara and Vidara U.S. Vidara Holdings conducts no operations and holds no assets other than the equity interests of Vidara and Vidara U.S. Prior to the Merger, Vidara Holdings owns all of the ordinary shares of Vidara and Vidara U.S. Immediately following the Merger, Vidara Holdings will own approximately 26% of New Horizon, on a fully diluted basis.

Vidara Therapeutics International Limited

c/o Virinder Nohria, M.D., Ph.D.

Adelaide Chambers, Peter Street, Dublin 8, Ireland

Vidara Therapeutics International Limited is a privately-held, specialty pharmaceutical company with operations in Dublin, Ireland. The Vidara Group markets ACTIMMUNE[®], a bioengineered form of interferon gamma-1b, a protein

that acts as a biologic response modifier, in the United States. ACTIMMUNE is approved by the U.S. Food and Drug Administration for use in children and adults with *chronic granulomatous disease* (CGD) and *severe, malignant osteopetrosis* (SMO). Additional information is available at Vidara s website at www.vidararx.com.

Prior to the completion of the Merger, Vidara will be renamed Horizon Pharma plc.

Hamilton Holdings (USA), Inc.

c/o Virinder Nohria, M.D., Ph.D.

1000 Holcomb Woods Parkway, Suite 270, Roswell, Georgia 30076

Table of Contents

Hamilton Holdings (USA), Inc., is a Delaware corporation formed as part of the restructuring of Vidara to hold U.S. subsidiaries of New Horizon and is referred to as U.S. HoldCo. U.S. HoldCo owns all of the outstanding capital stock of Hamilton Merger Sub, Inc. U.S. HoldCo has not conducted any activities other than those incidental to its formation and the matters contemplated by the Merger Agreement.

Hamilton Merger Sub, Inc.

c/o Virinder Nohria, M.D., Ph.D.

1000 Holcomb Woods Parkway, Suite 270, Roswell, Georgia 30076

Hamilton Merger Sub, Inc., referred to as Merger Sub, a wholly-owned subsidiary of U.S. HoldCo, is a Delaware corporation formed solely for the purpose of effecting the Merger with Horizon. Upon the terms and conditions set forth in the Merger Agreement, Merger Sub will be merged with and into Horizon and the separate existence of Merger Sub will cease. Horizon will be the surviving corporation in the Merger as an indirect wholly-owned subsidiary of New Horizon. Merger Sub has not conducted any activities other than those incidental to its formation and the matters contemplated by the Merger Agreement.

The Reorganization and the Merger (Page 37)

On March 18, 2014, Horizon, Vidara Holdings, a Delaware limited liability company, Vidara, an Irish private limited company, U.S. HoldCo, a Delaware corporation and an indirect wholly-owned subsidiary of Vidara, and Merger Sub, a Delaware corporation and a wholly-owned subsidiary of U.S. HoldCo, entered into a Transaction Agreement and Plan of Merger (the Merger Agreement). The Merger Agreement provides that, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Horizon, with Horizon continuing as the surviving corporation and as a wholly-owned, indirect subsidiary of Vidara (the Merger), and that Vidara will change its name to Horizon Pharma plc (New Horizon).

Immediately following the proposed transaction, stockholders of Horizon are expected to own approximately 74 percent of New Horizon on a fully diluted basis, and Vidara Holdings, the sole historical shareholder of Vidara, is expected to own approximately 26 percent of New Horizon on a fully diluted basis, in each case, excluding the shares that may be issued on the conversion of the 5.00% Convertible Senior Notes due 2018. Stockholders of Horizon would receive one ordinary share of New Horizon in exchange for each whole share of Horizon common stock they own at closing. The combined company is expected to have a capitalization of approximately 122 million ordinary shares, on a fully diluted basis. New Horizon would be a U.S. Securities and Exchange Commission reporting company, and its ordinary shares are expected to trade on NASDAQ. The transaction will be taxable to the Horizon U.S. stockholders.

Post-Merger Management of New Horizon (Page 201)

Timothy P. Walbert, chairman, president and chief executive officer of Horizon would be chairman, president and chief executive officer of New Horizon and current officers of Horizon would be officers of New Horizon. Vidara executives would join New Horizon in important leadership and management roles within the combined company. Horizon expects that each of its current directors, plus one additional director to be nominated by Vidara Holdings, who will initially be Virinder Nohria, M.D., Ph.D., will become directors of New Horizon pursuant to the Merger Agreement.

Horizon's Reasons for the Merger (Page 45)

In reaching its conclusion to approve the Merger Agreement, the Horizon board of directors considered a number of factors in its deliberations and concluded that the Merger is likely to result in significant strategic and financial benefits to New Horizon, which would accrue to the Horizon stockholders, as shareholders of New Horizon, including that:

The combination of Horizon and Vidara as New Horizon would accelerate the date by which Horizon is expected to become a profitable specialty pharmaceutical company;

14.

Table of Contents

New Horizon would have a broader revenue base resulting from a deeper portfolio of marketed drugs, including Horizon's DUEXIS®, VIMOVO® and RAYOS® marketed in the United States, Vidara's ACTIMMUNE® marketed in the United States and Horizon's LODOTRA® marketed outside the United States;

New Horizon would have a strong overall financial position, with expected pro forma combined full year revenue in 2014 of \$270 to \$280 million and expected pro forma combined full year adjusted EBITDA, excluding transaction expenses, of \$80 to \$90 million in 2014 (in each case, assuming the Merger occurred on or before July 31, 2014);

New Horizon would have an efficient corporate structure based in Ireland to support New Horizon's organic growth and acquisition strategy with the expected non-GAAP effective tax rate in the low 20% range compared to the non-GAAP effective tax rate in the high 30% range that was expected for Horizon as it transitioned to tax paying status;

The Horizon board of directors' belief that New Horizon's anticipated market capitalization, strong balance sheet, free cash flow, liquidity and capital structure would enhance New Horizon's ability to execute on its strategy of both organic growth and growth through acquisitions and in-licensing; and

The Horizon board of directors' belief that New Horizon would be able to leverage the commercial and specialty product marketing experience of Horizon in maximizing the potential of ACTIMMUNE.

See also the factors listed in *The Reorganization and the Merger Horizon's Reasons for the Merger and Recommendation of Horizon's Board of Directors*, beginning on page 45 of this proxy statement/prospectus.

Recommendations of Horizon's Board of Directors (Page 45)

After careful consideration, the Horizon board of directors has approved and declared advisable the Merger Agreement and the Merger, and has determined that the Merger Agreement and the Merger are fair to and in the best interests of Horizon and its stockholders. The Horizon board of directors has adopted resolutions approving the Merger Agreement, recommending that the holders of Horizon common stock vote to adopt the Merger Agreement and approve the Merger and directing that the Merger Agreement and Merger be submitted to a vote of the Horizon stockholders. The Horizon board of directors recommends that you vote **FOR** the adoption of the Merger Agreement and approval of the Merger, and **FOR** the other proposals described in this proxy statement/prospectus.

Opinion of Horizon's Financial Advisor (Page 50)

Citigroup Global Markets Inc., referred to as Citi, delivered a written opinion to Horizon's board of directors on March 18, 2014 that, as of such date, the Transaction Consideration was fair, from a financial point of view, to Horizon and its stockholders (other than Vidara and its affiliates). Transaction Consideration is defined herein as the 31,350,000 ordinary shares of Vidara to be retained by Vidara Holdings (the **Vidara Shares**) and the \$200,000,000 in cash payable to Vidara Holdings at closing (the **Cash Consideration**).

The full text of the written opinion of Citi, dated March 18, 2014, which contains assumptions made, procedures followed, matters and factors considered and limitations and qualifications on the review undertaken in connection

with the opinion, is attached as Annex B to this proxy statement/prospectus and is incorporated herein by reference. The opinion should be read in its entirety. Citi's financial advisory services and opinion were provided for the information and assistance of Horizon's board of directors in connection with its consideration of the proposed transaction. Citi was not requested to consider, and its opinion did not address, the underlying business decision of Horizon to effect the transaction, the relative merits of the transaction as compared to any alternative business strategy or transaction that might exist for Horizon or the effect of any other transaction in which Horizon might engage. Under the terms of its engagement, Citi has acted as an independent contractor, not as an agent or fiduciary. **Citi's opinion is not intended to be and does not constitute a recommendation as to how any stockholder should vote or act on any matter relating to the transaction, or otherwise.**

15.

Table of Contents

The Special Meeting of Horizon Stockholders (Page 1)

Date, Time & Place of the Horizon Special Meeting

Horizon will hold a Special Meeting on _____, _____, 2014, at 8:00 a.m. Central Time, at the offices of Horizon located at 520 Lake Cook Road, Suite 520, Deerfield, IL 60015.

Proposals

At the Special Meeting, Horizon stockholders will vote upon proposals to:

Adopt the Merger Agreement and approve the Merger (Proposal 1);

Approve, on an advisory basis, certain compensatory arrangements between Horizon and its named executive officers relating to the Merger contemplated by the Merger Agreement (Proposal 2);

Approve the Horizon Pharma Public Limited Company 2014 Equity Incentive Plan (Proposal 3);

Approve the Horizon Pharma Public Limited Company 2014 Non-Employee Equity Plan (Proposal 4);

Approve the Horizon Pharma Public Limited Company 2014 Employee Stock Purchase Plan (Proposal 5);
and

Approve the adjournment of the Special Meeting, if necessary, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to adopt the Merger Agreement and approve the Merger (Proposal 6).

Record Date; Outstanding Shares; Shares Entitled to Vote

Only stockholders of record of Horizon at the close of business on July 30, 2014 will be entitled to vote at the Special Meeting. On this record date, there were _____ shares of common stock outstanding and entitled to vote. Each share of Horizon common stock outstanding as of July 30, 2014 is entitled to one vote on each proposal and any other matter properly coming before the Special Meeting.

Stock Ownership and Voting by Horizon's Directors and Officers

As of the record date, Horizon's executive officers and directors, together with the stockholders with which certain of Horizon's directors and former directors are affiliated or associated, had the right to vote approximately _____ shares of Horizon common stock, representing approximately _____ % of the Horizon common stock then outstanding and entitled to vote at the Special Meeting. Horizon expects that its executive officers and directors, and the stockholders with which certain of Horizon's directors are affiliated or associated, will vote For each of the

proposals described above.

Voting Agreements

In addition, the directors and officers of Horizon and certain of the stockholders with which certain of Horizon's directors and former directors are affiliated or associated entered into voting agreements with Horizon and Vidara pursuant to which these stockholders agreed, among other things, to vote their shares of Horizon common stock in favor of the adoption of the Merger Agreement and approval of the Merger, and in favor of any proposal to adjourn or postpone the Special Meeting to a later date if there are not sufficient votes in favor of the adoption of the Merger Agreement. These stockholders also granted Vidara irrevocable proxies to vote their shares of Horizon common stock in favor of, among other things, the adoption of the Merger Agreement and approval of the Merger, and any proposal to adjourn or postpone the Special Meeting to a later date if there are

Table of Contents

not sufficient votes in favor of the adoption of the Merger Agreement and approval of the Merger. Approximately _____ shares of Horizon common stock, which represent approximately _____ % of the outstanding shares of Horizon common stock as of the record date, are subject to these voting agreements and irrevocable proxies. For more information regarding the voting agreements, see the section entitled *Other Related Agreements The Voting Agreements* on page 112 of this proxy statement/prospectus.

Vote Required

The affirmative vote of the holders of at least a majority of the shares of Horizon common stock outstanding on the record date for the Special Meeting is required for approval of Proposal 1. If you *Abstain* from voting, it will have the same effect as an *Against* vote. Broker non-votes will also have the same effect as an *Against* vote. Approval of Proposals 2 through 6 requires an affirmative vote from the holders of at least a majority of the shares of Horizon common stock represented and voting either in person or by proxy at the Special Meeting and entitled to vote. If you *Abstain* from voting, it will have the same effect as an *Against* vote. Broker non-votes will have no effect.

The Horizon board of directors recommends that Horizon stockholders vote *For* each of the proposals set forth above.

Interests of Certain Persons in the Merger (Page 58)

In considering the recommendation of the Horizon board of directors, you should be aware that certain directors and officers of Horizon and Vidara may have interests in the proposed transactions that are different from, or in addition to, your interests as a Horizon stockholder generally and which may create potential conflicts of interest. The Horizon board of directors was aware of these interests and considered them when they adopted the Merger Agreement and approved the transactions contemplated thereby.

Management

Horizon

As of the date of the proxy statement/prospectus, it is expected that the current executive officers of Horizon will be appointed as the executive officers of New Horizon following the Merger. Except as described below under *The Reorganization and the Merger Interests of Certain Persons in the Merger Golden Parachute Compensation*, no member of Horizon's management will receive additional compensation or acceleration of payment of existing compensation on the basis of the transactions contemplated by the Merger Agreement.

Vidara

Certain current key employees of Vidara and its affiliates will continue their employment following the Merger with New Horizon or a subsidiary of New Horizon pursuant to the terms and conditions set forth in employment agreements that were amended in connection with the Merger Agreement. These key employees' positions with New Horizon or Vidara will entitle them to compensation.

Certain of the key employees entered into retention bonus agreements with Vidara, which amended all prior employment-related agreements between such employees and Vidara. The retention bonus agreements provide that such employees will continue their employment on the same terms and conditions as their pre-existing employment agreement and that, if such employees remain employed through the earlier of one year after the closing of the Merger and the closing of a change of control of New Horizon, such employee will be entitled to a bonus cash payment.

17.

Table of Contents

Directors

It is expected that all of the current directors of Horizon will become directors of New Horizon following the completion of the Merger, and the non-employee directors of New Horizon may be entitled to compensation from New Horizon for such services. Additionally, Vidara Holdings will be entitled to appoint one member to the New Horizon board of directors, which member is expected to initially be Virinder Nohria, M.D., Ph.D. However, as of the date of this proxy statement/prospectus, a final determination as to who will be appointed to the New Horizon board of directors has not been made and the requisite corporate action to appoint the persons who will serve as directors of New Horizon following the completion of the Merger has not been effected; accordingly, the persons who will serve as directors of New Horizon following the completion of the Merger may differ from the persons currently expected to serve in such capacity.

Indemnification (Page 65)

New Horizon has agreed to indemnify and hold harmless, for at least six years after the closing of the Merger, all past and present officers and directors of Vidara and its affiliates to the same extent that such persons are currently indemnified by Vidara and its affiliates pursuant to the organizational documents of such entities for acts or omissions occurring on or prior to the closing of the Merger. In addition, New Horizon must maintain for a period of six years from the closing of the Merger the existing policy of directors and officers liability insurance maintained by Vidara and its affiliates, subject to certain limitations, or New Horizon may purchase a directors and officers liability insurance tail policy with a claims period of six years from the closing of the Merger on specified terms.

Certain U.S. Federal Tax Consequences of the Merger to U.S. Stockholders (Page 73)

Horizon expects that generally, a U.S. stockholder of Horizon should recognize gain or loss, if any, on the receipt of New Horizon ordinary shares in exchange for Horizon common stock pursuant to the Merger. The amount of gain or loss recognized should equal the difference between the fair market value of the New Horizon ordinary shares received in the Merger and the U.S. stockholder's adjusted tax basis in the shares of Horizon common stock surrendered. Horizon recommends that U.S. holders consult their own tax advisers as to the particular tax consequences of the Merger, including the effect of U.S. federal, state and local tax laws or foreign tax laws. Please see *Certain Tax Consequences of the Merger* for a more detailed description of the U.S. federal income tax consequences of the Merger.

No Appraisal Rights (Page 87)

Appraisal rights are statutory rights under Delaware law that enable stockholders who object to certain extraordinary transactions to demand that the corporation pay such stockholders the fair value of their shares instead of receiving the consideration offered to stockholders in connection with the extraordinary transaction. However, appraisal rights are not available in all circumstances. Appraisal rights are not available to Horizon stockholders in connection with the Merger.

Regulatory Approvals Required (Page 71)

Under the HSR Act, and the rules and regulations promulgated thereunder by the Federal Trade Commission, which is referred to in this proxy statement/prospectus as the FTC, the Merger cannot be consummated until notifications have been submitted and certain information has been furnished to the Antitrust Division and the FTC, and specified waiting period requirements have been satisfied.

Horizon and Mr. Balaji Venkataraman, the former Executive Chairman of the Vidara Group, each filed a Pre-Merger Notification and Report Form pursuant to the HSR Act with the Antitrust Division and the FTC. The waiting period under the HSR Act was scheduled to expire at 11:59 p.m. Eastern Time on May 1, 2014. However, early termination of the waiting period under the HSR Act was granted effective April 11, 2014.

18.

Table of Contents

Listing of New Horizon Ordinary Shares on NASDAQ (Page 87)

Vidara ordinary shares are not currently traded or quoted on a stock exchange or quotation system. The New Horizon ordinary shares are expected to be listed on The NASDAQ Global Market under the symbol HZNP following the Merger. There are no plans to publicly list the warrants to purchase New Horizon ordinary shares into which outstanding warrants to purchase Horizon common stock will be converted in the Merger.

Conditions to the Completion of the Merger (Page 106)

The completion of the Merger depends upon the satisfaction or waiver of a number of conditions, all of which, to the extent permitted by applicable law, may be waived by Vidara Holdings and/or Horizon, as applicable.

Termination of the Merger Agreement (Page 109)

Either Horizon or Vidara Holdings can terminate the Merger Agreement under certain circumstances, which would prevent the Merger from being consummated.

Accounting Treatment of the Merger (Page 72)

The Merger will be accounted for using the acquisition method of accounting, with Horizon being treated as the accounting acquirer under accounting principles generally accepted in the United States, which are referred to in this proxy statement/prospectus as U.S. GAAP. Accordingly, the assets and liabilities of Vidara will be, as of the effective time, recorded at their respective fair values and added to those of Horizon, including an amount for goodwill representing the difference between the acquisition consideration and the fair value of the identifiable net assets.

Restrictions on Resales (Page 72)

All New Horizon ordinary shares received by Horizon stockholders in the Merger will be freely tradable, except that New Horizon ordinary shares received in the Merger by persons who become affiliates of New Horizon for purposes of Rule 144 under the Securities Act of 1933, as amended, which is referred to in this proxy statement/prospectus as the Securities Act, may be resold by them only in transactions permitted by Rule 144, or as otherwise permitted under the Securities Act.

Comparison of the Rights of Holders of Horizon Common Stock and New Horizon Ordinary Shares (Page 246)

As a result of the Merger, the holders of Horizon common stock will become holders of New Horizon ordinary shares and their rights will be governed by Irish law and the memorandum and articles of association of New Horizon instead of the Delaware General Corporation Law, which is referred to in this proxy statement/prospectus as the DGCL, and Horizon's amended and restated certificate of incorporation and amended and restated bylaws, which are collectively referred to in this proxy statement/prospectus as the Horizon charter documents. The form of the New Horizon memorandum and articles of association substantially as it will be in effect from and after the closing is attached as Annex C to this proxy statement/prospectus. Following the Merger, former Horizon stockholders will have different rights as New Horizon shareholders from the rights they had as Horizon stockholders. For a summary of the material differences between the rights of Horizon stockholders and New Horizon shareholders, please see *Description of New Horizon Ordinary Shares* and *Comparison of the Rights of Holders of Horizon Common Stock and New Horizon Ordinary Shares*.

19.

Table of Contents

RISK FACTORS

Horizon stockholders should carefully consider the following factors in evaluating whether to vote to adopt the merger agreement and approve the merger. These factors should be considered in conjunction with the other information included in or incorporated by reference into this proxy statement/prospectus, including the risks discussed in Horizon's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2014 under the heading Risk Factors. See Where You Can Find More Information. Additional risks and uncertainties not presently known to Horizon or Vidara, or that are not currently believed to be important to you, also may adversely affect the merger and New Horizon following the merger. Unless expressly stated otherwise, all references in this section to we, us, our or similar references refer to New Horizon.

Risks Related to the Proposed Transactions

The number of New Horizon ordinary shares that Horizon stockholders will receive as consideration in the Merger will be based on a fixed exchange ratio, which will not be adjusted to reflect changes in the market value of Horizon common stock or changes in the fair value of Vidara prior to the consummation of the transaction.

As consideration in the Merger, each share of Horizon common stock then issued and outstanding will be cancelled and automatically converted into the right to receive one ordinary share of New Horizon, pursuant to a fixed exchange ratio. Each New Horizon ordinary share will be issued in accordance with, and subject to the rights and obligations of, the memorandum and articles of association of New Horizon, which is expected to be amended and restated prior to the effective time in the form attached as Annex C. For a comparison of the rights and privileges of a holder of shares of New Horizon to a holder of shares of Horizon, please see *Comparison of the Rights of Holders of Horizon Common Stock and New Horizon Ordinary Shares*. The one-for-one fixed exchange ratio will not adjust upwards or downwards to compensate for changes in the price of Horizon's common stock or as a result of changes in the fair value of Vidara prior to the closing of the transactions.

The market value of New Horizon ordinary shares that stockholders of Horizon will be entitled to receive when the transaction is completed could vary significantly from the market value of Horizon common stock on the date of this proxy statement/prospectus or the date of the Horizon Special Meeting. Because the exchange ratio will not be adjusted, such market price fluctuations may affect the value that Horizon stockholders receive at the effective time. Horizon's share price may change as a result of many factors, including changes in the business, operations or prospects of Horizon or Vidara, market assessment of the likelihood that the transaction will be completed, the timing of the transactions and general market and economic conditions. Vidara's shares are held by one shareholder and do not have an established market price. Horizon stockholders are urged to obtain current market quotations for Horizon common stock.

Failure to consummate the Merger could negatively impact the stock price and the future business and financial results of Horizon.

If the Merger is not consummated, the ongoing business of Horizon may be adversely affected and, without realizing any of the benefits of having consummated the Merger, Horizon will be subject to a number of risks, including the following:

Horizon may be required to reimburse Vidara for certain expenses incurred by Vidara in connection with certain governmental filings, as described in the Merger Agreement and summarized under the caption

Transaction Agreement and Plan of Merger Expenses and Termination Fees ;

if the Merger Agreement is terminated under specified circumstances, Horizon may be required to pay to Vidara Holdings a termination fee equal to \$23 million;

if the Merger is not consummated because the Horizon stockholders do not approve the Merger, Horizon will be obligated to pay Vidara Holdings \$13.5 million for expenses;

Table of Contents

if the Merger is not consummated because Horizon is not able to complete the Merger after the conditions to closing are satisfied and Vidara Holdings is ready, willing and able to close the Merger, then Horizon will be obligated to pay Vidara Holdings \$44 million as a termination fee;

Horizon will be required to pay certain costs relating to the proposed reorganization and Merger, including legal, accounting, filing and possible other fees and mailing, financial printing and other expenses in connection with the transaction whether or not the Merger is consummated;

the current prices of Horizon common stock may reflect a market assumption that the Merger will occur, meaning that a failure to complete the Merger could result in a decline in the price of Horizon common stock; and

matters relating to the reorganization and Merger (including integration planning) have required and will continue to require substantial commitments of time and resources by Horizon management, which could otherwise have been devoted to other opportunities that may have been beneficial to Horizon.

Horizon also could be subject to litigation related to any failure to consummate the Merger or to perform its obligations under the Merger Agreement, or related to any enforcement proceeding commenced against Horizon. If the Merger is not consummated, these risks may materialize and may adversely affect Horizon's business, financial results and stock price.

The combination of the businesses currently conducted by Horizon and Vidara will create numerous risks and uncertainties, which could adversely affect New Horizon's operating results or prevent New Horizon from realizing the expected benefits of the Merger.

Strategic transactions like the Merger create numerous uncertainties and risks and require significant efforts and expenditures. Horizon will transition from a standalone public Delaware corporation to being part of a combined company organized in Ireland. This combination will entail many changes, including the integration of Vidara and its personnel with those of Horizon, and changes in systems. These transition activities are complex, and New Horizon may encounter unexpected difficulties or incur unexpected costs, including:

the diversion of New Horizon management's attention to integration of operations and corporate and administrative infrastructures;

difficulties in achieving growth prospects from combining the business of Vidara with that of Horizon;

difficulties in the integration of operations and systems;

difficulties in the assimilation of employees and corporate cultures;

challenges in keeping existing customers and obtaining new customers; and

challenges in attracting and retaining key personnel.

If any of these factors impair New Horizon's ability to integrate the operations of Horizon with those of Vidara successfully or on a timely basis, New Horizon may not be able to realize the business opportunities, growth prospects and anticipated tax synergies from combining the businesses. In addition, New Horizon may be required to spend additional time or money on integration that otherwise would be spent on the development and expansion of its business.

In addition, the market price of New Horizon ordinary shares may decline following the business combination if the integration of Horizon and Vidara is unsuccessful, takes longer than expected or fails to achieve financial benefits to the extent anticipated by financial analysts or investors, or the effect of the business combination on the financial results of the combined company is otherwise not consistent with the expectations of financial analysts or investors.

Table of Contents

Horizon's and Vidara's respective business relationships, including customer relationships, may be subject to disruption due to uncertainty associated with the Merger.

Parties with which Horizon and Vidara currently do business or may do business in the future, including customers and suppliers, may experience uncertainty associated with the Merger, including with respect to current or future business relationships with Horizon, Vidara or New Horizon. As a result, Horizon's and Vidara's business relationships may be subject to disruptions if customers, suppliers and others attempt to negotiate changes in existing business relationships or consider entering into business relationships with parties other than Horizon or Vidara. These disruptions could have an adverse effect on the business, financial condition, results of operations or prospects of New Horizon following the closing. The adverse effect of such disruptions could be exacerbated by a delay in the consummation of the Merger or termination of the Merger Agreement.

Loss of key personnel could impair the integration of the two businesses, lead to loss of customers and a decline in revenues, adversely affect the progress of pipeline products or otherwise adversely affect the operations of Horizon, Vidara and New Horizon.

The success of New Horizon after the completion of the Merger will depend, in part, upon its ability to retain key employees, especially during the integration phase of the two businesses. Although Vidara has put in place twelve month retention agreements for certain of its employees, current and prospective employees of Vidara might experience uncertainty about their future roles with New Horizon following completion of the Merger, which might adversely affect New Horizon's ability to retain key managers and other employees. In addition, competition for qualified personnel in the biotechnology industry is very intense. If Horizon or Vidara lose key personnel or New Horizon is unable to attract, retain and motivate qualified individuals or the associated costs to New Horizon increase significantly, New Horizon's business could be adversely affected.

Obtaining required approvals necessary to satisfy the conditions to the completion of the Merger may delay or prevent completion of the Merger, result in additional expenditures of money and resources and/or reduce the anticipated benefits of the Merger.

The Merger is subject to customary closing conditions. These closing conditions include, among others, the receipt of the requisite approval of Horizon's stockholders, the effectiveness of the registration statement of which this proxy statement/prospectus is a part, the consummation of the reorganization and the expiration or termination of the waiting period under the HSR Act (early termination of the waiting period under the HSR Act was granted effective April 11, 2014).

The governmental agencies from which the parties will seek certain of these approvals have broad discretion in administering the governing regulations. As a condition to their approval, agencies may impose requirements, limitations or costs or require divestitures or place restrictions on the conduct of New Horizon's business after the closing. These requirements, limitations, costs, divestitures or restrictions could jeopardize or delay the consummation of the Merger or may reduce the anticipated benefits of the Merger. Further, no assurance can be given that the required stockholder approval will be obtained or that the required closing conditions will be satisfied, and, if all required consents and approvals are obtained and the closing conditions are satisfied, no assurance can be given as to the terms, conditions and timing of the approvals. If Horizon and Vidara agree to any material requirements, limitations, costs or restrictions in order to obtain any approvals required to consummate the reorganization and the Merger, these requirements, limitations, costs or restrictions could adversely affect the anticipated benefits of the Merger. This could result in a failure to consummate these transactions or have a material adverse effect on New Horizon's business and results of operations. Please see *Transaction Agreement and Plan of Merger Conditions to the Completion of the Merger* beginning on page 106, for a discussion of the conditions to the completion of the Merger,

and *The Reorganization and the Merger Regulatory Approvals Required* beginning on page 71.

22.

Table of Contents

Horizon may waive one or more of the conditions to the Merger without resoliciting stockholder approval.

If the Horizon stockholders approve the Merger, Horizon may determine to waive, in whole or in part, one or more of the other conditions to its obligations to complete the Merger, to the extent permitted by applicable laws. Horizon will evaluate the materiality of any such waiver and its effect on Horizon stockholders in light of the facts and circumstances at the time to determine whether any amendment of this proxy statement/prospectus and resolicitation of proxies is required or warranted. In some cases, if the Horizon board of directors determines that such a waiver is warranted but that such waiver or its effect on Horizon stockholders is not sufficiently material to warrant resolicitation of proxies, Horizon has the discretion to complete the Merger without seeking further stockholder approval. Any determination whether to waive any condition to the Merger or as to resoliciting stockholder approval or amending this proxy statement/prospectus as a result of a waiver will be made by Horizon at the time of such waiver based on the facts and circumstances as they exist at that time.

Horizon's directors and executive officers have interests in the Merger in addition to those of stockholders.

In considering the recommendations of the Horizon board of directors with respect to the Merger Agreement, you should be aware that some of Horizon's directors and executive officers have financial and other interests in the proposed transactions in addition to interests they might have as stockholders. Please see *The Reorganization and the Merger Interests of Certain Persons in the Merger*. In particular, members of the Horizon board of directors and executive officers will become directors and executive officers of New Horizon and are party to certain compensatory arrangements in connection with the Merger. You should consider these interests in connection with your vote on the related proposal. See *Stockholder Advisory Vote on Certain Compensatory Arrangements*.

As a result of the Merger, New Horizon will incur additional direct and indirect costs.

New Horizon will incur additional costs and expenses in connection with and as a result of the Merger. These costs and expenses include professional fees to comply with Irish corporate and tax laws and financial reporting requirements, costs and expenses incurred in connection with holding a majority of the meetings of the New Horizon board of directors and certain executive management meetings in Ireland, as well as any additional costs New Horizon may incur going forward as a result of its new corporate structure. There can be no assurance that these costs will not exceed the costs historically borne by Horizon and Vidara.

If goodwill or other intangible assets that New Horizon records in connection with the Merger become impaired, New Horizon could have to take significant charges against earnings.

In connection with the accounting for the Merger, it is expected that New Horizon will record a significant amount of intangible assets and may also record goodwill. Under U.S. GAAP, New Horizon must assess, at least annually and potentially more frequently, whether the value of goodwill and other indefinite-lived intangible assets has been impaired. Amortizing intangible assets will be assessed for impairment in the event of an impairment indicator. Any reduction or impairment of the value of goodwill or other intangible assets will result in a charge against earnings, which could materially adversely affect New Horizon's results of operations and shareholders' equity in future periods.

Existing Horizon stockholders will own a smaller share of New Horizon following completion of the Merger.

Following completion of the Merger, Horizon stockholders will own the same number of shares of New Horizon that they owned in Horizon immediately before the closing. Each New Horizon ordinary share, however, will represent a smaller ownership percentage of a significantly larger company. Horizon security holders, who currently own 100% of the Horizon capital stock, will, immediately following the Merger, own approximately 74% of New Horizon on a

fully diluted basis, and Vidara Holdings, the sole historical shareholder of Vidara, will own the remaining approximately 26%. See *The Reorganization and the Merger* *The Reorganization of Vidara*.

Table of Contents**Risks Related to the Business of New Horizon**

Vidara's business has been entirely reliant upon the successful marketing and sale of ACTIMMUNE and there can be no assurance that New Horizon will be able to continue to grow or maintain sales of ACTIMMUNE.

Vidara's only commercial product and source of revenue is ACTIMMUNE® (interferon gamma-1b), an injectable biologic drug prescribed for the management of two rare disorders: (i) *chronic granulomatous disease* (CGD) and (ii) *severe, malignant osteopetrosis* (SMO). Since its acquisition of the ACTIMMUNE product line in June 2012, Vidara has been successful in growing sales and profitability of ACTIMMUNE. However, there are a number of risks related to the ACTIMMUNE product line and there can be no assurance that we will be able to continue to grow or maintain sales of ACTIMMUNE or its profitability.

First, part of the reason for the success of ACTIMMUNE is that it presently faces little competition. ACTIMMUNE is the only drug currently approved by the FDA specifically for the treatment for CGD and SMO. While there are additional or alternative approaches used to treat patients with CGD and SMO, there are currently no products on the market that compete directly with ACTIMMUNE. The current clinical standard of care to treat CGD patients in the United States is the use of concomitant triple prophylactic therapy comprising ACTIMMUNE, an oral antibiotic agent and an oral antifungal agent. However, the FDA-approved labeling for ACTIMMUNE does not discuss this triple prophylactic therapy, and physicians may choose to prescribe one or both of the other modalities in the absence of ACTIMMUNE. Because of the immediate and life-threatening nature of SMO, the preferred treatment option for SMO is often to have the patient undergo a bone marrow transplant which, if successful, will likely obviate the need for further use of ACTIMMUNE in that patient. Vidara is aware of a number of research programs investigating the potential of gene therapy as a possible cure for CGD. Additionally, other companies may be pursuing the development of products and treatments that target the same diseases and conditions which ACTIMMUNE is currently approved to treat. As a result, it is possible that New Horizon's competitors may develop new drugs that manage CGD or SMO more effectively, cost less or possibly even cure CGD or SMO. The development and commercialization of any competing drugs or the discovery of any new alternative treatment for CGD or SMO could have a material adverse effect on sales of ACTIMMUNE and its profitability.

Second, the number of people afflicted with CGD or SMO is relatively small and Vidara's commercial rights to ACTIMMUNE are currently limited to the United States, Canada and Japan and Vidara currently only markets ACTIMMUNE in the United States. Based on Vidara's market research, Vidara estimates that there are currently between 900 and 1,600 patients with CGD, and between 85 and 215 patients with SMO living in the United States. As a result, if a competing drug were developed and commercialized or a new alternative treatment for CGD or SMO were discovered, the decision by a relatively small number of doctors to prescribe or recommend the competing drug or alternative treatment to manage or treat CGD or SMO would most likely have a significant impact on the market share of ACTIMMUNE. Likewise, the development of any drug or the discovery of an alternative treatment that cures patients of CDG or SMO would significantly reduce the size of the end market for ACTIMMUNE, unless New Horizon is successful in expanding the number of indications for which ACTIMMUNE is approved by the FDA, and there can be no assurance in this regard. Because the indications for which ACTIMMUNE is presently approved (i.e., CGD and SMO) are relatively rare, the size of the end-market for ACTIMMUNE and the volume of product sales of ACTIMMUNE are also relatively small. As a result, in order for ACTIMMUNE to be profitable, the prices that Vidara has historically had to charge for ACTIMMUNE have been relatively high and sales have been significantly dependent on the availability of coverage and adequate reimbursement for ACTIMMUNE from third party payers, including government payers, such as Medicare and Medicaid, and private health insurers. If New Horizon is unable to expand or maintain the sales volume of ACTIMMUNE at adequate pricing levels, the profitability of ACTIMMUNE could be adversely affected which could have a material adverse effect on the results of operations, financial condition and business in general of New Horizon. Under the terms of the Merger Agreement, New Horizon

has agreed not to raise the price of ACTIMMUNE until at least December 31, 2014.

24.

Table of Contents

Third, U.S. healthcare legislation passed in March 2010 authorized the FDA to approve biological products, known as biosimilars, that are similar to or interchangeable with previously approved biological products based upon potentially abbreviated data packages. If a biosimilar version of ACTIMMUNE were approved, it could reduce New Horizon's sales of ACTIMMUNE. Biosimilars are likely to be sold at substantially lower prices than branded products because the biosimilar manufacturer would not have to recoup the research and development and marketing costs associated with the branded product. Accordingly, the introduction of biosimilar versions of ACTIMMUNE likely would significantly reduce both the price that New Horizon receives for ACTIMMUNE and the volume that New Horizon sells, which may have an adverse impact on our results of operations.

Fourth, successfully marketing and promoting products such as ACTIMMUNE is a complex and uncertain process dependent on the efforts of management, sales and marketing personnel, manufacturers, distributors and outside consultants. New Horizon's ability to increase or maintain sales of ACTIMMUNE will depend upon a number of factors, including, but not limited to:

the continued safety and efficacy of ACTIMMUNE and the potential or perceived advantages or disadvantages of ACTIMMUNE over alternative treatments, including the cost of treatment, the relative convenience and ease of administration and the prevalence and severity of side effects;

the introduction of competing drugs or treatments and the quality, safety, efficacy, cost and market acceptance of any such competing drugs or treatments;

the percentage of the population afflicted with CDG and/or SMO or any other indications for which ACTIMMUNE may receive FDA approval;

the strength of sales, marketing and distribution support and the ability to maintain or enhance brand awareness for ACTIMMUNE;

acceptance of ACTIMMUNE by healthcare practitioners, especially those who specialize in fields such as pediatric immunology, allergy, infectious diseases and hematology/oncology, and by patients;

the performance of third party manufacturers and distributors of ACTIMMUNE, over which New Horizon will have limited control;

the availability of coverage and adequate pricing and reimbursement for ACTIMMUNE from third party payers, including government payers, such as Medicare and Medicaid, and private health insurers;

the effect of current and future healthcare laws and regulations;

the impact of past and future price increases for ACTIMMUNE;

product labeling or product insert requirements of the FDA or other regulatory authorities with respect to ACTIMMUNE; and

critical reviews and other publicity relating to ACTIMMUNE.

Any of the factors described above could have a significant impact on New Horizon's ability to grow or maintain sales and profitability of ACTIMMUNE and any failure to do so could have a material adverse effect on our results of operations, financial condition and the market price of New Horizon ordinary shares.

Vidara relies, and New Horizon intends to rely, on third parties to manufacture, package, and distribute ACTIMMUNE.

Vidara does not have its own manufacturing, packaging or distribution capability for ACTIMMUNE and, as a result, it has relied upon, and New Horizon will continue to rely upon, third parties for these critical functions. Vidara has an exclusive supply agreement with Boehringer Ingelheim for the manufacture of ACTIMMUNE,

Table of Contents

which has a term that runs until July 31, 2020. Under this supply agreement, either Vidara or Boehringer Ingelheim may terminate the agreement for an uncured material breach by the other party or upon the other party's bankruptcy or insolvency.

The manufacture of biopharmaceutical products, such as ACTIMMUNE, is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Drug manufacturers, like Boehringer Ingelheim, and their facilities must comply with strict regulatory requirements, including the FDA's current good manufacturing practice (cGMP) regulations and guidelines, and are subject to frequent inspection. If ACTIMMUNE's manufacturer fails to comply with any of these regulatory requirements, its facilities could be shut down until the FDA or other regulatory authorities are satisfied that the facilities and manufacturing and packaging processes are in compliance, which could cause a significant delay or halt in the supply of ACTIMMUNE. In addition, failure or difficulties faced at any level of our supply chain could materially adversely affect New Horizon's business and delay or impede the development and commercialization of ACTIMMUNE and could have a material adverse effect on its business, results of operations, financial condition, and prospects.

Manufacturers of biopharmaceutical products often encounter difficulties in production. These problems include difficulties with quality control, including stability of the product, quality assurance testing, operator error and shortages of qualified personnel. Furthermore, if microbial, viral or other contaminations are discovered in the drug products or in the manufacturing facilities in which its products are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination and the contract manufacturer or Vidara (or, following the Merger, New Horizon) may face regulatory action, including warning letters and recalls. New Horizon cannot assure you that any stability or other issues relating to the manufacture of ACTIMMUNE will not occur in the future. ACTIMMUNE's manufacturer may also experience manufacturing difficulties due to resource constraints or as a result of labor disputes. If ACTIMMUNE's manufacturer were to encounter any of these difficulties, or otherwise fail to comply with its contractual obligations to supply New Horizon with the quantity of ACTIMMUNE that it requires, New Horizon's business will be materially adversely effected. Additionally, Boehringer Ingelheim manufactures interferon gamma 1-b to supply its own commercial needs in its licensed territory, and this may lead to capacity allocation issues and supply constraints to New Horizon. Furthermore, Vidara does not have a substitute supplier for ACTIMMUNE and the process of identifying a substitute supplier and getting that supplier approved by the applicable regulatory authorities for manufacture and packaging of ACTIMMUNE can be a lengthy and costly process.

ACTIMMUNE is manufactured by starting with cells from working cell bank samples which are derived from a master cell bank. Each of Vidara and Boehringer Ingelheim separately store multiple vials of the master cell bank. In the event of catastrophic loss at Vidara's or Boehringer Ingelheim's storage facility, it is possible that New Horizon could lose multiple cell banks and have the manufacturing capacity of ACTIMMUNE severely impacted by the need to substitute or replace the cell banks.

New Horizon's business plan is highly dependent upon its ability to successfully execute on its sales and marketing strategy for the further growth in sales of ACTIMMUNE.

Since its acquisition of the ACTIMMUNE product line in June 2012, Vidara has focused on building a marketing platform to support the growth of ACTIMMUNE sales. While Vidara's sales force has achieved success in growing sales of ACTIMMUNE, New Horizon may be required to further expand the ACTIMMUNE sales force to continue to grow sales of ACTIMMUNE in the future. New Horizon does not currently intend to use the existing Horizon sales force to support the sale of ACTIMMUNE, so any such expansion of the ACTIMMUNE sales force will require the hiring of additional experienced personnel. There can be no assurance that New Horizon will be able to attract and retain qualified personnel to support the sale of ACTIMMUNE and any failure on its part to do so could have a

material adverse effect on New Horizon's ability to grow or maintain sales of ACTIMMUNE.

26.

Table of Contents

Biologic drugs, such as ACTIMMUNE, are subject to extensive regulation and failure to comply with FDA or other regulatory authority requirements may subject New Horizon to administrative or judicial sanctions.

The manufacturing, labeling, packaging, storage, recordkeeping, advertising, promotion, export, import, marketing and distribution and other possible activities relating to a biologic drug, such as ACTIMMUNE, are subject to extensive regulation by the FDA in the United States and other regulatory agencies in foreign jurisdictions. Failure to comply with the applicable U.S. requirements at any time during the product development or approval process, or after approval, may subject New Horizon to administrative or judicial sanctions, including refusal to approve an application, withdrawal of an approval, imposition of a clinical hold, warning or untitled letters, product seizures or recalls, total or partial suspension of production or distribution, and injunctions, fines, disgorgements, or civil or criminal penalties or prosecution.

In addition, if ACTIMMUNE causes serious or unexpected side effects, FDA or other regulatory authorities may require the addition of labeling statements, such as black box warnings or contraindications, or limitations on the indications for use, withdraw their approval of ACTIMMUNE or place restrictions on the way it is prescribed or distributed, deny regulatory approval for any future indication for ACTIMMUNE, require us to conduct additional clinical trials or to change the labeling of ACTIMMUNE, or implement a risk evaluation and mitigation strategy (REMS).

Biologic drugs may not be marketed in the United States prior to submission of a Biologics License Application (BLA) and approval by the FDA. Once a BLA is approved for a product, such as ACTIMMUNE, that product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of biologic drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. Biologic drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. In the event New Horizon is unable to continue to comply with current and future FDA regulations and standards, it may be forced to delay or discontinue the manufacture and/or sale of ACTIMMUNE.

ACTIMMUNE is currently marketed only in the United States. To market any biologic drugs outside of the United States, New Horizon and current or future collaborators must comply with numerous and varying regulatory and compliance related requirements of other countries. Approval procedures vary among countries and can involve additional product testing and additional administrative review periods, including obtaining reimbursement and pricing approval in select markets. The time required to obtain approval in other countries might differ from that required to obtain FDA approval. The regulatory approval process in other countries may include all of the risks associated with FDA approval as well as additional, presently unanticipated, risks. Regulatory approval in one country does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country may negatively impact the regulatory process in others, including the risk that our product candidates may not be approved for all indications requested and that such approval may be subject to limitations on the indicated uses for which the drug may be marketed. Certain countries have a difficult reimbursement environment and we may not obtain reimbursement or pricing approval for ACTIMMUNE, if required, in all countries where New Horizon seeks to market ACTIMMUNE, or New Horizon may obtain reimbursement approval at a level that would make marketing ACTIMMUNE in certain countries not viable.

If New Horizon fails to comply with its obligations in its intellectual property licenses with third parties, New Horizon could lose license rights that are important to its business.

Vidara is party to various license agreements and New Horizon may enter into additional license agreements in the future. For example, Vidara licenses rights to patents, know-how and trademarks for ACTIMMUNE from Genentech,

which agreement remains in effect for so long as Vidara continues to commercialize and sell ACTIMMUNE. However, Genentech may terminate the agreement upon Vidara's material default, if not cured within a specified period of time. Genentech may also terminate the agreement in the event of Vidara's

Table of Contents

bankruptcy or insolvency. Upon such a termination of the agreement, all intellectual property rights conveyed to Vidara under the agreement, including the rights to the ACTIMMUNE trademark, revert to Genentech.

In addition, New Horizon could have disputes with its current and future licensors regarding, for example, the interpretation of terms in its agreements. Any such disagreements could lead to curtailment or loss of rights or could result in time-consuming and expensive litigation or arbitration, which may not be resolved in New Horizon's favor.

If New Horizon fails to comply with its obligations under these agreements, New Horizon could lose the ability to market and distribute ACTIMMUNE, which would have a material adverse effect on the business, financial condition or results of operations of New Horizon.

If New Horizon is unable to obtain and maintain protection for the intellectual property relating to its technology and products, the value of its technology and products will be adversely affected.

New Horizon's success depends in large part on its ability to obtain and maintain protection in the United States and other countries for the intellectual property covering or incorporated into its technology and products. The patent situation in the field of biotechnology and pharmaceuticals is highly uncertain and involves complex legal and scientific questions. New Horizon may not be able to obtain additional issued patents relating to its technology or products. Even if issued, patents may be challenged, narrowed, invalidated or circumvented, which could limit New Horizon's ability to stop competitors from marketing similar products or limit the length or term of patent protection New Horizon may have for its products. The composition of matter and methods of manufacturing patents relating to ACTIMMUNE expire between 2014 and 2022. Changes in either patent laws or in the interpretations of patent laws in the United States or other countries may diminish the value of New Horizon's intellectual property or narrow the scope of its patent protection. For example, The Patient Protection and Affordable Care Act allows applicants seeking approval of biosimilar or interchangeable versions of biological products such as ACTIMMUNE to initiate a process for challenging some or all of the patents covering the innovator biological product used as the reference product. This process is complicated and could result in the limitation or loss of certain patent rights. In addition, such patent litigation is costly and time-consuming and may adversely affect New Horizon's overall financial condition and liquidity.

If New Horizon is unable to protect the confidentiality of its proprietary information and know-how, the value of its technology and products could be adversely affected.

In addition to patented technology, Vidara relies upon unpatented proprietary technology, processes and know-how. Vidara seeks to protect this information in part through confidentiality agreements with its employees, consultants and third parties. If any of these agreements are breached, New Horizon may not have adequate remedies for any such breach. In addition, any remedies New Horizon may seek may prove costly. Furthermore, New Horizon's trade secrets may otherwise become known or be independently developed by competitors. If New Horizon is unable to protect the confidentiality of its proprietary information and know-how, competitors may be able to use this information to develop products that compete with New Horizon's products, which could adversely affect New Horizon's business.

Vidara is exposed to concentration of credit risk relating to its major customers.

At March 31, 2014, Vidara's five main specialty pharmacies and wholesale pharmaceutical distributors, including Accredo Health Group Inc., CuraScript Specialty Distribution, Walgreens, Caremark LLC and McKesson Corporation, accounted for over 85% of its sales. Due to this concentration of sales, the credit risk associated with these customers is of particular significance to us. If one or several of these customers fails to fulfill its payment obligations or reduces their business with us, there may be a material adverse effect on our business, financial

condition or results of operations.

28.

Table of Contents***The IRS may not agree with the conclusion that New Horizon should be treated as a foreign corporation for U.S. federal income tax purposes following the transaction.***

Although New Horizon will be incorporated in Ireland, the U.S. Internal Revenue Service, referred to as the IRS in this proxy statement/prospectus, may assert that it should be treated as a U.S. corporation (and, therefore, a U.S. tax resident) for U.S. federal income tax purposes pursuant to Section 7874 of the Internal Revenue Code of 1986, as amended (the Code). A corporation is generally considered a tax resident in the jurisdiction of its organization or incorporation for U.S. federal income tax purposes. Because New Horizon is an Irish incorporated entity, it would generally be classified as a foreign corporation (and, therefore, a non-U.S. tax resident) under these rules. Section 7874 provides an exception pursuant to which a foreign incorporated entity may, in certain circumstances, be treated as a U.S. corporation for U.S. federal income tax purposes.

Under Section 7874, New Horizon would be treated as a foreign corporation for U.S. federal income tax purposes if the former shareholders of Horizon own (within the meaning of Section 7874) less than 80% (by both vote and value) of New Horizon stock by reason of holding shares in Horizon (the ownership test). The Horizon shareholders are expected to own less than 80% (by both vote and value) of the shares in New Horizon after the merger by reason of their ownership of shares of Horizon common stock. As a result, under current law, New Horizon is expected to be treated as a foreign corporation for U.S. federal income tax purposes. However, there can be no assurance that there will not exist in the future a subsequent change in the facts or in law which might cause New Horizon to be treated as a domestic corporation for U.S. federal income tax purposes, including with retroactive effect.

Further, there can be no assurance that the IRS will agree with the position that the ownership test is satisfied. There is limited guidance regarding the application of Section 7874 of the Code, including with respect to the provisions regarding the application of the ownership test.

See *Certain Tax Consequences of the Merger Tax Consequences of the Merger to Horizon and New Horizon U.S. Federal Tax Classification of New Horizon as a Result of the Merger* beginning on page 74 of this proxy statement/prospectus for a more detailed discussion of the application of Section 7874 of the Code to the transaction.

Section 7874 of the Code likely will limit Horizon's and its U.S. affiliates' ability to utilize their U.S. tax attributes to offset certain U.S. taxable income, if any, generated by the merger and ancillary transactions for a period of time following the merger.

Following certain acquisitions of a U.S. corporation by a foreign corporation, Section 7874 of the Code limits the ability of the acquired U.S. corporation and its U.S. affiliates to utilize U.S. tax attributes such as net operating losses to offset U.S. taxable income resulting from certain transactions as more fully described in *Certain Tax Consequences of the Merger Tax Consequences of the Merger to Horizon and New Horizon Potential Limitation on the Utilization of Horizon's (and Its Domestic Affiliates') Tax Attributes*. Based on the limited guidance available, it is currently expected that this limitation should apply following the Merger. As a result, it is not currently expected that Horizon or its U.S. affiliates will be able to utilize their U.S. tax attributes to offset their U.S. taxable income, if any, resulting from certain taxable transactions following the merger. Please see *Certain Tax Consequences of the Merger Tax Consequences of the Merger to Horizon and New Horizon Potential Limitation on the Utilization of Horizon's (and Its Domestic Affiliates') Tax Attributes*. Notwithstanding this limitation, it is expected that Horizon will be able to fully utilize its U.S. net operating losses prior to their expiration. As a result of this limitation, however, it may take Horizon longer to use its net operating losses. Moreover, contrary to these expectations, it is possible that the limitation under Section 7874 of the Code on the utilization of U.S. tax attributes could prevent Horizon from fully utilizing its U.S. tax attributes prior to their expiration if Horizon does not generate taxable income consistent with its expectations.

Table of Contents***Future changes to U.S. and non-U.S. tax laws could materially adversely affect New Horizon.***

Under current law, New Horizon is expected to be treated as a foreign corporation for U.S. federal income tax purposes. However, changes to the rules in Section 7874 of the Code or regulations promulgated thereunder or other guidance issued by the Treasury or the IRS could adversely affect New Horizon's status as a foreign corporation for U.S. federal income tax purposes, and any such changes could have prospective or retroactive application to New Horizon, Horizon, their respective shareholders and affiliates, and/or the transaction. On May 20, 2014 Senator Carl Levin and Representative Sander M. Levin introduced The Stop Corporate Inversions Act of 2014 (the "bill") in the Senate and House of Representatives, respectively. In its current form, the bill would treat New Horizon as a U.S. Corporation if the former shareholders of Horizon own 50% or more of New Horizon stock under the ownership test. If enacted, the bill would apply to taxable years ending after May 8, 2014 and does not contain an exception for transactions subject to a binding commitment on that date. Because the Horizon shareholders are expected to own more than 50% of the shares in New Horizon after the Merger, New Horizon would be treated as a U.S. corporation if the bill becomes law.

In addition, the U.S. Congress, the Organization for Economic Co-operation and Development, and other Government agencies in jurisdictions where New Horizon and its affiliates do business have had an extended focus on issues related to the taxation of multinational corporations and there are several current legislative proposals that, if enacted, would substantially change the U.S. federal income tax system as it relates to the taxation of multinational corporations. One example is in the area of base erosion and profit shifting, where payments are made between affiliates from a jurisdiction with high tax rates to a jurisdiction with lower tax rates. As a result, the tax laws in the United States and other countries in which New Horizon and its affiliates do business could change on a prospective or retroactive basis, and any such changes could materially and adversely affect New Horizon.

Vidara is currently not subject to the compliance obligations of the Sarbanes-Oxley Act of 2002 and New Horizon may not be able to timely and effectively implement controls and procedures over Vidara's operations as required under the Sarbanes-Oxley Act of 2002.

Vidara is currently not subject to the information and reporting requirements of the Exchange Act or other U.S. or Irish securities laws, or the compliance obligations of the Sarbanes-Oxley Act of 2002. Subsequent to the completion of the transactions, New Horizon will need to timely and effectively implement the internal controls over financial reporting and other disclosure controls and procedures necessary to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, which requires, among other things, annual management assessments of the effectiveness of internal controls over financial reporting and a report by our independent registered public accounting firm addressing these assessments. New Horizon intends to take appropriate measures to establish or implement an internal control environment at Vidara aimed at successfully adopting the requirements of Section 404 of the Sarbanes-Oxley Act of 2002. However, it is possible that New Horizon may experience delays in implementing or be unable to implement the required internal controls over financial reporting and other disclosure controls and procedures, which could result in enforcement actions, the assessment of penalties and civil suits, failure to meet reporting obligations and other material and adverse events that could have a negative effect on the market price for New Horizon ordinary shares.

Risks Related to the Financial Condition of New Horizon***Growing the business of New Horizon will require the commitment of substantial capital and other resources, which may not be available, and which in turn, could result in future losses or otherwise limit the opportunities of New Horizon.***

Growing the New Horizon business over the longer-term will require us to commit substantial capital and other resources towards in-licensing and/or acquiring new products and product candidates, or towards costly and time-consuming product development and clinical trials of New Horizon product candidates. It will also require

Table of Contents

continued investment in the commercial operations of New Horizon. New Horizon's future capital requirements will depend on many factors, including many of those discussed above, such as:

the revenues from New Horizon commercial products and the costs of New Horizon's commercial operations;

the extent of generic competition for New Horizon products;

the cost of acquiring and/or licensing new products and product candidates;

the cost of debt and required debt service on debt incurred to finance the combination with Vidara and any new product acquisitions;

the scope, rate of progress, results and costs of New Horizon's potential development and clinical activities;

the cost and timing of obtaining regulatory approvals and of compliance with laws and regulations;

the cost of preparing, filing, prosecuting, defending and enforcing patent claims and other intellectual property rights;

the cost of investigations, litigation and/or settlements related to regulatory activities and third-party claims; and

changes in laws and regulations, including, for example, healthcare reform legislation.

One of New Horizon's goals will be to expand the business through the licensing, acquisition and/or development of additional products and product candidates. There can be no assurance that debt or equity financing will be available on reasonable terms, or at all, or that New Horizon's cash flow from operations will be sufficient to fund these activities if opportunities arise. If capital is not available, New Horizon may be unable to expand the business if it does not have sufficient capital or cannot borrow or raise additional capital on attractive terms.

Servicing Horizon's debt requires a significant amount of cash, and New Horizon may not have sufficient cash flow from its business to pay its substantial debt.

In connection with this transaction, Horizon will incur senior secured debt in the aggregate principal amount of approximately \$300.0 million and will be required to make principal and interest payments in accordance with the terms of the credit agreement entered into between Horizon and the lenders providing such senior secured debt financing. In November 2013, Horizon issued 5.00% Convertible Senior Notes due 2018 in the aggregate principal amount of \$150.0 million (the 5.00% Convertible Senior Notes) to investors pursuant to note purchase agreements

with such investors. As of July 23, 2014, all \$150.0 million of principal on the 5.00% Convertible Senior Notes remained outstanding. New Horizon's ability to make scheduled payments of the principal of, to pay interest on or to refinance its indebtedness, including the new senior secured debt and the 5.00% Convertible Senior Notes, depends on New Horizon's future performance, which is subject to economic, financial, competitive and other factors beyond its control. New Horizon's business may not continue to generate cash flow from operations in the future sufficient to service New Horizon's debt and make necessary capital expenditures. If New Horizon is unable to generate such cash flow, New Horizon may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. New Horizon's ability to refinance its indebtedness will depend on the capital markets and its financial condition at such time. New Horizon may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on New Horizon's debt obligations.

New Horizon may not be able to successfully maintain its low tax rates, which could adversely affect its business and financial condition, results of operations and growth prospects.

New Horizon will be incorporated in Ireland and will maintain subsidiaries in the United States, Ireland, Luxembourg, Switzerland, Germany and Bermuda. Vidara was able to achieve a low blended tax rate through the

Table of Contents

performance of certain functions and ownership of certain assets in tax-efficient jurisdictions, including Bermuda and Ireland, together with intra-group service and transfer pricing agreements, each on an arm's length basis. New Horizon intends to continue a similar structure and arrangements following the completion of the transaction. Taxing authorities, such as the IRS, actively audit and otherwise challenge these types of arrangements, and have done so in the pharmaceutical industry. The IRS may challenge the New Horizon structure and transfer pricing arrangements through an audit or lawsuit. Responding to or defending such a challenge could be expensive and consume time and other resources, and divert management's time and focus from operating the New Horizon business. New Horizon cannot predict whether taxing authorities will conduct an audit or file a lawsuit challenging this structure, the cost involved in responding to any such audit or lawsuit, or the outcome. If New Horizon is unsuccessful, it may be required to pay taxes for prior periods, interest, fines or penalties, and may be obligated to pay increased taxes in the future, any of which could require New Horizon to reduce its operating expenses, decrease efforts in support of its products or seek to raise additional funds, all of which could have a material adverse effect on the New Horizon business, financial condition, results of operations and growth prospects.

New Horizon's actual financial position and results of operations may differ materially from the unaudited pro forma financial data included in this proxy statement/prospectus.

The pro forma financial data contained in this proxy statement/prospectus are presented for illustrative purposes only and may not be an indication of what New Horizon's financial condition or results of operations would have been had the Merger been completed on the dates indicated. The pro forma financial data have been derived from the audited historical financial statements of Horizon and the Vidara Group, and certain adjustments and assumptions have been made regarding the combined company after giving effect to the Merger. Furthermore, the parties expect to have additional, currently unforeseen expenses relating to effecting the merger and combining the companies' operations. The pro forma financial data do not reflect these potential expenses and efficiencies. Accordingly, the actual financial condition and results of operations of the combined company following the Merger may not be consistent with, or evident from, the pro forma financial data.

In addition, the assumptions used in preparing the pro forma financial information may not prove to be accurate, and other factors may affect New Horizon's financial condition or results of operations following the merger. Any potential decline in New Horizon's financial condition or results of operations may cause significant variations in the share price of New Horizon. See *Unaudited Pro Forma Financial Data*.

Risks Related to the New Horizon Ordinary Shares

The market price of New Horizon ordinary shares may be volatile, and the value of your investment could decline significantly.

Investors who hold New Horizon ordinary shares may not be able to sell their shares at or above the price at which they purchased the shares of Horizon common stock. The price of Horizon common stock has fluctuated significantly from time to time, and New Horizon cannot predict the price of its ordinary shares. The risk factors described in this proxy statement/prospectus and incorporated by reference from Horizon's Annual Report on Form 10-K for the year-ended December 31, 2013 and Horizon's Quarterly Report on Form 10-Q for the quarter ended March 31, 2014 could cause the price of New Horizon ordinary shares to fluctuate significantly. In addition, the stock market in general, including the market for life sciences companies, has experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of those companies. These broad market and industry factors may seriously harm the market price of New Horizon ordinary shares, regardless of New Horizon's operating performance. In addition, the New Horizon stock price may be dependent upon the valuations and recommendations of the analysts who cover the New Horizon business, and if its results do not meet the analysts

forecasts and expectations, New Horizon's stock price could decline as a result of analysts lowering their valuations and recommendations or otherwise. In the past, following periods of volatility in the market, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against New Horizon, could result in substantial costs and diversion of management's attention and resources, which could materially and adversely affect New Horizon's business, financial condition, results of operations and growth prospects.

Table of Contents

Future sales of New Horizon ordinary shares in the public market could cause volatility in the price of New Horizon shares or cause the share price to fall.

Sales of a substantial number of New Horizon ordinary shares in the public market, or the perception that these sales might occur, could depress the market price of New Horizon ordinary shares, and could impair New Horizon's ability to raise capital through the sale of additional equity securities.

It is expected that New Horizon will file registration statements on Form S-8 under the Securities Act to register the ordinary shares reserved for issuance under its equity incentive and employee stock purchase plans, and intends to file additional registration statements on Form S-8 to register the ordinary shares automatically added each year to the share reserves under these plans, which may impair New Horizon's ability to raise capital.

The Merger Agreement contemplates that Vidara and Vidara Holdings, the sole shareholder of Vidara, and members of Vidara Holdings, which are collectively referred to in this proxy statement/prospectus as the Vidara rights parties, will enter into a registration rights agreement, which is referred to in this proxy statement/prospectus as the registration rights agreement, providing for the registration for resale under the Securities Act of the New Horizon ordinary shares held by the Vidara rights parties immediately following the closing, which are referred to in this proxy statement/prospectus as the registrable securities. Pursuant to the registration rights agreement, Vidara will be committed to file a registration statement with the SEC covering the resale of all of the registrable securities as soon as reasonably practicable following the date the registration statement of which this proxy statement/prospectus is a part is declared effective by the SEC, and to use its reasonable best efforts to cause such resale registration statement, which is referred to in this proxy statement/prospectus as the Vidara resale registration statement, to become effective under the Securities Act by the closing date or as soon as reasonably practicable thereafter. See *Other Related Agreements Registration Rights Agreement*.

We expect that generally, the receipt of New Horizon ordinary shares in exchange for Horizon common stock pursuant to the merger will result in a taxable transaction. Since the stockholders of Horizon are not receiving cash in the merger and may be subject to tax on the gain recognized, if any, they may choose to sell New Horizon ordinary shares to generate cash to satisfy their tax obligations, which could increase the number of New Horizon ordinary shares being sold in the public market and the volatility of the price of New Horizon ordinary shares.

New Horizon may not have sufficient distributable reserves to pay dividends or repurchase or redeem shares following the Merger even if considered appropriate by the New Horizon board of directors. New Horizon can provide no assurance that Irish High Court approval of the creation of distributable reserves will be forthcoming.

If New Horizon proposes to pay dividends in the future, it may be unable to do so under Irish law. Under Irish law, dividends may be paid, and share repurchases and redemptions must generally be funded, only out of distributable reserves. The creation or increase of distributable reserves, through the reclassification of existing share capital or other un-distributable reserves, requires the approval of the Irish High Court. New Horizon is not aware of any reason why the Irish High Court would not approve the creation or increase of distributable reserves; however, the issuance of the required order is a matter for the discretion of the Irish High Court and there is no guarantee that such approval will be forthcoming. Even if the Irish High Court does approve the creation or increase of distributable reserves, it may take substantially longer than the parties anticipate.

New Horizon does not expect to pay dividends for the foreseeable future, and you must rely on increases in the trading prices of the New Horizon ordinary shares for returns on your investment.

Horizon has never paid cash dividends on its common stock. New Horizon does not expect to pay dividends in the immediate future. New Horizon anticipates that it will retain all earnings, if any, to support its operations and its proprietary drug development programs. Any future determination as to the payment of dividends will, subject to Irish legal requirements, be at the sole discretion of the New Horizon board of directors and will

Table of Contents

depend on New Horizon's financial condition, results of operations, capital requirements and other factors the New Horizon board of directors deems relevant. Holders of New Horizon ordinary shares must rely on increases in the trading price of their shares for returns on their investment in the foreseeable future.

After the completion of the merger, attempted takeovers of New Horizon will be subject to Irish Takeover Rules and subject to review by the Irish Takeover Panel.

Delaware's anti-takeover statutes and laws regarding directors' fiduciary duties give the boards of directors broad latitude to defend against unwanted takeover proposals. Following the closing, New Horizon will become subject to Irish takeover rules, as discussed in greater detail under *Description of New Horizon Ordinary Shares Antitakeover Provisions*, under which the New Horizon board of directors will not, other than with the consent of New Horizon shareholders or the Irish Takeover Panel, be permitted to take any action which might frustrate an offer for New Horizon ordinary shares once it has received an approach which may lead to an offer or where the board of directors of New Horizon has reason to believe an offer is imminent. Further, it could be more difficult for New Horizon to obtain shareholder approval for a merger or negotiated transaction after the closing of the business combination because the shareholder approval requirements for certain types of transactions differ, and in some cases are greater, under Irish law than under Delaware law. Please see *Description of New Horizon Ordinary Shares*.

Following the completion of the merger, a future transfer of New Horizon ordinary shares may be subject to Irish stamp duty.

In certain circumstances, the transfer of shares in an Irish incorporated company will be subject to Irish stamp duty, which is a legal obligation of the buyer of the shares. This duty is currently charged at the rate of 1.0% of the price paid or the market value of the shares acquired, if higher. However, transfers of book-entry interests in the Depository Trust Company, which is referred to in this proxy statement/prospectus as DTC, representing New Horizon ordinary shares should not be subject to Irish stamp duty. Accordingly, transfers by shareholders who hold their New Horizon ordinary shares beneficially through brokers which in turn hold those shares through DTC, should not be subject to Irish stamp duty on transfers to holders who also hold through DTC. This exemption should be available because New Horizon ordinary shares will be traded on a recognized stock exchange in the United States.

New Horizon, in its absolute discretion and insofar as the Companies Acts or any other applicable law permit, may, or may provide that a subsidiary of New Horizon will, pay Irish stamp duty arising on a transfer of New Horizon ordinary shares on behalf of the transferee of such New Horizon ordinary shares. If stamp duty resulting from the transfer of New Horizon ordinary shares which would otherwise be payable by the transferee is paid by New Horizon or any subsidiary of New Horizon on behalf of the transferee, then in those circumstances, New Horizon will, on its behalf or on behalf of its subsidiary (as the case may be), be entitled to (i) seek reimbursement of the stamp duty from the transferee, (ii) set-off the stamp duty against any dividends payable to the transferee of those New Horizon ordinary shares and (iii) claim a first and permanent lien on the New Horizon ordinary shares on which stamp duty has been paid by New Horizon or its subsidiary for the amount of stamp duty paid. New Horizon's lien shall extend to all dividends paid on those New Horizon ordinary shares.

Dividends paid by New Horizon may be subject to Irish dividend withholding tax.

In certain circumstances, as an Irish tax resident company, New Horizon will be required to deduct Irish dividend withholding tax (currently at the rate of 20%) from dividends paid to its shareholders. Shareholders that are resident in the United States, European Union member states (other than Ireland) or other countries with which Ireland has signed a tax treaty (whether the treaty has been ratified or not) generally should not be subject to Irish withholding tax so long as the shareholder has provided its broker, for onward transmission to New Horizon's qualifying intermediary or

other designated agent (in the case of shares held beneficially), or New

34.

Table of Contents

Horizon or its transfer agent (in the case of shares held directly), with all the necessary documentation by the appropriate due date prior to payment of the dividend. However, some shareholders may be subject to withholding tax, which could adversely affect the price of New Horizon ordinary shares. See *Certain Tax Consequences of the Merger Irish Tax Considerations*.

Table of Contents

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This proxy statement/prospectus and the documents that Horizon has filed with the SEC that are incorporated in this proxy statement/prospectus by reference contain certain forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 with respect to the respective financial conditions, results of operations, financial projections and businesses of Horizon, Vidara and New Horizon, and the expected impact of the proposed merger on New Horizon and its business. Words such as anticipates, expects, intends, plans, predicts, believes, seeks, estimates, could, would, will, may, can, continue, potential, of these terms or other comparable terminology often identify forward-looking statements. Statements included or incorporated in this proxy statement/prospectus that are not historical facts are hereby identified as forward-looking statements for the purpose of the safe harbor provided by Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from the results contemplated by the forward-looking statements. Many of these risks, uncertainties and other factors are discussed under the sections captioned *Risk Factors* contained in this proxy statement/prospectus and in Horizon's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2014, as updated or superseded by the risks and uncertainties described under similar headings in the other documents that are filed by Horizon after the date hereof and incorporated by reference into this proxy statement/prospectus. These forward-looking statements include, but are not limited to, statements about:

the completion of the proposed merger and the timing thereof;

the expected synergies and other benefits, including tax, financial and strategic benefits, to New Horizon and the respective stockholders of Horizon and Vidara of the proposed merger;

the expected tax consequences to holders of Horizon common stock and New Horizon ordinary shares;

the expected accounting treatment for the proposed merger;

future sales of DUEXIS®, VIMOVO®, RAYOS®, ACTIMMUNE® and the other products of Horizon, Vidara and New Horizon;

the expected financial performance and results of New Horizon following completion of the proposed merger;

the ability to obtain adequate clinical and commercial supplies of products of Horizon, Vidara and New Horizon from current and new single source suppliers and manufacturers;

the ability of each of Horizon, Vidara and New Horizon to protect its intellectual property and defend its patents;

the sufficiency of each of Horizon's, Vidara's and New Horizon's cash resources, and expectations regarding their respective future cash flow, expenses, revenues, financial results and capital requirements; and

financial projections of Horizon and Vidara and assumptions related thereto.

Many of the important factors that will determine these results are beyond the ability of Horizon and Vidara to control or predict. You are cautioned not to put undue reliance on any forward-looking statements, which speak only as of the date of this proxy statement/prospectus or the date of any document incorporated by reference. You should carefully read this proxy statement/prospectus together with the information incorporated herein by reference as described under the heading *Where You Can Find More Information*, completely and with the understanding that actual future results may be materially different from those that are expected by Horizon and Vidara. Except as otherwise required by law, none of Horizon, Vidara or New Horizon undertakes any obligation to update publicly or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Table of Contents**THE REORGANIZATION AND THE MERGER****The Reorganization of Vidara**

Prior to the effective time of the Merger, Vidara will carry out a reorganization of its capital structure (the reorganization). The reorganization consists of a series of corporate actions as a result of which: (i) Vidara has formed a new non-resident Irish company that is a tax resident in Bermuda referred to as Newco, (ii) Vidara has assigned all of its contracts and has sold and transferred all of its intellectual property to Newco in exchange for a promissory note with an original principal amount equal to the fair market value of such assets, which will be repaid in consideration for the issuance of two promissory notes of the same aggregate original principal amount, one of which will be repaid in cash on the closing date, (iii) Vidara has moved its tax residence from Bermuda to Ireland, (iv) Vidara has created a new class of ordinary shares denominated in US dollars (as well as created additional euro-denominated share capital up to a par value of 40,000) such that the aggregate number of US dollar denominated ordinary shares is sufficient to cover the ordinary shares to be issued in exchange for the outstanding shares of Horizon common stock and shares of Horizon common stock reserved for issuance under outstanding Horizon equity awards and warrants and Horizon's outstanding convertible notes, and ordinary shares and bonus shares equal to 31,350,000 shares representing Vidara Holdings' agreed shareholdings in New Horizon following the closing and a bonus issue of shares to be held by Vidara Holdings and redeemed by Vidara from distributable reserves for cash as of the closing, (v) Vidara will be re-registered as a public limited company in Ireland, (vi) Vidara will redeem the bonus issue of shares for cash in the amount of \$200,000,000 plus cash on hand at Vidara on the closing date, less Vidara's unpaid indebtedness and unpaid transaction expenses, and plus or minus an adjustment to the extent that Vidara working capital as of the closing is more or less than target working capital of \$123,000 and (vii) Vidara will be renamed Horizon Pharma plc.

The Merger

Following the completion of the reorganization, Merger Sub, which is a wholly-owned subsidiary of U.S. HoldCo, will merge with and into Horizon, with Horizon as the surviving corporation becoming an indirect wholly-owned subsidiary of Vidara. At the effective time, (i) each share of Horizon's common stock issued and outstanding will be converted into one ordinary share of New Horizon; (ii) each equity plan of Horizon will be assumed by New Horizon and each outstanding option under Horizon's equity plans will be converted into an option to acquire the number of ordinary shares of New Horizon equal to the number of shares of common stock underlying such option immediately prior to the effective time at the same exercise price per share as such Horizon option, and each other stock award that is outstanding under Horizon equity plans will be converted into a right to receive, on substantially the same terms and conditions as were applicable to such equity award before the effective time, the number of ordinary shares of New Horizon equal to the number of shares of common stock of Horizon subject to such stock award immediately prior to the effective time; (iii) each warrant to acquire Horizon common stock outstanding immediately prior to the effective time and not terminated as of the effective time will be converted into a warrant to acquire, on substantially the same terms and conditions as were applicable under such warrant before the effective time, the number of ordinary shares of New Horizon equal to the number of shares of common stock underlying such warrant immediately prior to the effective time; and (iv) the 5.00% Convertible Senior Notes due 2018 will remain outstanding and, pursuant to a supplemental indenture to be entered into effective as of the effective time, will become convertible into the same number of ordinary shares of New Horizon at the same conversion rate in effect immediately prior to the effective time.

Upon consummation of the Merger, the security holders of Horizon (excluding the holder 1pt solid #000000; border-bottom: 2px solid #000000">

65.8700

08:53:39
LSE
635246
6,145
65.8700
08:53:39
LSE
635244
6,822
65.8700
08:53:39
LSE
635242
6,604
65.8400
08:55:04
LSE
639580
885
65.8600
08:55:48
LSE
641704
5,196
65.8600
08:55:48
LSE
641702
6,395
65.8600
08:55:48
LSE
641698
2,000
65.8600
08:55:48
LSE
641692
5,127
65.8600
08:55:48
LSE
641694
7,231
65.8600
08:55:48
LSE
641696
7,131
65.8400
08:56:45

LSE
644686
6,838
65.8400
08:56:45
LSE
644684
6,806
65.8400
08:57:55
LSE
648243
6,941
65.8400
08:57:55
LSE
648241
6,716
65.8400
08:57:55
LSE
648239
7,112
65.8300
08:58:02
LSE
648616
6,122
65.8000
08:59:19
LSE
653190
6,493
65.8000
08:59:19
LSE
653188
6,025
65.8000
08:59:19
LSE
653186
5,922
65.8000
08:59:19
LSE
653192
6,010
65.8000
08:59:19
LSE

653194
4,793
65.7900
08:59:22
LSE
653474
2,658
65.7900
08:59:22
LSE
653472
3,889
65.7900
08:59:22
LSE
653470
19,602
65.7900
08:59:25
LSE
653632
6,393
65.7900
08:59:25
LSE
653630
1,276
65.7900
08:59:25
LSE
653628
1,290
65.7800
08:59:28
LSE
653843
384
65.7600
09:00:00
LSE
655988
20,042
65.7800
09:00:00
LSE
655953
5,958
65.7800
09:00:00
LSE
655951

6,511
65.7800
09:00:00
LSE
655955
1,619
65.7800
09:00:00
LSE
655957
6,434
65.7800
09:00:00
LSE
655959
7,384
65.7600
09:00:01
LSE
656108
9,596
65.8400
09:04:57
LSE
668160
9,209
65.8400
09:04:57
LSE
668158
9,640
65.8400
09:04:57
LSE
668156
10,154
65.8400
09:04:57
LSE
668154
8,366
65.8300
09:05:03
LSE
668390
6,956
65.8300
09:05:03
LSE
668392
7,127

65.8300
09:05:03
LSE
668396
7,560
65.8300
09:05:03
LSE
668394
6,424
65.8200
09:05:05
LSE
668542
7,114
65.8200
09:05:05
LSE
668540
6,269
65.8200
09:05:05
LSE
668538
3,423
65.7800
09:05:10
LSE
668778
9,105
65.8000
09:05:10
LSE
668766
5,641
65.8000
09:05:10
LSE
668764
101,648
65.8000
09:07:11
LSE
673186
6,848
65.8000
09:07:11
LSE
673171
14,129
65.8000

09:07:11
LSE
673167
6,889
65.8000
09:07:11
LSE
673169
6,900
65.8000
09:07:11
LSE
673175
6,834
65.8000
09:07:11
LSE
673173
6,260
65.7900
09:07:12
LSE
673224
6,200
65.7300
09:08:20
LSE
675960
1,482
65.7200
09:09:12
LSE
681041
5,007
65.7200
09:09:12
LSE
681043
6,369
65.7200
09:09:12
LSE
681039
6,115
65.7200
09:09:12
LSE
681035
885
65.7200
09:09:12

LSE
681037
6,470
65.7200
09:10:33
LSE
686827
6,488
65.7200
09:10:33
LSE
686829
6,556
65.8000
09:11:52
LSE
692174
6,706
65.8000
09:11:52
LSE
692172
362
65.8000
09:11:52
LSE
692170
6,247
65.8000
09:11:52
LSE
692168
6,033
65.8000
09:11:52
LSE
692166
937
65.8000
09:11:52
LSE
692164
6,425
65.8000
09:12:53
LSE
696760
6,531
65.7900
09:13:23
LSE

698991
6,979
65.7900
09:13:23
LSE
698989
6,228
65.7900
09:13:23
LSE
698987
7,235
65.8000
09:15:30
LSE
709144
800
65.8000
09:15:37
LSE
709642
8,004
65.8000
09:16:21
LSE
712641
8,135
65.8000
09:16:21
LSE
712639
7,154
65.8000
09:16:21
LSE
712637
6,037
65.8000
09:16:21
LSE
712635
7,131
65.8000
09:16:21
LSE
712633
5,383
65.7900
09:16:51
LSE
714416

6,647
65.7900
09:16:51
LSE
714414
6,704
65.7900
09:16:51
LSE
714412
1,836
65.7900
09:16:51
LSE
714410
5,893
65.7900
09:16:51
LSE
714408
6,141
65.7800
09:17:38
LSE
717683
6,004
65.7800
09:17:38
LSE
717681
166
65.7500
09:17:42
LSE
717970
6,882
65.7500
09:17:48
LSE
718298
6,099
65.7500
09:17:48
LSE
718296
915
65.7500
09:18:20
LSE
720456
6,618

65.8000
09:19:35
LSE
724550
7,223
65.8100
09:19:35
LSE
724547
6,425
65.8100
09:19:35
LSE
724545
655
65.8100
09:19:35
LSE
724543
6,345
65.8100
09:19:35
LSE
724541
6,761
65.8100
09:19:35
LSE
724539
7,240
65.7800
09:20:09
LSE
726929
6,208
65.8300
09:22:07
LSE
730860
653
65.8300
09:22:49
LSE
732516
2,712
65.8300
09:22:49
LSE
732514
5,928
65.8300

09:22:49
LSE
732512
3,296
65.8300
09:22:49
LSE
732510
7,285
65.8300
09:22:49
LSE
732508
4,110
65.8300
09:22:49
LSE
732506
3,087
65.8300
09:22:49
LSE
732504
6,330
65.8200
09:22:57
LSE
732766
5,875
65.8100
09:23:07
LSE
733232
48
65.8000
09:23:22
LSE
733678
7,000
65.8000
09:23:22
LSE
733676
7,063
65.8000
09:23:22
LSE
733672
191
65.8000
09:23:23

LSE
733796
6,031
65.8100
09:23:45
LSE
734468
6,416
65.8100
09:23:45
LSE
734466
6,303
65.8000
09:24:27
LSE
735733
797
65.7900
09:24:32
LSE
735939
797
65.7900
09:24:34
LSE
736015
800
65.7900
09:24:34
LSE
735995
800
65.7900
09:24:34
LSE
735979
800
65.7900
09:24:35
LSE
736057
800
65.7900
09:24:38
LSE
736211
800
65.7900
09:24:38
LSE

736191
602
65.7900
09:24:38
LSE
736184
800
65.7900
09:24:39
LSE
736243
800
65.7900
09:24:39
LSE
736236
725
65.7900
09:24:39
LSE
736222
72
65.7900
09:24:39
LSE
736220
797
65.7900
09:24:40
LSE
736296
800
65.7900
09:24:40
LSE
736264
800
65.7900
09:24:40
LSE
736255
797
65.7900
09:24:40
LSE
736246
215
65.7900
09:24:41
LSE
736307

800
65.7900
09:24:41
LSE
736305
6,408
65.8800
09:26:46
LSE
740750
6,623
65.8800
09:26:54
LSE
741032
6,441
65.8800
09:26:54
LSE
741030
6,903
65.8800
09:26:54
LSE
741028
733
65.8700
09:27:06
LSE
741527
6,044
65.8700
09:27:06
LSE
741525
5,726
65.8700
09:27:06
LSE
741523
6,581
65.9200
09:29:35
LSE
746006
6,155
65.9200
09:29:35
LSE
746004
5,924

65.9200
09:29:35
LSE
746002
6,505
65.9200
09:29:35
LSE
746000
6,918
65.9000
09:29:39
LSE
746115
6,686
65.9000
09:29:39
LSE
746113
5,941
65.9000
09:29:39
LSE
746111
6,670
65.8800
09:30:45
LSE
748171
6,220
65.8800
09:30:45
LSE
748169
6,251
65.8900
09:32:10
LSE
751327
6,368
65.8900
09:32:10
LSE
751325
6,676
65.8900
09:32:10
LSE
751323
6,787
65.8800

09:32:14
LSE
751412
6,708
65.9100
09:33:20
LSE
754401
6,286
65.9100
09:33:20
LSE
754403
6,228
65.9100
09:33:20
LSE
754399
6,764
65.8600
09:34:12
LSE
755970
6,701
65.8600
09:34:12
LSE
755968
5,853
65.8700
09:35:12
LSE
758731
6,496
65.8700
09:35:12
LSE
758729
6,980
65.8400
09:36:06
LSE
760613
6,849
65.8100
09:36:42
LSE
761979
6,838
65.8100
09:36:45

LSE
762083
6,768
65.8000
09:36:55
LSE
762445
6,927
65.8000
09:36:55
LSE
762443
5,643
65.7900
09:37:12
LSE
763008
11,157
65.8000
09:38:06
LSE
765112
5,902
65.8000
09:38:06
LSE
765114
6,349
65.8000
09:39:05
LSE
766924
6,317
65.8000
09:39:05
LSE
766922
6,282
65.8000
09:39:05
LSE
766920
6,275
65.8000
09:39:05
LSE
766918
7,164
65.8000
09:39:05
LSE

766916
7,780
65.7900
09:39:09
LSE
767069
6,515
65.7800
09:39:38
LSE
768043
6,390
65.8200
09:41:44
LSE
771564
7,187
65.8200
09:41:44
LSE
771570
7,004
65.8200
09:41:44
LSE
771567
7,010
65.8200
09:41:44
LSE
771562
6,955
65.8100
09:41:57
LSE
772335
6,716
65.8300
09:43:41
LSE
775693
65
65.8300
09:43:41
LSE
775684
6,635
65.8300
09:43:41
LSE
775682

2,698
65.8300
09:43:41
LSE
775680
4,861
65.8300
09:43:41
LSE
775678
4,472
65.8300
09:43:41
LSE
775676
1,548
65.8300
09:43:41
LSE
775674
6,407
65.8000
09:44:36
LSE
777785
7,122
65.8200
09:45:17
LSE
779292
6,930
65.8200
09:45:17
LSE
779297
5,983
65.8200
09:45:17
LSE
779295
7,104
65.8700
09:48:21
LSE
784650
6,621
65.8700
09:48:21
LSE
784648
6,953

65.8700
09:48:21
LSE
784646
6,374
65.8700
09:48:21
LSE
784644
6,854
65.8500
09:49:16
LSE
786040
7,271
65.8500
09:49:16
LSE
786038
6,661
65.8500
09:49:16
LSE
786036
5,923
65.8500
09:49:16
LSE
786034
6,330
65.8200
09:52:01
LSE
791627
2,075
65.8200
09:52:01
LSE
791623
6,693
65.8200
09:52:01
LSE
791625
497
65.8200
09:52:01
LSE
791629
6,645
65.8200

09:52:01
LSE
791631
5,150
65.8200
09:52:01
LSE
791621
7,082
65.8100
09:52:02
LSE
791659
6,609
65.8100
09:52:02
LSE
791657
6,311
65.8100
09:52:02
LSE
791655
6,720
65.8100
09:52:02
LSE
791653
9,003
65.8000
09:52:05
LSE
792045
2,747
65.7900
09:52:06
LSE
792098
156
65.7900
09:52:26
LSE
792893
6,703
65.7900
09:52:26
LSE
792897
7,369
65.7900
09:52:26

LSE
792895
6,811
65.7600
09:52:31
LSE
793093
8,268
65.7600
09:52:31
LSE
793028
5,945
65.7400
09:52:55
LSE
793856
6,702
65.7100
09:54:09
LSE
796131
7,136
65.7100
09:54:09
LSE
796129
6,169
65.7100
09:54:09
LSE
796127
7,004
65.7100
09:54:09
LSE
796125
6,505
65.7200
09:56:30
LSE
800130
7,051
65.7200
09:56:30
LSE
800122
6,495
65.7200
09:56:30
LSE

800124
6,995
65.7200
09:56:30
LSE
800126
6,387
65.7200
09:56:30
LSE
800128
5,852
65.6900
09:57:26
LSE
801479
3,421
65.6900
09:57:26
LSE
801477
3,385
65.6900
09:57:26
LSE
801475
6,232
65.6600
09:58:20
LSE
802787
5,127
65.6600
09:58:20
LSE
802785
5,970
65.6600
09:58:20
LSE
802791
7,072
65.6600
09:58:20
LSE
802789
1,323
65.6600
09:58:20
LSE
802783

6,044
65.5900
09:58:50
LSE
803555
7,097
65.6800
10:02:29
LSE
809517
5,873
65.6800
10:02:29
LSE
809515
6,989
65.6800
10:02:29
LSE
809513
5,991
65.6800
10:02:29
LSE
809511
5,979
65.6800
10:02:29
LSE
809509
865
65.6800
10:02:29
LSE
809507
3,533
65.6700
10:02:32
LSE
809571
5,897
65.6700
10:02:32
LSE
809569
2,466
65.6700
10:02:32
LSE
809575
5,800

65.6700
10:02:32
LSE
809573
868
65.6700
10:02:32
LSE
809567
6,160
65.6800
10:04:51
LSE
815830
5,244
65.7000
10:04:51
LSE
815828
6,622
65.7000
10:04:51
LSE
815826
1,585
65.7000
10:04:51
LSE
815824
2,834
65.7000
10:04:51
LSE
815820
6,998
65.7000
10:04:51
LSE
815814
4,166
65.7000
10:04:51
LSE
815818
1,715
65.7000
10:04:51
LSE
815816
5,896
65.6700

10:05:25
LSE
816623
6,131
65.6500
10:05:36
LSE
816855
787
65.6500
10:05:36
LSE
816853
775
65.6600
10:08:08
LSE
821036
5,347
65.6600
10:08:08
LSE
821034
7,034
65.6600
10:08:08
LSE
821032
7,343
65.6700
10:08:08
LSE
821030
6,899
65.6700
10:08:08
LSE
821026
6,190
65.6700
10:08:08
LSE
821022
7,177
65.6700
10:08:08
LSE
821024
7,368
65.6700
10:08:08

LSE
821028
6,557
65.6400
10:08:25
LSE
821480
7,150
65.6500
10:09:37
LSE
823097
5,851
65.6400
10:10:02
LSE
823787
7,116
65.6600
10:11:12
LSE
825587
5,939
65.6600
10:11:12
LSE
825583
5,931
65.6600
10:11:12
LSE
825585
6,412
65.6000
10:11:49
LSE
826432
1,072
65.5900
10:13:01
LSE
827543
6,778
65.5900
10:13:25
LSE
828266
7,104
65.5900
10:13:25
LSE

828264
6,914
65.5900
10:13:25
LSE
828262
5,831
65.5900
10:13:25
LSE
828260
433
65.5500
10:14:07
LSE
829326
6,116
65.5500
10:14:07
LSE
829324
6,376
65.5600
10:14:33
LSE
830073
6,197
65.5400
10:15:22
LSE
831359
7,026
65.5400
10:15:22
LSE
831357
7,154
65.5200
10:15:33
LSE
831686
1,107
65.4900
10:16:41
LSE
833477
40,992
65.4900
10:16:41
LSE
833475

7,785
65.5000
10:16:41
LSE
833466
1,423
65.5000
10:16:41
LSE
833457
42,367
65.5000
10:16:41
LSE
833449
30,215
65.5000
10:16:41
LSE
833445
972
65.5000
10:16:41
LSE
833447
2,883
65.5000
10:16:41
LSE
833455
21,047
65.5000
10:16:41
LSE
833451
3,183
65.5000
10:16:41
LSE
833453
28,153
65.5000
10:16:41
LSE
833443
12,307
65.5000
10:16:41
LSE
833438
1,762

65.5000
10:16:41
LSE
833428
6,950
65.5000
10:16:41
LSE
833424
5,466
65.5000
10:16:41
LSE
833426
6,970
65.5000
10:16:41
LSE
833431
6,089
65.5000
10:16:41
LSE
833434
6,388
65.5000
10:16:41
LSE
833436
6,046
65.5000
10:16:41
LSE
833421
6,515
65.5000
10:16:41
LSE
833419
6,642
65.5000
10:16:41
LSE
833417
6,256
65.5000
10:16:41
LSE
833414
6,261
65.5000

10:16:41
LSE
833412
6,610
65.5000
10:16:41
LSE
833410
6,998
65.5000
10:16:41
LSE
833408
6,286
65.5000
10:16:41
LSE
833406
6,349
65.5000
10:16:41
LSE
833394
7,160
65.5000
10:16:41
LSE
833388
6,526
65.5000
10:16:41
LSE
833390
6,874
65.5000
10:16:41
LSE
833392
6,026
65.5000
10:16:41
LSE
833404
7,008
65.5000
10:16:41
LSE
833396
6,754
65.5000
10:16:41

LSE
833398
7,145
65.5000
10:16:41
LSE
833400
6,478
65.5000
10:16:41
LSE
833402
6,507
65.5000
10:16:41
LSE
833380
6,057
65.5000
10:16:41
LSE
833378
6,062
65.5000
10:16:41
LSE
833376
7,124
65.5000
10:16:41
LSE
833382
7,099
65.5000
10:16:41
LSE
833384
7,185
65.5000
10:16:41
LSE
833386
6,375
65.5000
10:16:41
LSE
833364
8,127
65.5000
10:16:41
LSE

833358
3,690
65.5000
10:16:41
LSE
833360
5,643
65.5000
10:16:41
LSE
833362
1,213
65.5000
10:16:41
LSE
833374
944
65.5000
10:16:41
LSE
833366
6,369
65.5000
10:16:41
LSE
833368
6,592
65.5000
10:16:41
LSE
833370
512
65.5000
10:16:41
LSE
833372
6,892
65.5100
10:16:41
LSE
833356
6,306
65.5100
10:16:41
LSE
833354
6,921
65.4900
10:16:42
LSE
833501

8,989
65.4900
10:16:42
LSE
833496
7,873
65.4900
10:16:42
LSE
833494
744
65.4900
10:16:42
LSE
833492
7,522
65.4900
10:16:42
LSE
833490
11,826
65.4900
10:16:42
LSE
833488
7,384
65.4900
10:16:42
LSE
833486
1,655
65.4800
10:16:44
LSE
833532
14,121
65.4800
10:16:44
LSE
833526
1,164
65.4700
10:16:45
LSE
833585
9,292
65.4700
10:16:45
LSE
833581
4,943

65.4700
10:16:45
LSE
833583
4,352
65.4700
10:16:45
LSE
833571
1,144
65.4800
10:16:45
LSE
833568
6,801
65.4800
10:16:45
LSE
833566
4,081
65.4800
10:16:45
LSE
833564
892
65.4800
10:16:45
LSE
833562
7,505
65.4800
10:16:45
LSE
833560
2,637
65.4800
10:16:45
LSE
833558
9,716
65.4700
10:16:48
LSE
833630
4,296
65.4600
10:16:49
LSE
833646
5,666
65.4600

10:16:51
LSE
833721
6,037
65.4600
10:16:51
LSE
833719
7,563
65.4600
10:16:51
LSE
833717
6,132
65.4600
10:16:54
LSE
833762
1,246
65.4600
10:16:54
LSE
833758
6,944
65.4600
10:16:54
LSE
833756
6,680
65.4100
10:17:02
LSE
834057
6,363
65.4000
10:17:24
LSE
834605
6,075
65.4700
10:18:52
LSE
837028
6,833
65.4700
10:18:52
LSE
837026
6,714
65.4700
10:18:52

LSE
837024
5,963
65.4700
10:18:52
LSE
837022
2,249
65.4400
10:20:11
LSE
838526
7,022
65.4500
10:20:11
LSE
838523
4,332
65.4500
10:20:24
LSE
838834
1,778
65.4500
10:20:34
LSE
838994
6,676
65.4500
10:20:34
LSE
838996
4,361
65.4500
10:20:34
LSE
838998
1,610
65.4500
10:20:34
LSE
839000
7,242
65.4500
10:20:34
LSE
839002
6,142
65.4400
10:20:43
LSE

839166
6,709
65.3600
10:21:28
LSE
840511
6,167
65.3600
10:21:28
LSE
840509
6,260
65.3200
10:22:00
LSE
841159
584
65.2700
10:22:15
LSE
841530
5,799
65.2700
10:22:18
LSE
841618
6,088
65.3400
10:24:14
LSE
845080
6,996
65.3400
10:24:14
LSE
845072
6,562
65.3400
10:24:14
LSE
845068
1,227
65.3400
10:24:14
LSE
845070
3,292
65.3400
10:24:14
LSE
845078

3,978
65.3400
10:24:14
LSE
845074
4,625
65.3400
10:24:14
LSE
845076
7,394
65.3600
10:28:23
LSE
852146
6,938
65.3600
10:28:23
LSE
852144
8,305
65.3600
10:28:23
LSE
852142
6,764
65.3600
10:28:23
LSE
852140
8,118
65.3600
10:28:23
LSE
852138
8,468
65.3600
10:28:23
LSE
852136
217
65.3500
10:28:39
LSE
852452
6,048
65.3500
10:28:39
LSE
852448
875

65.3500
10:28:39
LSE
852450
7,224
65.3500
10:28:39
LSE
852446
4,983
65.3500
10:28:39
LSE
852454
5,628
65.3500
10:28:39
LSE
852456
3,705
65.3500
10:28:39
LSE
852458
2,154
65.3500
10:28:39
LSE
852460
5,848
65.3500
10:28:39
LSE
852444
1,250
65.3000
10:29:24
LSE
853394
6,259
65.3000
10:29:36
LSE
853626
6,472
65.3000
10:29:36
LSE
853622
5,257
65.3000

10:29:36
LSE
853624
336
65.2900
10:30:19
LSE
855109
6,388
65.2900
10:30:22
LSE
855248
6,580
65.2900
10:30:22
LSE
855246
5,648
65.2900
10:30:22
LSE
855244
6,367
65.2300
10:31:09
LSE
856807
6,726
65.2300
10:31:09
LSE
856805
7,232
65.2200
10:31:21
LSE
857201
6,978
65.2500
10:32:12
LSE
858687
6,904
65.2500
10:32:12
LSE
858685
5,890
65.2100
10:32:27

LSE
858990
5,182
65.2400
10:32:59
LSE
859806
1,350
65.2400
10:32:59
LSE
859804
7,225
65.2400
10:33:49
LSE
860934
6,770
65.2400
10:33:49
LSE
860932
6,216
65.2400
10:33:49
LSE
860936
3,448
65.2400
10:35:05
LSE
863665
6,964
65.2400
10:35:05
LSE
863663
3,664
65.2400
10:35:11
LSE
864081
7,169
65.2300
10:35:50
LSE
865477
7,000
65.1900
10:37:10
LSE

867512
141,176
65.2000
10:37:10
LSE
867516
9,599
65.1900
10:37:10
LSE
867514
4,873
65.1900
10:37:10
LSE
867502
2,217
65.1900
10:37:10
LSE
867500
42,928
65.1900
10:37:10
LSE
867508
6,460
65.1900
10:37:10
LSE
867504
8,074
65.1900
10:37:10
LSE
867506
7,000
65.2000
10:37:10
LSE
867498
57,326
65.2000
10:37:10
LSE
867496
108,456
65.2000
10:37:10
LSE
867494

6,298
65.2000
10:37:10
LSE
867491
7,075
65.2000
10:37:10
LSE
867481
6,034
65.2000
10:37:10
LSE
867475
6,889
65.2000
10:37:10
LSE
867477
7,006
65.2000
10:37:10
LSE
867479
6,200
65.2000
10:37:10
LSE
867485
7,195
65.2000
10:37:10
LSE
867483
6,692
65.2000
10:37:10
LSE
867487
6,771
65.2000
10:37:10
LSE
867489
6,818
65.2000
10:37:10
LSE
867465
5,974

65.2000
10:37:10
LSE
867459
6,022
65.2000
10:37:10
LSE
867461
6,442
65.2000
10:37:10
LSE
867463
6,577
65.2000
10:37:10
LSE
867467
6,521
65.2000
10:37:10
LSE
867471
6,480
65.2000
10:37:10
LSE
867473
6,722
65.2000
10:37:10
LSE
867469
6,094
65.2000
10:37:10
LSE
867457
5,904
65.2000
10:37:10
LSE
867455
6,776
65.2000
10:37:10
LSE
867453
6,146
65.2000

10:37:10
LSE
867451
6,853
65.2000
10:37:10
LSE
867449
7,136
65.2000
10:37:10
LSE
867447
6,122
65.2000
10:37:10
LSE
867445
6,500
65.2000
10:37:10
LSE
867443
7,147
65.2000
10:37:10
LSE
867433
6,416
65.2000
10:37:10
LSE
867427
6,376
65.2000
10:37:10
LSE
867429
6,534
65.2000
10:37:10
LSE
867431
7,131
65.2000
10:37:10
LSE
867441
6,630
65.2000
10:37:10

LSE
867435
5,975
65.2000
10:37:10
LSE
867437
6,946
65.2000
10:37:10
LSE
867439
7,019
65.2100
10:37:10
LSE
867409
6,034
65.2100
10:37:10
LSE
867411
7,120
65.2000
10:37:10
LSE
867415
11,832
65.2000
10:37:10
LSE
867413
6,902
65.2000
10:37:10
LSE
867421
7,181
65.2000
10:37:10
LSE
867417
6,901
65.2000
10:37:10
LSE
867423
6,092
65.2000
10:37:10
LSE

867425
7,153
65.2000
10:37:10
LSE
867419
11,142
65.2100
10:37:10
LSE
867407
6,006
65.2100
10:37:10
LSE
867405
3,596
65.1800
10:37:11
LSE
867532
3,778
65.1800
10:37:16
LSE
867634
6,043
65.1700
10:37:23
LSE
867809
6,191
65.1800
10:38:27
LSE
869182
6,812
65.1400
10:38:35
LSE
869436
6,200
65.1600
10:38:35
LSE
869430
6,595
65.1600
10:38:35
LSE
869428

7,170
65.1100
10:39:00
LSE
870179
6,501
65.0300
10:39:53
LSE
871737
2,257
65.0300
10:39:53
LSE
871739
4,828
65.0300
10:39:53
LSE
871741
2,054
65.0500
10:41:28
LSE
874299
4,477
65.0500
10:41:28
LSE
874297
6,682
65.0500
10:41:28
LSE
874295
7,169
65.0500
10:41:28
LSE
874293
6,741
65.0500
10:41:28
LSE
874291
7,027
65.0500
10:41:28
LSE
874289
6,172

65.0500
10:41:28
LSE
874287
300
65.0300
10:42:55
LSE
876467
6,288
65.0300
10:42:55
LSE
876465
492
65.0300
10:42:55
LSE
876460
5,900
65.0400
10:42:55
LSE
876453
725
65.0400
10:42:55
LSE
876451
2,975
65.0400
10:42:55
LSE
876455
3,486
65.0400
10:42:55
LSE
876457
6,937
65.0400
10:42:55
LSE
876449
230
65.0300
10:43:01
LSE
876616
5,745
65.0300

10:43:01
LSE
876614
375
65.0300
10:43:01
LSE
876612
3,306
65.0800
10:45:57
LSE
880859
3,953
65.0800
10:45:57
LSE
880856
7,305
65.0800
10:45:57
LSE
880854
6,956
65.0800
10:45:57
LSE
880852
6,069
65.0800
10:45:57
LSE
880850
529
65.0800
10:45:57
LSE
880848
6,572
65.0800
10:45:57
LSE
880846
6,722
65.0800
10:45:57
LSE
880824
6,757
65.0800
10:45:57

LSE
880822
7,079
65.0800
10:45:57
LSE
880820
400
65.0700
10:46:23
LSE
881702
5,931
65.0700
10:46:23
LSE
881704
5,735
65.0700
10:46:23
LSE
881700
5,268
65.0700
10:46:23
LSE
881694
6,630
65.0700
10:46:23
LSE
881698
7,082
65.0700
10:46:23
LSE
881696
2,000
65.0700
10:46:23
LSE
881692
767
65.0300
10:47:40
LSE
883456
1,975
65.0500
10:48:36
LSE

884625
6,539
65.0500
10:48:36
LSE
884627
1,681
65.0200
10:48:51
LSE
885059
7,279
65.0500
10:48:51
LSE
885048
5,833
65.0500
10:48:51
LSE
885042
1,596
65.0500
10:48:51
LSE
885044
4,091
65.0500
10:48:51
LSE
885046
4,750
65.0500
10:48:51
LSE
885054
225
65.0500
10:48:51
LSE
885050
2,181
65.0500
10:48:51
LSE
885052
5,914
65.0500
10:48:51
LSE
885056

5,242
65.0500
10:48:51
LSE
885040
1,854
65.0500
10:48:51
LSE
885038
4,623
65.0500
10:48:51
LSE
885036
4,352
65.0200
10:48:54
LSE
885168
6,121
65.0100
10:49:25
LSE
886590
3,013
64.9900
10:50:27
LSE
888141
7,093
64.9900
10:50:27
LSE
888139
4,238
64.9900
10:50:27
LSE
888137
3,357
64.9900
10:50:27
LSE
888135
3,768
64.9900
10:50:27
LSE
888133
6,750

65.0000
10:50:27
LSE
888131
7,303
65.0000
10:50:27
LSE
888129
6,620
64.9300
10:50:52
LSE
888840
6,658
64.9000
10:50:59
LSE
888942
11,158
64.9000
10:50:59
LSE
888938
1,499
65.0600
10:54:43
LSE
894128
8,988
65.0900
10:56:31
LSE
896868
5,994
65.0800
10:56:54
LSE
897698
109
65.0800
10:56:54
LSE
897685
787
65.0900
10:56:54
LSE
897667
5,568
65.0900

10:56:54
LSE
897665
6,891
65.0800
10:56:54
LSE
897669
6,744
65.0800
10:56:54
LSE
897661
256
65.0800
10:56:54
LSE
897663
2,521
65.0900
10:56:54
LSE
897658
4,046
65.0900
10:56:54
LSE
897656
2,954
65.0900
10:56:54
LSE
897654
3,838
65.0900
10:56:54
LSE
897652
7,753
65.0900
10:56:54
LSE
897650
7,226
65.0900
10:56:54
LSE
897648
8,331
65.0900
10:56:54

LSE
897638
5,213
65.0900
10:56:54
LSE
897634
6,380
65.0900
10:56:54
LSE
897636
8,598
65.0900
10:56:54
LSE
897642
8,606
65.0900
10:56:54
LSE
897640
8,056
65.0900
10:56:54
LSE
897644
8,493
65.0900
10:56:54
LSE
897646
181
65.0900
10:56:54
LSE
897632
4,954
65.0900
10:56:54
LSE
897630
7,991
65.0900
10:56:54
LSE
897628
6,247
65.0000
10:57:27
LSE

898363
7,590
65.1000
11:01:17
LSE
903404
9,158
65.1000
11:01:17
LSE
903406
7,365
65.1000
11:01:17
LSE
903402
7,733
65.1000
11:01:17
LSE
903400
7,312
65.1000
11:01:17
LSE
903398
7,473
65.1000
11:01:17
LSE
903396
7,798
65.1000
11:01:17
LSE
903394
6,631
65.1000
11:01:17
LSE
903392
6,288
65.0900
11:01:57
LSE
904233
6,524
65.0900
11:01:57
LSE
904231

5,948
65.0900
11:01:57
LSE
904229
6,914
65.0900
11:01:57
LSE
904227
6,375
65.0900
11:01:57
LSE
904225
6,587
65.0900
11:01:57
LSE
904223
6,003
65.0900
11:01:57
LSE
904221
5,875
65.0700
11:02:11
LSE
904512
3,311
65.0700
11:02:11
LSE
904510
2,911
65.0700
11:02:11
LSE
904508
6,966
65.1100
11:03:12
LSE
905476
6,114
65.1000
11:04:20
LSE
906539
7,103

65.1000
11:04:37
LSE
906762
7,241
65.1000
11:04:37
LSE
906760
6,630
65.1000
11:04:37
LSE
906758
7,044
65.1000
11:04:37
LSE
906756
6,471
65.1000
11:04:37
LSE
906754
5,929
65.1000
11:04:37
LSE
906752
816
65.1000
11:04:37
LSE
906750
6,054
65.0800
11:05:32
LSE
907701
1
65.0600
11:06:30
LSE
908675
6,040
65.0600
11:06:30
LSE
908673
6,497
65.0600

11:06:30
LSE
908671
2,745
65.0500
11:06:31
LSE
908725
6,436
65.0500
11:06:36
LSE
908769
7,059
65.0500
11:06:36
LSE
908767
6,065
65.0500
11:06:36
LSE
908765
6,485
65.0500
11:06:36
LSE
908761
6,200
65.0200
11:07:39
LSE
909805
6,884
65.0000
11:09:22
LSE
911748
6,935
65.0000
11:09:22
LSE
911746
6,772
65.0000
11:09:22

LSE
911744
6,215
65.0100
11:09:22
LSE
911738
6,066
65.0100
11:09:22
LSE
911742
7,254
65.0100
11:09:22
LSE
911740
6,229
65.0100
11:09:22
LSE
911736
477
65.0900
11:11:53
LSE
914866
5,794
65.0900
11:11:53
LSE
914864
176
65.0900
11:13:34
LSE
916295
7,210
65.0900
11:13:34
LSE
916293
6,301
65.0900
11:13:45
LSE
916503
1,632
65.0900
11:13:45
LSE

916513
1,752
65.0900
11:13:45
LSE
916497
5,976
65.0900
11:13:45
LSE
916501
4,697
65.0900
11:13:45
LSE
916499
6,987
65.0900
11:13:45
LSE
916505
6,379
65.0900
11:13:45
LSE
916507
7,012
65.0900
11:13:45
LSE
916509
4,258
65.0900
11:13:45
LSE
916511
1,515
65.0900
11:13:45
LSE
916495
5,164
65.0900
11:13:45
LSE
916484
6,755
65.1000
11:14:40
LSE
917497

6,735
65.1000
11:14:40
LSE
917495
174
65.1000
11:14:40
LSE
917489
1,339
65.1000
11:14:40
LSE
917487
4,783
65.1000
11:14:40
LSE
917483
6,627
65.1000
11:14:40
LSE
917491
7,231
65.1000
11:14:40
LSE
917493
4,550
65.1000
11:14:40
LSE
917485
1,156
65.1000
11:14:40
LSE
917481
6,391
65.1000
11:15:45
LSE
918426
6,916
65.1000
11:15:45
LSE
918428
6,942

65.1000
11:15:45
LSE
918430
6,606
65.1000
11:15:45
LSE
918432
6,870
65.1000
11:15:45
LSE
918424
5,897
65.1000
11:15:45
LSE
918422
6,880
65.1000
11:15:45
LSE
918420
6,048
65.0900
11:16:43
LSE
919366
5,786
65.1000
11:19:34
LSE
922398
5,846
65.1000
11:19:34
LSE
922396
5,928
65.1000
11:20:21
LSE
923045
6,422
65.1000
11:20:21
LSE
923041
5,871
65.1000

11:20:21
LSE
923043
6,822
65.1000
11:20:21
LSE
923049
6,811
65.1000
11:20:21
LSE
923047
6,232
65.1000
11:20:21
LSE
923051
6,567
65.1000
11:20:21
LSE
923039
6,783
65.1000
11:20:21
LSE
923035
1,013
65.1000
11:20:21
LSE
923037
6,413
65.1000
11:22:45
LSE
925736
7,074
65.1000
11:22:45
LSE
925734
6,208
65.1000
11:22:45
LSE
925732
6,950
65.1000
11:22:45

LSE
925730
6,517
65.1000
11:22:45
LSE
925728
7,214
65.1000
11:22:45
LSE
925726
6,466
65.1000
11:22:45
LSE
925724
6,099
65.1000
11:22:45
LSE
925722
6,467
65.1000
11:24:30
LSE
927756
6,574
65.1000
11:24:30
LSE
927750
6,328
65.1000
11:24:30
LSE
927754
6,631
65.1000
11:24:30
LSE
927752
3,026
65.1000
11:24:30
LSE
927758
5,859
65.1000
11:24:30
LSE

927760
678
65.1000
11:24:30
LSE
927762
3,089
65.1000
11:24:30
LSE
927764
7,166
65.1000
11:24:55
LSE
928300
7,184
65.1000
11:24:55
LSE
928298
5,851
65.1000
11:24:55
LSE
928296
6,014
65.1000
11:24:55
LSE
928294
5,946
65.1400
11:25:55
LSE
929930
6,451
65.1400
11:25:55
LSE
929924
6,575
65.1400
11:25:55
LSE
929922
6,522
65.1400
11:25:55
LSE
929920

6,473
65.1400
11:25:55
LSE
929926
6,457
65.1400
11:25:55
LSE
929928
4,305
65.1000
11:29:54
LSE
934179
6,507
65.1000
11:29:54
LSE
934175
407
65.1000
11:29:54
LSE
934177
5,852
65.1000
11:29:54
LSE
934181
6,134
65.1000
11:29:54
LSE
934183
6,624
65.1000
11:29:54
LSE
934185
2,419
65.1000
11:29:54
LSE
934173
6,450
65.1000
11:29:54
LSE
934171
6,166

65.1000
11:29:54
LSE
934169
6,050
65.1000
11:29:54
LSE
934167
6,886
65.0800
11:30:07
LSE
934563
7,049
65.0800
11:30:07
LSE
934561
6,048
65.0800
11:30:07
LSE
934559
5,854
65.0600
11:30:25
LSE
934972
6,090
65.0400
11:30:46
LSE
935354
4,653
65.0300
11:31:46
LSE
936337
5,846
65.0300
11:31:46
LSE
936333
6,542
65.0300
11:31:46
LSE
936327
2,415
65.0300

11:31:46
LSE
936335
6,509
65.0400
11:33:00
LSE
937584
7,287
65.0400
11:33:00
LSE
937578
6,611
65.0400
11:33:00
LSE
937582
7,231
65.0400
11:33:00
LSE
937580
7,299
65.0400
11:33:00
LSE
937576
7,305
65.0300
11:33:07
LSE
937684
6,515
65.0500
11:36:47
LSE
940987
7,802
65.0500
11:36:47
LSE
940989
1,967
65.0500
11:36:47
LSE
940991
7,103
65.0500
11:36:47

LSE
940985
5,146
65.0500
11:36:47
LSE
940983
7,236
65.0500
11:36:47
LSE
940981
6,517
65.0500
11:36:47
LSE
940979
313
65.0500
11:36:47
LSE
940977
6,235
65.0500
11:36:47
LSE
940975
6,384
65.0500
11:36:47
LSE
940973
2,279
65.0400
11:37:44
LSE
941828
6,069
65.0400
11:37:44
LSE
941826
4,108
65.0400
11:37:44
LSE
941824
7,189
65.0400
11:37:44
LSE

941822
7,119
65.0400
11:37:44
LSE
941820
2,460
65.0300
11:37:56
LSE
942068
6,670
65.0300
11:37:56
LSE
942060
757
65.0300
11:37:56
LSE
942058
5,964
65.0300
11:37:56
LSE
942056
9,140
65.1000
11:42:49
LSE
947132
7,915
65.1000
11:42:49
LSE
947130
7,380
65.1000
11:42:49
LSE
947128
6,615
65.1000
11:42:49
LSE
947126
6,871
65.1000
11:42:49
LSE
947124

6,709
65.1000
11:42:49
LSE
947118
7,490
65.1000
11:42:49
LSE
947116
8,287
65.1000
11:42:49
LSE
947120
803
65.1000
11:42:49
LSE
947122
7,156
65.0800
11:43:15
LSE
947518
7,260
65.0800
11:43:15
LSE
947514
7,013
65.0800
11:43:15
LSE
947512
7,082
65.0800
11:43:15
LSE
947510
5,888
65.0800
11:43:15
LSE
947508
6,798
65.0800
11:43:15
LSE
947516
3,000

65.1000
11:46:43
LSE
950340
3,460
65.1000
11:46:43
LSE
950338
7,119
65.1000
11:46:43
LSE
950336
6,278
65.1000
11:46:43
LSE
950334
7,291
65.1000
11:46:43
LSE
950330
6,306
65.1000
11:46:43
LSE
950320
3,731
65.1000
11:46:43
LSE
950316
2,825
65.1000
11:46:43
LSE
950318
7,169
65.1000
11:46:43
LSE
950328
6,503
65.1000
11:46:43
LSE
950322
6,223
65.1000

11:46:43
LSE
950324
7,273
65.1000
11:46:43
LSE
950326
7,045
65.1000
11:46:43
LSE
950314
5,756
65.1000
11:49:02
LSE
952504
1,451
65.1000
11:49:02
LSE
952502
7,122
65.1000
11:49:02
LSE
952500
7,080
65.1000
11:49:02
LSE
952498
6,598
65.1000
11:49:02
LSE
952485
5,913
65.1000
11:49:02
LSE
952483
6,405
65.1000
11:49:02
LSE
952481
7,205
65.1000
11:49:02

LSE
952479
2,061
65.1000
11:49:02
LSE
952477
1,168
65.1000
11:49:02
LSE
952475
2,712
65.1000
11:49:02
LSE
952473
6,714
65.1000
11:51:37
LSE
955000
5,868
65.1000
11:51:37
LSE
954998
5,988
65.1000
11:51:37
LSE
954996
7,042
65.1000
11:51:37
LSE
954994
7,054
65.1000
11:51:37
LSE
954992
6,875
65.1000
11:51:37
LSE
954990
6,722
65.1000
11:51:37
LSE

954988
4,293
65.1000
11:51:37
LSE
954986
2,576
65.1000
11:51:37
LSE
954984
6,659
65.1000
11:52:36
LSE
955800
6,712
65.1000
11:52:36
LSE
955798
4,778
65.1000
11:53:36
LSE
957289
1,534
65.1000
11:53:36
LSE
957286
6,353
65.1000
11:54:07
LSE
957861
6,333
65.1000
11:54:07
LSE
957859
6,878
65.1000
11:54:07
LSE
957857
6,736
65.1000
11:54:07
LSE
957855

6,517
65.1000
11:54:07
LSE
957853
6,287
65.1000
11:55:42
LSE
960095
6,963
65.1000
11:55:42
LSE
960087
5,436
65.1000
11:55:42
LSE
960089
6,515
65.1000
11:55:42
LSE
960093
1,491
65.1000
11:55:42
LSE
960091
2,175
65.1000
11:55:42
LSE
960097
6,187
65.1000
11:55:42
LSE
960099
6,326
65.1000
11:55:42
LSE
960101
4,640
65.1000
11:55:42
LSE
960103
6,521

65.1000
11:55:42
LSE
960085
6,014
65.0800
11:55:50
LSE
960309
6,033
65.0800
11:55:50
LSE
960307
6,275
65.0900
11:57:28
LSE
962576
5,990
65.0900
11:57:28
LSE
962574
6,842
65.0900
11:57:28
LSE
962572
3,154
65.0900
11:57:28
LSE
962570
7,121
65.0900
11:57:28
LSE
962566
7,066
65.0900
11:57:28
LSE
962564
3,765
65.0900
11:57:28
LSE
962568
6,487
65.0900

11:57:28
LSE
962562
7,212
65.0900
11:57:28
LSE
962560
6,217
65.0600
11:58:54
LSE
964842
7,085
65.0600
11:58:54
LSE
964840
6,201
65.0600
11:58:54
LSE
964838
6,868
65.0600
11:58:54
LSE
964836
6,544
65.0600
11:59:35
LSE
965802
6,536
65.0600
11:59:35
LSE
965804
6,958
65.0500
11:59:39
LSE
965972
164
65.0500
11:59:39
LSE
965970
6,836
65.0500
11:59:39

LSE
965968
6,057
65.0100
11:59:56
LSE
966574
2,077
65.0100
12:02:53
LSE
971458
7,279
65.0100
12:03:08
LSE
971844
4,649
65.0100
12:03:08
LSE
971840
7,033
65.0100
12:03:08
LSE
971842
6,895
65.0100
12:03:08
LSE
971848
7,553
65.0100
12:03:08
LSE
971846
7,077
65.0100
12:03:08
LSE
971852
8,044
65.0100
12:03:08
LSE
971850
2,397
65.0100
12:03:08
LSE

971838
5,036
65.0100
12:03:08
LSE
971836
4,740
65.0000
12:03:16
LSE
971978
6,352
65.0000
12:03:16
LSE
971976
1,258
65.0100
12:03:44
LSE
972596
4,995
65.0100
12:03:52
LSE
972738
1,652
65.0100
12:03:52
LSE
972734
5,961
65.0100
12:03:52
LSE
972736
6,402
65.0100
12:03:52
LSE
972740
6,113
65.0100
12:03:52
LSE
972742
6,722
65.0100
12:03:52
LSE
972730

4,908
65.0100
12:03:52
LSE
972728
1,112
65.0100
12:03:52
LSE
972726
1,225
65.0100
12:03:52
LSE
972732
2,115
65.0000
12:04:32
LSE
973459
4,226
65.0000
12:05:13
LSE
974492
2,842
65.0000
12:05:24
LSE
974767
5,867
65.0000
12:05:30
LSE
974911
5,988
64.9900
12:05:50
LSE
975321
2,079
64.9900
12:05:50
LSE
975319
6,579
64.9900
12:05:50
LSE
975317
6,907

64.9900
12:05:50
LSE
975311
6,750
64.9900
12:05:50
LSE
975315
4,229
64.9900
12:05:50
LSE
975313
3,205
64.9800
12:06:16
LSE
975854
3,576
64.9800
12:06:17
LSE
975877
1,561
64.9800
12:06:46
LSE
976560
5,563
64.9800
12:06:46
LSE
976558
151
64.9800
12:06:54
LSE
976758
7,035
64.9800
12:07:48
LSE
977673
5,846
64.9800
12:07:48
LSE
977671
1,290
65.0100

12:08:54
LSE
978678
3,737
65.0100
12:08:54
LSE
978676
1,290
65.0100
12:08:54
LSE
978674
6,583
65.0100
12:08:54
LSE
978672
2,480
65.0100
12:08:54
LSE
978670
6,005
65.0100
12:08:54
LSE
978668
6,450
65.0100
12:08:54
LSE
978666
4,196
65.0100
12:08:54
LSE
978664
6,094
65.0100
12:08:54
LSE
978660
6,660
65.0100
12:08:54
LSE
978662
306
65.0100
12:08:54

LSE
978658
6,913
64.9800
12:09:31
LSE
979820
1,545
65.0000
12:10:35
LSE
980885
4,364
65.0000
12:10:35
LSE
980887
7,173
65.0000
12:10:35
LSE
980883
705
65.0400
12:11:40
LSE
981993
6,302
65.0400
12:11:40
LSE
981991
4,102
65.0400
12:11:49
LSE
982123
6,835
65.0400
12:11:49
LSE
982121
1,938
65.0400
12:11:49
LSE
982127
711
65.0400
12:11:49
LSE

982125
6,518
65.0400
12:11:49
LSE
982119
7,134
65.0400
12:11:49
LSE
982117
3,392
65.0400
12:11:49
LSE
982115
2,649
65.0400
12:11:49
LSE
982113
3,190
65.0900
12:13:04
LSE
983698
6,206
65.0900
12:13:04
LSE
983696
6,275
65.0900
12:13:04
LSE
983694
6,778
65.1000
12:14:20
LSE
985008
6,560
65.1000
12:14:20
LSE
985006
6,171
65.1000
12:14:20
LSE
985004

6,245
65.1000
12:14:20
LSE
985002
7,126
65.1000
12:14:20
LSE
985000
8,096
65.1000
12:14:20
LSE
985010
420
65.0900
12:15:04
LSE
985737
6,140
65.0900
12:15:14
LSE
986062
2,441
65.0900
12:15:14
LSE
986060
5,453
65.0900
12:15:14
LSE
986058
5,948
65.0900
12:15:25
LSE
986297
1,401
65.0900
12:15:25
LSE
986295
3,536
65.0900
12:15:25
LSE
986291
4,484

65.0900
12:15:25
LSE
986293
1,761
65.0900
12:17:17
LSE
988313
4,163
65.0900
12:17:17
LSE
988311
2,837
65.0900
12:17:17
LSE
988309
4,449
65.0900
12:17:17
LSE
988307
6,934
65.0900
12:17:17
LSE
988305
7,217
65.0900
12:17:17
LSE
988303
836
65.0900
12:17:17
LSE
988300
7,141
65.0900
12:17:17
LSE
988298
5,400
65.0900
12:17:17
LSE
988296
6,217
65.0900

12:17:17
LSE
988294
5,199
65.0900
12:17:17
LSE
988292
6,060
65.0900
12:17:17
LSE
988290
858
65.0900
12:17:17
LSE
988288
7,141
65.0500
12:18:16
LSE
989436
6,871
65.0500
12:18:16
LSE
989434
6,871
65.1000
12:20:34
LSE
991629
6,597
65.1000
12:20:34
LSE
991623
7,066
65.1000
12:20:34
LSE
991621
6,283
65.1000
12:20:34
LSE
991625
6,729
65.1000
12:20:34

LSE
991627
6,865
65.1000
12:20:34
LSE
991619
6,529
65.1000
12:20:34
LSE
991617
7,115
65.1000
12:20:34
LSE
991615
5,659
65.1000
12:21:29
LSE
992519
853
65.1000
12:21:29
LSE
992517
782
65.1000
12:21:29
LSE
992515
6,450
65.1000
12:22:34
LSE
993900
3,626
65.1000
12:22:34
LSE
993902
5,913
65.1000
12:22:34
LSE
993904
6,126
65.1000
12:22:34
LSE

993908
2,738
65.1000
12:22:34
LSE
993906
1,104
65.1000
12:22:34
LSE
993898
6,188
65.1000
12:22:34
LSE
993896
7,278
65.1000
12:23:04
LSE
994466
6,867
65.1000
12:23:04
LSE
994464
6,685
65.1000
12:23:04
LSE
994462
5,584
65.0900
12:23:43
LSE
995501
1,144
65.0900
12:24:26
LSE
996202
6,604
65.0800
12:24:52
LSE
996818
6,544
65.0800
12:24:52
LSE
996816

6,600
65.0800
12:24:52
LSE
996814
7,057
65.0800
12:24:52
LSE
996812
5,939
65.0800
12:24:52
LSE
996810
6,280
65.0700
12:24:54
LSE
996883
7,041
65.0600
12:26:27
LSE
999157
6,286
65.0600
12:26:27
LSE
999155
5,858
65.0600
12:26:27
LSE
999153
7,081
65.1000
12:27:30
LSE
1000635
6,429
65.1000
12:27:30
LSE
1000633
6,164
65.1000
12:27:30
LSE
1000631
6,993

65.1000
12:27:30
LSE
1000629
6,919
65.0900
12:27:37
LSE
1000760
4,222
65.0500
12:28:37
LSE
1002085
1,372
65.0500
12:28:37
LSE
1002083
381
65.0500
12:28:37
LSE
1002081
5,883
65.0500
12:28:37
LSE
1002079
5,885
65.0500
12:28:37
LSE
1002077
2,895
65.0500
12:29:00
LSE
1002520
1,069
65.0500
12:29:00
LSE
1002518
2,420
65.0500
12:29:00
LSE
1002516
500
65.0500

12:29:00
LSE
1002514
6,080
65.0300
12:29:40
LSE
1003300
6,890
65.0300
12:29:40
LSE
1003298
395
65.0300
12:29:40
LSE
1003296
6,614
65.0300
12:29:40
LSE
1003294
3,430
65.0200
12:30:40
LSE
1004962
846
65.0300
12:30:40
LSE
1004960
5,827
65.0300
12:30:40
LSE
1004958
846
65.0300
12:30:40
LSE
1004952
5,473
65.0300
12:30:40
LSE
1004954
6,413
65.0300
12:30:40

LSE
1004956
6,859
65.0200
12:31:29
LSE
1006296
3,511
65.0200
12:31:29
LSE
1006283
6,276
65.0300
12:32:49
LSE
1008001
6,587
65.0300
12:32:49
LSE
1007999
827
65.0300
12:32:49
LSE
1008003
7,080
65.0300
12:32:49
LSE
1007997
6,057
65.0300
12:32:49
LSE
1007995
7,141
65.0300
12:32:49
LSE
1007993
1,089
65.0300
12:32:49
LSE
1007991
7,061
65.0300
12:34:09
LSE

1009152
6,777
65.0300
12:34:09
LSE
1009150
6,907
65.0300
12:34:09
LSE
1009148
5,872
65.0300
12:34:09
LSE
1009146
6,424
64.9700
12:34:48
LSE
1009855
6,009
64.9500
12:35:08
LSE
1010236
1,023
64.9400
12:35:10
LSE
1010272
7,008
64.9300
12:35:38
LSE
1010678
6,342
64.9300
12:35:38
LSE
1010680
6,633
64.9300
12:35:38
LSE
1010682
5,832
64.9400
12:35:38
LSE
1010676

6,290
64.9300
12:37:50
LSE
1013855
7,218
64.9300
12:37:50
LSE
1013853
6,481
64.9300
12:37:50
LSE
1013851
7,012
64.9200
12:37:59
LSE
1014002
6,825
64.9900
12:40:04
LSE
1016340
6,195
64.9900
12:40:04
LSE
1016342
7,114
64.9900
12:40:04
LSE
1016338
6,913
64.9900
12:40:04
LSE
1016336
6,524
64.9900
12:40:04
LSE
1016334
6,213
64.9900
12:40:04
LSE
1016332
7,163

64.9900
12:40:04
LSE
1016330
6,509
64.9600
12:40:34
LSE
1016760
7,085
64.9600
12:40:34
LSE
1016758
6,873
64.9600
12:40:34
LSE
1016756
3,117
64.9600
12:40:34
LSE
1016754
3,411
64.9600
12:40:34
LSE
1016752
82,304
64.9000
12:41:20
LSE
1017512
6,097
64.9100
12:41:20
LSE
1017509
6,460
64.9100
12:41:20
LSE
1017507
7,013
64.9000
12:41:26
LSE
1017717
957
64.9000

12:41:26
LSE
1017721
12,770
64.9000
12:41:26
LSE
1017719
7,065
64.9000
12:41:29
LSE
1017808
6,861
64.9000
12:41:29
LSE
1017796
7,068
64.9000
12:41:29
LSE
1017788
6,225
64.9000
12:41:29
LSE
1017790
10,008
64.9000
12:41:29
LSE
1017792
6,922
64.9000
12:41:29
LSE
1017794
6,596
64.9000
12:41:29
LSE
1017800
33,158
64.9000
12:41:29
LSE
1017798
6,157
64.9000
12:41:29

LSE
1017804
6,199
64.9000
12:41:29
LSE
1017806
6,893
64.9000
12:41:29
LSE
1017802
7,110
64.9000
12:41:29
LSE
1017786
4,917
64.9000
12:41:29
LSE
1017784
5,845
64.9000
12:41:29
LSE
1017782
1,759
64.8800
12:41:36
LSE
1017921
19,217
64.8800
12:41:36
LSE
1017919
3,118
64.8800
12:41:36
LSE
1017917
1,867
64.8800
12:41:36
LSE
1017915
6,580
64.8800
12:41:36
LSE

1017923
9,945
64.8800
12:41:36
LSE
1017913
6,080
64.8700
12:42:25
LSE
1018577
7,149
64.8700
12:42:25
LSE
1018575
38,631
64.8700
12:42:25
LSE
1018579
6,242
64.8800
12:42:25
LSE
1018572
48,860
64.8800
12:42:25
LSE
1018570
7,147
64.8500
12:42:52
LSE
1019084
4,327
64.8500
12:42:52
LSE
1019082
1,623
64.8500
12:42:52
LSE
1019080
6,349
64.8600
12:42:52
LSE
1019078

27,082
64.8600
12:42:52
LSE
1019076
6,848
64.8500
12:43:07
LSE
1019315
8,043
64.8500
12:43:07
LSE
1019313
13,402
64.8000
12:43:16
LSE
1019443
12,480
64.8100
12:43:16
LSE
1019441
13,351
64.8400
12:43:16
LSE
1019439
6,247
64.8400
12:43:16
LSE
1019437
7,096
64.8400
12:43:16
LSE
1019435
12,937
64.7900
12:43:17
LSE
1019449
3,979
64.7800
12:43:22
LSE
1019501
8,290

64.7800
12:43:22
LSE
1019499
6,922
64.7800
12:43:22
LSE
1019497
6,239
64.8000
12:44:04
LSE
1020349
3,944
64.8000
12:44:04
LSE
1020347
5,594
64.8000
12:44:04
LSE
1020345
6,576
64.7900
12:44:42
LSE
1021056
6,101
64.7900
12:44:42
LSE
1021058
9,096
64.7900
12:44:42
LSE
1021060
9,744
64.7900
12:44:42
LSE
1021054
6,291
64.7800
12:44:46
LSE
1021103
6,078
64.7700

12:45:22
LSE
1021950
6,446
64.7600
12:45:26
LSE
1022130
6,597
64.7600
12:45:26
LSE
1022128
6,619
64.7600
12:45:26
LSE
1022126
3,525
64.7500
12:45:45
LSE
1022496
2,777
64.7500
12:45:45
LSE
1022494
3,475
64.7500
12:45:45
LSE
1022498
2,683
64.7500
12:45:45
LSE
1022500
5,856
64.7500
12:45:45
LSE
1022491
6,004
64.7500
12:45:45
LSE
1022488
6,314
64.7000
12:47:56

LSE
1025277
6,481
64.7000
12:47:56
LSE
1025275
6,254
64.7000
12:47:56
LSE
1025273
5,951
64.7000
12:47:56
LSE
1025271
6,678
64.8100
12:50:09
LSE
1027547
563
64.8100
12:50:09
LSE
1027545
6,838
64.8200
12:50:09
LSE
1027524
6,651
64.8200
12:50:09
LSE
1027528
6,910
64.8200
12:50:09
LSE
1027526
7,264
64.8200
12:50:09
LSE
1027532
4,944
64.8200
12:50:09
LSE

1027530
1,676
64.8200
12:50:09
LSE
1027534
7,002
64.8200
12:50:09
LSE
1027522
3,236
64.8200
12:50:09
LSE
1027518
7,241
64.8200
12:50:09
LSE
1027516
2,708
64.8200
12:50:09
LSE
1027520
785
64.8100
12:51:18
LSE
1029021
6,215
64.8100
12:51:18
LSE
1029019
1,626
64.8100
12:51:18
LSE
1029017
4,587
64.8100
12:51:18
LSE
1029015
2,413
64.8100
12:51:18
LSE
1029013

4,160
64.8100
12:51:18
LSE
1029011
5,880
64.8100
12:51:18
LSE
1029009
6,816
64.8300
12:51:58
LSE
1030018
6,603
64.8300
12:51:58
LSE
1030016
6,786
64.8300
12:51:58
LSE
1030014
6,862
64.8500
12:54:34
LSE
1033819
6,252
64.8500
12:54:34
LSE
1033817
6,488
64.8500
12:54:34
LSE
1033821
6,032
64.8500
12:54:34
LSE
1033815
6,294
64.8500
12:54:34
LSE
1033813
5,896

64.8500
12:54:34
LSE
1033811
6,680
64.8500
12:54:34
LSE
1033809
6,375
64.8500
12:54:34
LSE
1033807
6,906
64.8500
12:54:34
LSE
1033805
6,767
64.8100
12:55:06
LSE
1034411
1,943
64.8100
12:55:06
LSE
1034409
2,254
64.8100
12:55:06
LSE
1034407
1,943
64.8100
12:55:06
LSE
1034405
1,943
64.8100
12:55:06
LSE
1034403
3,903
64.8100
12:55:06
LSE
1034401
2,198
64.7700

12:56:52
LSE
1036578
4,082
64.7700
12:56:52
LSE
1036576
6,498
64.7700
12:56:52
LSE
1036580
3,929
64.7700
12:56:53
LSE
1036612
6,718
64.7800
12:57:33
LSE
1037509
6,072
64.7800
12:57:33
LSE
1037507
6,745
64.7800
12:57:33
LSE
1037505
869
64.7800
12:57:33
LSE
1037503
7,270
64.7800
12:57:33
LSE
1037501
6,560
64.7800
12:57:33
LSE
1037499
6,462
64.7700
12:57:36

LSE
1037522
2,011
64.7700
12:57:36
LSE
1037520
6,186
64.7800
12:59:31
LSE
1039973
6,425
64.7800
12:59:31
LSE
1039971
5,896
64.7800
12:59:31
LSE
1039963
6,796
64.7800
12:59:31
LSE
1039961
5,897
64.7800
12:59:31
LSE
1039967
6,073
64.7800
12:59:31
LSE
1039965
6,397
64.7800
12:59:31
LSE
1039969
7,072
64.7700
12:59:33
LSE
1040033
6,888
64.7500
13:00:05
LSE

1040813
6,092
64.7400
13:00:19
LSE
1041069
6,075
64.7300
13:00:35
LSE
1041485
1,870
64.7200
13:01:08
LSE
1042374
4,862
64.7200
13:01:08
LSE
1042370
6,073
64.7200
13:01:08
LSE
1042372
6,917
64.7100
13:01:12
LSE
1042443
6,198
64.7100
13:01:12
LSE
1042445
7,249
64.6800
13:01:42
LSE
1043089
6,213
64.6700
13:01:48
LSE
1043227
7,140
64.6300
13:02:28
LSE
1044099

7,176
64.6300
13:02:28
LSE
1044097
5,892
64.6300
13:02:28
LSE
1044095
2,967
64.6500
13:03:29
LSE
1045179
6,969
64.6500
13:03:29
LSE
1045177
9,608
64.9400
13:11:03
LSE
1053701
10,062
64.9400
13:11:03
LSE
1053697
9,900
64.9400
13:11:03
LSE
1053699
8,653
64.9400
13:11:03
LSE
1053703
11,155
64.9400
13:11:03
LSE
1053705
9,256
64.9400
13:11:03
LSE
1053707
10,004

64.9400
13:11:03
LSE
1053693
9,322
64.9400
13:11:03
LSE
1053695
6,795
64.9200
13:12:08
LSE
1054727
6,607
64.9200
13:12:08
LSE
1054721
6,771
64.9200
13:12:08
LSE
1054723
6,614
64.9200
13:12:08
LSE
1054725
8,261
64.9200
13:12:08
LSE
1054733
6,195
64.9200
13:12:08
LSE
1054729
6,277
64.9200
13:12:08
LSE
1054731
6,728
64.9200
13:12:08
LSE
1054735
6,455
64.9000

13:12:23
LSE
1054984
7,791
64.9000
13:12:23
LSE
1054982
1,124
64.9000
13:12:23
LSE
1054990
6,604
64.9000
13:12:23
LSE
1054986
4,917
64.9000
13:12:23
LSE
1054988
6,435
64.9000
13:12:23
LSE
1054980
6,827
64.9000
13:12:23
LSE
1054978
5,930
64.9000
13:12:23
LSE
1054976
6,084
64.9000
13:12:23
LSE
1054974
11,093
64.9000
13:12:23
LSE
1054972
3,063
64.8900
13:12:42

LSE
1055257
8,751
64.8900
13:12:42
LSE
1055261
3,148
64.8900
13:12:42
LSE
1055259
4,361
64.8700
13:13:20
LSE
1055940
4,145
64.8700
13:13:20
LSE
1055938
2,045
64.8700
13:13:20
LSE
1055936
1,157
64.8700
13:13:20
LSE
1055934
2,600
64.8700
13:13:20
LSE
1055942
6,392
64.8700
13:13:20
LSE
1055932
6,144
64.8700
13:13:20
LSE
1055930
7,586
64.8700
13:13:20
LSE

1055928
6,128
64.8600
13:13:24
LSE
1056015
3,462
64.8600
13:13:24
LSE
1056013
2,819
64.8600
13:13:24
LSE
1056011
5,921
64.8500
13:13:40
LSE
1056428
3,611
64.8600
13:14:23
LSE
1057361
6,047
64.8600
13:14:23
LSE
1057359
5,876
64.8600
13:14:23
LSE
1057357
2,958
64.8600
13:14:23
LSE
1057355
6,888
65.0000
13:19:28
LSE
1063718
6,231
65.0000
13:19:28
LSE
1063716

7,247
65.0000
13:19:28
LSE
1063708
2,863
65.0000
13:19:28
LSE
1063704
6,028
65.0000
13:19:28
LSE
1063706
6,757
65.0000
13:19:28
LSE
1063712
7,180
65.0000
13:19:28
LSE
1063710
5,922
65.0000
13:19:28
LSE
1063714
3,496
65.0000
13:19:28
LSE
1063702
6,641
64.9800
13:20:42
LSE
1065176
6,838
64.9800
13:20:42
LSE
1065172
6,677
64.9800
13:20:42
LSE
1065174
7,004

64.9800
13:20:42
LSE
1065180
7,131
64.9800
13:20:42
LSE
1065178
7,298
64.9800
13:20:42
LSE
1065182
6,320
64.9800
13:20:42
LSE
1065169
6,697
64.9800
13:20:42
LSE
1065167
165
64.9500
13:20:45
LSE
1065246
5,906
64.9500
13:20:45
LSE
1065244
5,919
64.9500
13:20:45
LSE
1065242
6,983
64.9500
13:20:45
LSE
1065240
7,285
64.9500
13:20:45
LSE
1065238
7,149
64.9500

13:20:45
LSE
1065236
7,095
64.9500
13:20:45
LSE
1065234
6,125
64.9500
13:20:45
LSE
1065232
6,392
64.9600
13:21:27
LSE
1065985
6,371
64.9600
13:21:27
LSE
1065987
6,637
64.9000
13:22:56
LSE
1067587
1,342
64.9000
13:22:56
LSE
1067585
6,310
64.9000
13:22:56
LSE
1067583
6,782
64.9000
13:22:56
LSE
1067581
3,712
64.9000
13:22:56
LSE
1067579
2,661
64.9000
13:22:56

LSE
1067577
6,589
64.9100
13:22:56
LSE
1067575
989
64.9000
13:23:03
LSE
1067712
983
64.9000
13:23:10
LSE
1067837
902
64.9000
13:23:16
LSE
1067897
136
64.9000
13:23:22
LSE
1068013
800
64.9000
13:23:22
LSE
1068011
6,442
64.9000
13:23:22
LSE
1068009
5,788
64.9000
13:23:22
LSE
1068007
2,104
64.9000
13:23:22
LSE
1068005
969
64.9000
13:23:30
LSE

1068162
983
64.9000
13:23:37
LSE
1068310
3,937
64.9000
13:24:05
LSE
1068900
1,216
64.9400
13:24:05
LSE
1068896
6,700
64.9400
13:24:05
LSE
1068894
4,806
64.9400
13:24:05
LSE
1068892
6,756
64.9000
13:24:15
LSE
1069051
3,086
64.9000
13:24:15
LSE
1069049
175
64.9000
13:24:15
LSE
1069047
1,492
64.9000
13:24:15
LSE
1069045
683
64.9000
13:24:32
LSE
1069349

4,536
64.9000
13:24:55
LSE
1069944
3,177
64.9000
13:24:55
LSE
1069933
6,777
64.9200
13:24:55
LSE
1069931
534
64.8900
13:25:14
LSE
1070274
2,440
64.8900
13:25:14
LSE
1070272
3,224
64.8900
13:25:14
LSE
1070270
6,991
64.9400
13:26:22
LSE
1071775
7,248
64.9400
13:26:22
LSE
1071771
6,054
64.9400
13:26:22
LSE
1071773
6,622
64.9400
13:26:22
LSE
1071779
6,753

64.9400
13:26:22
LSE
1071777
5,944
64.9400
13:26:22
LSE
1071781
6,117
64.9400
13:26:22
LSE
1071783
6,227
64.9000
13:26:27
LSE
1071874
6,252
64.9000
13:28:20
LSE
1073960
396
64.9000
13:28:20
LSE
1073958
1,569
64.9000
13:28:32
LSE
1074089
982
64.9000
13:28:39
LSE
1074156
982
64.9000
13:28:46
LSE
1074265
982
64.9000
13:28:53
LSE
1074419
7,497
64.9500

13:30:40
LSE
1076803
9,419
64.9500
13:30:40
LSE
1076801
7,668
64.9500
13:30:40
LSE
1076805
210
64.9500
13:30:40
LSE
1076807
6,986
64.9500
13:30:40
LSE
1076799
7,292
64.9500
13:30:40
LSE
1076793
8,335
64.9500
13:30:40
LSE
1076791
7,549
64.9500
13:30:40
LSE
1076797
7,500
64.9500
13:30:40
LSE
1076795
145
64.9200
13:31:10
LSE
1077533
6,093
64.9200
13:31:10

LSE
1077531
7,033
64.9200
13:31:10
LSE
1077529
1,819
64.9200
13:31:10
LSE
1077527
6,648
64.9200
13:31:10
LSE
1077525
6,695
64.9200
13:31:10
LSE
1077523
5,956
64.9200
13:31:10
LSE
1077521
4,636
64.9200
13:31:10
LSE
1077519
6,466
64.9700
13:33:06
LSE
1080076
744
64.9700
13:33:06
LSE
1080074
6,256
64.9700
13:33:06
LSE
1080072
6,907
64.9700
13:33:06
LSE

1080070
6,849
64.9700
13:33:06
LSE
1080060
6,512
64.9700
13:33:06
LSE
1080054
6,464
64.9700
13:33:06
LSE
1080058
6,991
64.9700
13:33:06
LSE
1080056
7,002
64.9700
13:33:06
LSE
1080062
5,997
64.9700
13:33:06
LSE
1080064
26
64.9700
13:33:06
LSE
1080066
8,463
64.9700
13:33:06
LSE
1080068
6,480
64.9500
13:35:09
LSE
1083044
6,409
64.9500
13:35:09
LSE
1083042

6,307
64.9500
13:35:09
LSE
1083040
1,917
64.9500
13:35:09
LSE
1083038
705
64.9500
13:35:09
LSE
1083036
6,711
64.9500
13:35:09
LSE
1083034
4,542
64.9500
13:35:09
LSE
1083032
5,888
64.9500
13:35:09
LSE
1083030
6,163
64.9500
13:35:09
LSE
1083028
6,886
64.9500
13:36:05
LSE
1084704
7,181
64.9500
13:36:05
LSE
1084702
6,142
64.9500
13:36:05
LSE
1084700
2,458

64.9400
13:36:08
LSE
1084893
5
64.9400
13:36:08
LSE
1084891
4,338
64.9400
13:36:08
LSE
1084889
107
64.9400
13:36:08
LSE
1084887
2,216
64.9300
13:36:57
LSE
1085881
4,238
64.9300
13:36:57
LSE
1085879
6,686
64.9200
13:38:13
LSE
1087341
5,708
64.9300
13:38:13
LSE
1087327
5,883
64.9300
13:38:13
LSE
1087329
263
64.9300
13:38:13
LSE
1087333
5,044
64.9300

13:38:13
LSE
1087331
2,082
64.9300
13:38:13
LSE
1087335
5,958
64.9300
13:38:13
LSE
1087325
5,851
64.9300
13:38:13
LSE
1087323
4,822
64.9000
13:38:22
LSE
1087647
2,281
64.9000
13:38:22
LSE
1087645
3,889
64.9000
13:38:22
LSE
1087643
4,822
64.9000
13:38:22
LSE
1087641
6,005
64.8900
13:38:25
LSE
1087853
9,913
64.8900
13:38:25
LSE
1087851
9,443
64.8800
13:38:41

LSE
1088124
3,908
64.8900
13:39:47
LSE
1089368
2,823
64.8900
13:39:47
LSE
1089366
7,241
64.8900
13:39:47
LSE
1089360
5,791
64.8900
13:39:47
LSE
1089347
510
64.8900
13:39:47
LSE
1089345
6,733
64.8900
13:39:47
LSE
1089343
6,369
64.8900
13:39:47
LSE
1089341
9,610
64.8900
13:39:47
LSE
1089339
4,370
64.8900
13:39:47
LSE
1089337
651
64.8900
13:39:47
LSE

1089335
6,113
64.8900
13:39:47
LSE
1089331
1,987
64.8900
13:39:47
LSE
1089333
6,966
64.9400
13:43:45
LSE
1095046
289
64.9400
13:43:45
LSE
1095044
6,208
64.9400
13:43:45
LSE
1095042
5,283
64.9400
13:43:45
LSE
1095038
792
64.9400
13:43:45
LSE
1095040
6,618
64.9400
13:43:45
LSE
1095036
6,796
64.9400
13:43:45
LSE
1095034
7,126
64.9400
13:43:45
LSE
1095032

6,689
64.9400
13:43:45
LSE
1095030
6,969
64.9400
13:43:45
LSE
1095028
6,450
64.9400
13:43:45
LSE
1095026
6,914
64.9400
13:43:45
LSE
1095024
7,009
64.9400
13:43:45
LSE
1095020
7,204
64.9400
13:43:45
LSE
1095018
6,752
64.9400
13:43:45
LSE
1095022
6,932
64.9300
13:44:56
LSE
1096601
4,653
64.9300
13:44:56
LSE
1096599
1,274
64.9300
13:44:56
LSE
1096597
3,799

64.9300
13:44:56
LSE
1096595
2,408
64.9300
13:44:56
LSE
1096593
6,620
64.9200
13:45:20
LSE
1097208
5,898
64.9200
13:45:20
LSE
1097204
7,043
64.9200
13:45:20
LSE
1097216
6,402
64.9200
13:45:20
LSE
1097210
6,926
64.9200
13:45:20
LSE
1097214
906
64.9200
13:45:20
LSE
1097200
6,628
64.9200
13:45:20
LSE
1097198
6,130
64.9000
13:46:30
LSE
1098429
6,033
64.9000

13:46:30
LSE
1098427
6,758
64.9000
13:46:30
LSE
1098425
6,517
64.9000
13:46:30
LSE
1098423
7,129
64.9000
13:46:30
LSE
1098421
1,823
64.8800
13:46:33
LSE
1098498
4,559
64.8800
13:46:33
LSE
1098496
1,823
64.8800
13:46:33
LSE
1098494
7,077
64.8700
13:46:52
LSE
1098874
6,010
64.8600
13:46:57
LSE
1098959
6,809
64.8900
13:49:22
LSE
1102140
1,353
64.8900
13:49:22

LSE
1102142
7,301
64.8900
13:49:22
LSE
1102144
1,137
64.8900
13:49:22
LSE
1102146
5,340
64.8900
13:49:22
LSE
1102148
668
64.8900
13:49:22
LSE
1102130
2,916
64.8900
13:49:22
LSE
1102124
7,072
64.8900
13:49:22
LSE
1102126
4,610
64.8900
13:49:22
LSE
1102128
3,254
64.8900
13:49:22
LSE
1102122
7,212
64.8900
13:49:22
LSE
1102132
5,765
64.8900
13:49:22
LSE

1102134
1,453
64.8900
13:49:22
LSE
1102136
5,935
64.8900
13:49:22
LSE
1102138
6,188
64.8700
13:49:27
LSE
1102305
6,824
64.8600
13:50:15
LSE
1103422
6,616
64.8600
13:50:15
LSE
1103420
7,049
64.8500
13:50:17
LSE
1103485
3,380
64.8500
13:50:17
LSE
1103483
3,787
64.8500
13:50:17
LSE
1103471
6,285
64.8500
13:50:17
LSE
1103469
6,843
64.8500
13:50:17
LSE
1103467

6,818
64.8400
13:52:14
LSE
1106077
3,861
64.8400
13:52:14
LSE
1106075
3,368
64.8400
13:52:14
LSE
1106073
7,139
64.8400
13:52:14
LSE
1106079
6,830
64.8400
13:52:14
LSE
1106081
6,875
64.8300
13:52:26
LSE
1106273
6,294
64.8300
13:52:26
LSE
1106271
6,276
64.8300
13:52:26
LSE
1106269
4,399
64.9000
13:53:36
LSE
1108043
6,780
64.9000
13:53:36
LSE
1108039
297

64.9000
13:53:36
LSE
1108041
5,899
64.9000
13:53:36
LSE
1108045
6,336
64.9000
13:53:36
LSE
1108047
5,912
64.9000
13:53:36
LSE
1108049
6,918
64.9000
13:53:36
LSE
1108051
1,614
64.9000
13:53:36
LSE
1108037
6,838
64.8800
13:54:08
LSE
1108924
6,030
64.8800
13:54:08
LSE
1108922
6,679
64.8900
13:54:08
LSE
1108858
719
64.8600
13:54:32
LSE
1109401
2,036
64.8600

13:54:32
LSE
1109399
3,205
64.8600
13:54:32
LSE
1109397
6,211
64.8400
13:54:38
LSE
1109578
6,429
64.8400
13:55:39
LSE
1110944
7,156
64.8400
13:55:39
LSE
1110942
7,052
64.8400
13:55:39
LSE
1110946
361
64.8400
13:55:39
LSE
1110940
5,510
64.8400
13:55:39
LSE
1110938
6,045
64.8300
13:55:47
LSE
1111069
5,158
64.8300
13:55:47
LSE
1111067
1,773
64.8300
13:55:47

LSE
1111065
6,800
64.8200
13:56:32
LSE
1112031
6,910
64.8400
13:59:22
LSE
1116350
6,719
64.8400
13:59:22
LSE
1116346
6,870
64.8400
13:59:22
LSE
1116348
7,487
64.8400
13:59:22
LSE
1116352
6,521
64.8400
13:59:22
LSE
1116354
7,621
64.8400
13:59:22
LSE
1116356
7,225
64.8400
13:59:22
LSE
1116344
7,079
64.8400
13:59:22
LSE
1116342
6,173
64.8400
13:59:22
LSE

1116340
246
64.8300
13:59:36
LSE
1116632
6,235
64.8300
13:59:36
LSE
1116626
6,620
64.8300
13:59:36
LSE
1116628
6,153
64.8300
13:59:36
LSE
1116630
5,961
64.8300
13:59:36
LSE
1116640
5,697
64.8300
13:59:36
LSE
1116634
6,745
64.8300
13:59:36
LSE
1116636
6,564
64.8300
13:59:36
LSE
1116638
6,153
64.8300
13:59:36
LSE
1116624
7,053
64.8500
14:00:53
LSE
1118752

7,002
64.8500
14:00:53
LSE
1118750
2,088
64.8500
14:00:53
LSE
1118748
3,775
64.8500
14:00:53
LSE
1118746
4,317
64.8500
14:00:53
LSE
1118744
6,077
64.8500
14:00:53
LSE
1118742
2,583
64.8500
14:00:53
LSE
1118740
6,596
64.8500
14:00:53
LSE
1118738
6,722
64.8400
14:01:06
LSE
1119108
6,217
64.8400
14:01:06
LSE
1119110
6,224
64.8400
14:01:06
LSE
1119112
5,892

64.8400
14:01:06
LSE
1119106
6,502
64.8300
14:01:20
LSE
1119487
3,762
64.8400
14:02:38
LSE
1120941
3,773
64.8400
14:02:39
LSE
1120953
2,503
64.8400
14:02:39
LSE
1120951
5,876
64.8600
14:03:28
LSE
1121934
6,528
64.8600
14:03:28
LSE
1121932
6,778
64.8600
14:03:28
LSE
1121922
6,051
64.8600
14:03:28
LSE
1121918
6,977
64.8600
14:03:28
LSE
1121920
6,456
64.8600

14:03:28
LSE
1121926
7,105
64.8600
14:03:28
LSE
1121924
6,433
64.8600
14:03:28
LSE
1121928
7,390
64.8600
14:03:28
LSE
1121930
7,181
64.8500
14:03:29
LSE
1121937
6,880
64.8800
14:04:56
LSE
1123846
469
64.8800
14:04:56
LSE
1123844
6,200
64.8800
14:04:56
LSE
1123842
4,174
64.9400
14:07:43
LSE
1128260
5,301
64.9400
14:07:43
LSE
1128258
6,237
64.9400
14:07:43

LSE
1128256
8,155
64.9400
14:07:43
LSE
1128254
3,820
64.9400
14:07:43
LSE
1128252
1,575
64.9400
14:07:43
LSE
1128250
6,429
64.9400
14:07:43
LSE
1128242
6,695
64.9400
14:07:43
LSE
1128240
7,208
64.9400
14:07:43
LSE
1128246
4,068
64.9400
14:07:43
LSE
1128244
7,772
64.9400
14:07:43
LSE
1128248
6,236
64.9300
14:07:53
LSE
1128465
6,518
64.9300
14:07:53
LSE

1128461
6,255
64.9300
14:07:53
LSE
1128467
7,447
64.9300
14:07:53
LSE
1128463
6,770
64.9300
14:07:53
LSE
1128458
6,802
64.9300
14:07:53
LSE
1128456
3,416
64.9500
14:09:59
LSE
1131105
1,042
64.9500
14:09:59
LSE
1131101
3,044
64.9500
14:09:59
LSE
1131103
5,866
64.9500
14:09:59
LSE
1131109
3,741
64.9500
14:09:59
LSE
1131107
6,635
64.9500
14:09:59
LSE
1131111

6,929
64.9500
14:09:59
LSE
1131099
1,597
64.9500
14:09:59
LSE
1131095
6,961
64.9500
14:09:59
LSE
1131093
3,147
64.9500
14:09:59
LSE
1131091
3,663
64.9500
14:09:59
LSE
1131089
6,731
64.9500
14:09:59
LSE
1131087
3,331
64.9500
14:09:59
LSE
1131097
3,987
64.9400
14:10:04
LSE
1131344
2,938
64.9400
14:10:04
LSE
1131342
6,885
64.9500
14:12:15
LSE
1134636
6,678

64.9500
14:12:15
LSE
1134630
2,942
64.9500
14:12:15
LSE
1134624
204
64.9500
14:12:15
LSE
1134626
6,187
64.9500
14:12:15
LSE
1134628
6,043
64.9500
14:12:15
LSE
1134638
7,297
64.9500
14:12:15
LSE
1134632
7,304
64.9500
14:12:15
LSE
1134634
6,291
64.9500
14:12:15
LSE
1134640
3,233
64.9500
14:12:15
LSE
1134622
8,696
65.0300
14:16:46
LSE
1141315
9,292
65.0300

14:16:46
LSE
1141313
9,451
65.0300
14:16:46
LSE
1141311
8,755
65.0300
14:16:46
LSE
1141309
8,653
65.0300
14:16:46
LSE
1141307
8,247
65.0300
14:16:46
LSE
1141305
8,979
65.0300
14:16:46
LSE
1141303
8,915
65.0300
14:16:46
LSE
1141301
1,193
65.0300
14:16:46
LSE
1141317
1,131
65.0400
14:18:01
LSE
1143168
7,172
65.0400
14:18:01
LSE
1143166
6,072
65.0400
14:18:01

LSE
1143164
4,352
65.0400
14:18:01
LSE
1143162
1,131
65.0400
14:18:01
LSE
1143160
5,994
65.0400
14:18:01
LSE
1143156
525
65.0400
14:18:01
LSE
1143158
883
65.0400
14:18:01
LSE
1143152
6,117
65.0400
14:18:01
LSE
1143150
5,929
65.0400
14:18:01
LSE
1143148
6,440
65.0400
14:18:01
LSE
1143146
7,027
65.0400
14:18:01
LSE
1143140
6,500
65.0400
14:18:01
LSE

1143138
9,277
65.0400
14:18:01
LSE
1143136
6,484
65.0400
14:18:01
LSE
1143134
6,184
65.0400
14:18:01
LSE
1143132
6,549
65.0400
14:18:01
LSE
1143130
3,576
65.0400
14:18:01
LSE
1143126
3,652
65.0400
14:18:01
LSE
1143124
6,983
65.0400
14:18:01
LSE
1143128
5,830
65.0200
14:18:06
LSE
1143304
247
65.0200
14:18:06
LSE
1143302
7,254
65.0100
14:18:22
LSE
1143736

5,566
65.0200
14:20:43
LSE
1147241
7,050
65.0200
14:20:43
LSE
1147239
6,838
65.0200
14:20:43
LSE
1147237
7,070
65.0200
14:20:43
LSE
1147231
6,241
65.0200
14:20:43
LSE
1147229
6,703
65.0200
14:20:43
LSE
1147233
6,526
65.0200
14:20:43
LSE
1147235
6,427
65.0200
14:21:21
LSE
1148040
6,637
65.0200
14:21:21
LSE
1148038
395
65.0200
14:21:21
LSE
1148036
1,924

65.0100
14:21:22
LSE
1148051
5,110
65.0100
14:21:22
LSE
1148049
6,543
65.0100
14:21:32
LSE
1148281
2,178
65.0100
14:21:32
LSE
1148277
590
65.0100
14:21:44
LSE
1148522
5,855
65.0100
14:21:44
LSE
1148520
6,530
65.0100
14:21:44
LSE
1148518
4,325
65.0100
14:21:44
LSE
1148516
2,759
65.0000
14:22:00
LSE
1148830
5,451
65.0000
14:22:00
LSE
1148828
424
65.0000

14:22:00
LSE
1148824
6,380
65.0300
14:22:15
LSE
1149318
6,239
65.0100
14:22:24
LSE
1149536
5,525
65.0000
14:24:08
LSE
1152238
1,859
65.0000
14:24:08
LSE
1152240
780
65.0000
14:24:08
LSE
1152235
3,743
65.0000
14:24:10
LSE
1152287
3,700
65.0000
14:24:10
LSE
1152285
2,179
65.0000
14:24:10
LSE
1152283
5,205
65.0000
14:24:10
LSE
1152281
8,844
65.0900
14:27:29

LSE
1157211
8,292
65.0900
14:27:29
LSE
1157205
8,033
65.0900
14:27:29
LSE
1157207
8,888
65.0900
14:27:29
LSE
1157209
8,601
65.0900
14:27:29
LSE
1157217
7,079
65.0900
14:27:29
LSE
1157213
2,815
65.0900
14:27:29
LSE
1157215
6,207
65.0900
14:27:29
LSE
1157219
6,040
65.0900
14:27:29
LSE
1157221
6,688
65.0800
14:27:35
LSE
1157357
6,913
65.0800
14:27:35
LSE

1157353
6,930
65.0800
14:27:35
LSE
1157351
7,256
65.0800
14:27:35
LSE
1157349
6,408
65.0800
14:27:35
LSE
1157347
6,245
65.0800
14:27:35
LSE
1157345
6,544
65.0800
14:27:35
LSE
1157355
7,030
65.0800
14:27:35
LSE
1157343
6,103
65.0200
14:27:51
LSE
1157734
2,205
65.0100
14:28:01
LSE
1157999
793
65.0100
14:28:01
LSE
1157997
6,773
65.0100
14:28:01
LSE
1157995

1,548
65.0100
14:28:04
LSE
1158083
3,521
65.0100
14:28:04
LSE
1158081
4,928
65.0100
14:28:05
LSE
1158130
2,600
65.0100
14:29:34
LSE
1160687
7,189
65.0100
14:29:34
LSE
1160689
966
65.0100
14:29:34
LSE
1160691
7,121
65.0100
14:29:34
LSE
1160683
6,350
65.0100
14:29:34
LSE
1160681
4,405
65.0100
14:29:34
LSE
1160679
3,464
65.0100
14:29:34
LSE
1160685
7,667

65.0100
14:29:34
LSE
1160669
7,121
65.0100
14:29:34
LSE
1160663
6,588
65.0100
14:29:34
LSE
1160665
7,267
65.0100
14:29:34
LSE
1160667
6,662
65.0100
14:29:34
LSE
1160671
249
65.0100
14:29:34
LSE
1160673
512
65.0100
14:29:34
LSE
1160675
2,184
65.0100
14:29:34
LSE
1160677
6,531
65.0100
14:29:34
LSE
1160661
5,375
65.0100
14:29:37
LSE
1160753
5,978
65.0100

14:29:37
LSE
1160751
3,624
65.0000
14:29:58
LSE
1161310
2,520
65.0000
14:29:58
LSE
1161308
1,177
65.0700
14:31:04
LSE
1166085
7,870
65.0700
14:31:04
LSE
1166083
7,099
65.0700
14:31:04
LSE
1166081
6,583
65.0700
14:31:04
LSE
1166079
7,418
65.0700
14:31:04
LSE
1166077
6,618
65.0900
14:31:47
LSE
1167962
7,252
65.0900
14:31:47
LSE
1167958
6,340
65.0900
14:31:47

LSE
1167960
2,220
65.0900
14:31:47
LSE
1167948
6,623
65.0900
14:31:47
LSE
1167944
6,151
65.0900
14:31:47
LSE
1167946
5,222
65.0900
14:31:47
LSE
1167942
7,436
65.0900
14:31:47
LSE
1167950
8,877
65.0900
14:31:47
LSE
1167952
2,500
65.0900
14:31:47
LSE
1167954
6,865
65.0900
14:31:47
LSE
1167956
8,324
65.0800
14:32:39
LSE
1170144
6,796
65.0800
14:32:39
LSE

1170116
181
65.0800
14:32:39
LSE
1170114
6,819
65.0800
14:32:39
LSE
1170112
5,959
65.0800
14:32:39
LSE
1170060
6,361
65.0800
14:32:39
LSE
1170058
6,392
65.0800
14:32:39
LSE
1170044
538
65.0800
14:32:39
LSE
1170048
6,073
65.0800
14:32:39
LSE
1170046
6,258
65.0800
14:32:39
LSE
1170056
7,057
65.0800
14:32:39
LSE
1170050
7,196
65.0800
14:32:39
LSE
1170054

6,121
65.0800
14:32:39
LSE
1170052
5,723
65.0900
14:33:49
LSE
1172833
2,450
65.0900
14:33:49
LSE
1172831
3,450
65.0900
14:33:49
LSE
1172821
6,348
65.0900
14:33:49
LSE
1172815
6,835
65.0900
14:33:49
LSE
1172817
6,895
65.0900
14:33:49
LSE
1172819
6,449
65.0900
14:33:49
LSE
1172825
7,078
65.0900
14:33:49
LSE
1172823
6,244
65.0900
14:33:49
LSE
1172827
3,062

65.0900
14:33:49
LSE
1172829
6,488
65.0800
14:34:10
LSE
1173803
1,242
65.0800
14:34:10
LSE
1173801
5,342
65.0800
14:34:10
LSE
1173799
6,419
65.0800
14:34:10
LSE
1173797
6,473
65.0800
14:34:10
LSE
1173795
6,621
65.0800
14:34:10
LSE
1173793
3,069
65.0900
14:34:36
LSE
1174757
6,114
65.0900
14:34:36
LSE
1174755
2,860
65.0900
14:34:36
LSE
1174759
6,693
65.0900

14:34:36
LSE
1174761
5,856
65.0800
14:34:38
LSE
1174824
1,185
65.0800
14:34:38
LSE
1174822
6,922
65.0500
14:35:11
LSE
1176174
6,550
65.0500
14:35:11
LSE
1176172
7,190
65.0400
14:35:16
LSE
1176414
6,337
65.0500
14:35:16
LSE
1176336
3,643
65.0500
14:35:16
LSE
1176334
3,555
65.0500
14:35:16
LSE
1176332
5,616
65.0100
14:35:32
LSE
1177183
1,075
65.0100
14:35:36

LSE
1177430
6,119
65.0300
14:36:14
LSE
1178845
7,087
65.0300
14:36:14
LSE
1178843
6,804
65.0300
14:36:14
LSE
1178841
6,512
65.0300
14:36:14
LSE
1178839
5,000
65.0000
14:36:43
LSE
1180050
7,234
65.0000
14:36:43
LSE
1180047
579
65.0000
14:36:43
LSE
1180045
7,223
65.0000
14:37:10
LSE
1180964
4,478
65.0000
14:37:10
LSE
1180966
421
65.0000
14:37:10
LSE

1180968
7,258
65.0000
14:37:10
LSE
1180970
6,607
65.0000
14:37:10
LSE
1180974
5,986
65.0000
14:37:10
LSE
1180972
1,943
65.0000
14:37:26
LSE
1181693
6,338
65.0600
14:37:54
LSE
1183176
5,874
65.0600
14:37:54
LSE
1183174
1,200
65.0600
14:37:54
LSE
1183172
697
65.0600
14:37:54
LSE
1183170
5,362
65.0600
14:37:54
LSE
1183168
6,912
65.0600
14:37:54
LSE
1183166

7,188
65.0600
14:37:54
LSE
1183164
6,151
65.0500
14:38:04
LSE
1183623
6,450
65.0400
14:38:05
LSE
1183647
6,929
65.0200
14:38:26
LSE
1184447
6,967
65.0400
14:38:49
LSE
1185276
6,410
65.0400
14:38:49
LSE
1185274
6,377
65.0400
14:38:49
LSE
1185272
6,396
65.0100
14:39:11
LSE
1186117
6,993
65.0100
14:39:11
LSE
1186115
130
65.0000
14:39:12
LSE
1186144
6,080

65.0000
14:39:12
LSE
1186142
5,992
65.0000
14:39:26
LSE
1186667
7,083
65.0000
14:39:26
LSE
1186665
423
65.0000
14:40:08
LSE
1188109
798
65.0000
14:40:16
LSE
1188382
1,455
65.0300
14:40:49
LSE
1189752
4,444
65.0300
14:40:49
LSE
1189750
6,407
65.0300
14:40:49
LSE
1189738
6,287
65.0300
14:40:49
LSE
1189732
6,133
65.0300
14:40:49
LSE
1189734
871
65.0300

14:40:49
LSE
1189736
2,290
65.0300
14:40:49
LSE
1189746
599
65.0300
14:40:49
LSE
1189740
5,729
65.0300
14:40:49
LSE
1189742
628
65.0300
14:40:49
LSE
1189744
5,111
65.0300
14:40:49
LSE
1189748
227
65.0300
14:40:49
LSE
1189730
5,962
65.0300
14:40:49
LSE
1189728
6,715
65.0100
14:41:21
LSE
1191063
6,547
65.0100
14:41:21
LSE
1191061
855
65.0100
14:41:21

LSE
1191059
5,313
65.0100
14:41:21
LSE
1191057
1,234
65.0000
14:41:48
LSE
1192230
6,014
65.0000
14:41:51
LSE
1192352
7,010
65.0000
14:41:51
LSE
1192350
5,411
65.0000
14:41:51
LSE
1192348
31
64.9900
14:42:12
LSE
1193296
7,000
64.9900
14:42:12
LSE
1193294
6,602
64.9900
14:42:12
LSE
1193292
5,820
64.9900
14:42:12
LSE
1193290
175
64.9900
14:42:12
LSE

1193288
6,825
64.9900
14:42:12
LSE
1193285
6,231
64.9600
14:43:13
LSE
1195846
7,300
64.9600
14:43:13
LSE
1195844
4,059
64.9600
14:43:13
LSE
1195824
2,058
64.9600
14:43:13
LSE
1195822
5,966
64.9600
14:43:13
LSE
1195820
6,825
64.9600
14:43:13
LSE
1195818
6,451
64.9400
14:43:21
LSE
1196373
2,370
64.9200
14:43:42
LSE
1197262
5,875
64.9200
14:43:42
LSE
1197260

2,778
64.9200
14:43:49
LSE
1197479
740
64.9200
14:43:49
LSE
1197477
6,511
64.9000
14:44:09
LSE
1198470
6,626
64.9000
14:44:09
LSE
1198458
6,515
64.9000
14:44:09
LSE
1198460
6,347
64.9000
14:44:09
LSE
1198462
2,480
64.9000
14:44:09
LSE
1198464
5,870
64.9000
14:44:09
LSE
1198466
3,515
64.9000
14:44:09
LSE
1198468
6,773
64.9000
14:44:09
LSE
1198472
6,403

64.9000
14:44:09
LSE
1198474
6,545
64.9000
14:44:09
LSE
1198476
755
64.9000
14:44:09
LSE
1198478
7,158
64.9000
14:44:09
LSE
1198480
6,995
64.9000
14:44:09
LSE
1198482
3,101
64.9000
14:44:09
LSE
1198484
6,972
64.9000
14:44:09
LSE
1198456
1,089
64.9100
14:44:34
LSE
1199431
5,384
64.9100
14:44:34
LSE
1199428
34,682
64.9000
14:44:43
LSE
1199669
3,539
64.9000

14:44:43
LSE
1199667
4,845
64.8800
14:44:48
LSE
1200032
155
64.8800
14:44:48
LSE
1200030
6,416
64.8800
14:44:48
LSE
1200027
8,910
64.8800
14:44:48
LSE
1200025
6,170
64.8800
14:44:48
LSE
1200023
6,408
64.8800
14:44:48
LSE
1200021
14,660
64.8800
14:44:49
LSE
1200050
6,374
64.8800
14:44:49
LSE
1200052
7,217
64.8800
14:44:49
LSE
1200048
6,014
64.8800
14:45:08

LSE
1201032
7,221
64.8800
14:45:08
LSE
1201036
12,471
64.8800
14:45:08
LSE
1201034
2,802
64.9000
14:45:28
LSE
1201767
3,101
64.9000
14:45:28
LSE
1201765
6,687
64.9000
14:45:28
LSE
1201763
9,374
64.9000
14:45:28
LSE
1201761
1,600
65.0000
14:46:12
LSE
1202991
232
65.0000
14:46:13
LSE
1202993
1,120
65.0100
14:46:22
LSE
1204318
6,762
65.0100
14:46:22
LSE

1204310
4,842
65.0100
14:46:22
LSE
1204312
6,904
65.0100
14:46:22
LSE
1204314
7,275
65.0100
14:46:22
LSE
1204316
7,213
65.0100
14:46:22
LSE
1204320
2,528
65.0100
14:46:22
LSE
1204324
4,178
65.0100
14:46:22
LSE
1204326
6,342
65.0100
14:46:22
LSE
1204322
5,984
65.0000
14:47:04
LSE
1205821
1,129
65.0000
14:47:04
LSE
1205819
5,250
65.0000
14:47:04
LSE
1205817

6,221
65.0000
14:47:04
LSE
1205815
6,416
65.0000
14:47:04
LSE
1205813
1,244
65.0400
14:47:36
LSE
1207292
5,162
65.0500
14:48:55
LSE
1210634
1,642
65.0500
14:48:55
LSE
1210628
6,442
65.0500
14:48:55
LSE
1210630
3,616
65.0500
14:48:55
LSE
1210632
2,958
65.0500
14:48:55
LSE
1210626
7,112
65.0500
14:48:55
LSE
1210636
6,918
65.0500
14:48:55
LSE
1210642
7,078

65.0500
14:48:55
LSE
1210640
6,819
65.0500
14:48:55
LSE
1210638
6,237
65.0500
14:48:55
LSE
1210624
993
65.0300
14:48:58
LSE
1210868
3,596
65.0300
14:48:58
LSE
1210866
1,991
65.0300
14:48:58
LSE
1210863
6,210
65.0300
14:48:58
LSE
1210861
6,225
65.0300
14:48:58
LSE
1210856
6,422
65.0300
14:48:58
LSE
1210854
7,274
65.0000
14:49:22
LSE
1211781
7,262
65.0100

14:49:22
LSE
1211779
6,809
64.9900
14:50:02
LSE
1213436
6,397
64.9900
14:50:02
LSE
1213434
7,239
64.9900
14:50:02
LSE
1213438
5,929
64.9900
14:50:05
LSE
1213619
671
64.9900
14:50:05
LSE
1213623
4,009
64.9900
14:50:05
LSE
1213621
5,979
64.9900
14:50:07
LSE
1213770
2,276
64.9900
14:50:07
LSE
1213772
2,661
64.9400
14:50:27
LSE
1214573
3,606
64.9400
14:50:27

LSE
1214571
7,071
64.9300
14:51:07
LSE
1216529
7,225
64.9300
14:51:07
LSE
1216527
7,212
64.9300
14:51:07
LSE
1216525
6,894
64.9300
14:51:07
LSE
1216523
5,889
64.9800
14:52:01
LSE
1219200
7,009
64.9800
14:52:01
LSE
1219198
6,807
64.9800
14:52:01
LSE
1219196
6,775
64.9800
14:52:01
LSE
1219194
6,585
64.9800
14:52:01
LSE
1219192
5,868
64.9800
14:52:01
LSE

1219190
6,620
64.9600
14:52:03
LSE
1219241
6,520
64.9900
14:52:21
LSE
1220069
6,198
64.9900
14:52:21
LSE
1220067
7,164
64.9800
14:52:26
LSE
1220213
6,166
64.9800
14:52:26
LSE
1220211
6,454
64.9800
14:52:58
LSE
1221498
5,851
64.9800
14:52:58
LSE
1221496
7,037
64.9500
14:53:32
LSE
1223081
1,437
64.9500
14:53:32
LSE
1223079
4,617
64.9500
14:53:32
LSE
1223077

6,811
64.9500
14:53:32
LSE
1223075
7,268
64.9700
14:53:56
LSE
1224194
6,032
64.9700
14:53:56
LSE
1224192
6,589
64.9700
14:53:56
LSE
1224196
6,838
64.9700
14:53:56
LSE
1224198
6,276
64.9700
14:54:24
LSE
1225391
6,044
64.9700
14:54:24
LSE
1225389
6,245
64.9700
14:54:24
LSE
1225387
6,964
64.9700
14:54:24
LSE
1225385
6,278
64.9600
14:54:41
LSE
1226182
6,812

64.9600
14:54:41
LSE
1226180
7,188
64.9700
14:54:41
LSE
1226125
681
64.9200
14:55:15
LSE
1227459
6,982
64.9200
14:55:15
LSE
1227457
6,750
64.9200
14:55:15
LSE
1227464
6,288
64.9200
14:55:15
LSE
1227462
7,104
64.9300
14:55:25
LSE
1227877
7,103
64.9200
14:55:43
LSE
1228582
3,001
64.9200
14:56:14
LSE
1230541
3,345
64.9200
14:56:14
LSE
1230539
7,035
64.9200

14:56:14
LSE
1230547
3,275
64.9200
14:56:14
LSE
1230543
7,144
64.9200
14:56:14
LSE
1230545
3,164
64.9200
14:56:14
LSE
1230537
3,837
64.9000
14:56:16
LSE
1230691
3,061
64.9000
14:56:16
LSE
1230686
6,996
64.9000
14:56:16
LSE
1230684
694
64.9100
14:56:16
LSE
1230642
6,326
64.9100
14:56:16
LSE
1230640
3,375
64.9500
14:58:07
LSE
1235455
3,890
64.9500
14:58:07

LSE
1235451
5,911
64.9500
14:58:07
LSE
1235453
7,267
64.9500
14:58:07
LSE
1235461
2,050
64.9500
14:58:07
LSE
1235457
2,895
64.9500
14:58:07
LSE
1235459
6,688
64.9500
14:58:07
LSE
1235463
6,260
64.9500
14:58:07
LSE
1235449
638
64.9500
14:58:07
LSE
1235447
6,326
64.9500
14:58:07
LSE
1235445
6,305
64.9500
14:58:07
LSE
1235443
7,648
64.9400
14:58:36
LSE

1236910
6,194
64.9400
14:58:36
LSE
1236908
6,368
64.9400
14:58:36
LSE
1236906
6,640
64.9400
14:58:36
LSE
1236904
7,214
64.9400
14:58:36
LSE
1236902
2,261
64.9400
14:58:36
LSE
1236900
4,818
64.9400
14:58:36
LSE
1236898
6,019
64.9400
14:58:36
LSE
1236896
6,259
64.9300
14:58:41
LSE
1237103
4,882
64.9700
14:59:28
LSE
1238676
1,118
64.9700
14:59:28
LSE
1238674

5,882
64.9700
14:59:28
LSE
1238672
6,708
64.9700
14:59:28
LSE
1238669
6,941
64.9700
14:59:28
LSE
1238667
6,267
64.9700
14:59:28
LSE
1238661
5,976
64.9700
14:59:28
LSE
1238659
1,087
64.9700
14:59:28
LSE
1238657
6,596
64.9700
14:59:28
LSE
1238663
6,121
64.9700
14:59:28
LSE
1238665
5,876
64.9800
15:00:15
LSE
1240784
1,196
64.9800
15:00:15
LSE
1240780
7,217

64.9800
15:00:15
LSE
1240782
6,834
64.9800
15:00:15
LSE
1240786
6,946
64.9800
15:00:15
LSE
1240788
4,821
64.9800
15:00:15
LSE
1240778
6,762
64.9800
15:00:15
LSE
1240776
6,493
64.9700
15:00:16
LSE
1240815
6,350
64.9600
15:00:46
LSE
1241957
6,838
64.9600
15:00:46
LSE
1241955
5,894
64.9600
15:01:27
LSE
1243625
4,019
64.9500
15:01:32
LSE
1244096
5,897
64.9500

15:01:32
LSE
1244090
6,633
64.9500
15:01:32
LSE
1244094
6,851
64.9500
15:01:32
LSE
1244092
1,596
64.9500
15:01:32
LSE
1244098
3,150
64.9500
15:01:32
LSE
1244102
5,401
64.9500
15:01:32
LSE
1244104
6,954
64.9500
15:01:32
LSE
1244100
6,928
64.9600
15:02:13
LSE
1245745
6,523
64.9600
15:02:13
LSE
1245743
5,794
64.9600
15:02:13
LSE
1245741
570
64.9600
15:02:13

LSE
1245739
5,850
64.9500
15:02:48
LSE
1246872
7,086
64.9500
15:02:48
LSE
1246870
6,964
64.9900
15:04:06
LSE
1250199
853
64.9900
15:04:06
LSE
1250192
1,037
64.9900
15:04:06
LSE
1250182
6,365
64.9900
15:04:06
LSE
1250174
7,196
64.9900
15:04:06
LSE
1250176
6,848
64.9900
15:04:06
LSE
1250180
6,414
64.9900
15:04:06
LSE
1250178
7,104
64.9900
15:04:06
LSE

1250184
6,219
64.9900
15:04:06
LSE
1250186
7,101
64.9900
15:04:06
LSE
1250188
5,709
64.9900
15:04:06
LSE
1250190
4,608
64.9900
15:04:24
LSE
1251116
6,885
64.9900
15:04:25
LSE
1251135
168
64.9900
15:04:25
LSE
1251137
1,814
64.9900
15:04:25
LSE
1251139
5,969
64.9900
15:04:27
LSE
1251212
6,659
64.9900
15:04:27
LSE
1251208
646
64.9900
15:04:27
LSE
1251206

6,954
64.9900
15:04:27
LSE
1251204
4,802
64.9600
15:04:35
LSE
1251485
2,000
64.9600
15:04:35
LSE
1251480
6,317
65.0300
15:05:14
LSE
1253704
6,702
65.0600
15:05:27
LSE
1254284
6,597
65.0600
15:05:56
LSE
1255197
6,213
65.0600
15:05:56
LSE
1255195
5,829
65.0600
15:05:56
LSE
1255199
6,076
65.0600
15:05:56
LSE
1255193
6,507
65.0600
15:06:16
LSE
1256176
6,796

65.0600
15:06:16
LSE
1256178
6,133
65.0600
15:06:16
LSE
1256170
7,103
65.0600
15:06:16
LSE
1256168
6,358
65.0600
15:06:16
LSE
1256166
2,929
65.0600
15:06:16
LSE
1256164
6,286
65.0600
15:06:16
LSE
1256162
3,407
65.0600
15:06:16
LSE
1256160
46
65.0600
15:06:16
LSE
1256158
35
65.0600
15:06:16
LSE
1256156
6,461
65.0600
15:07:09
LSE
1258445
902
65.0600

15:07:09
LSE
1258443
7,196
65.0600
15:07:12
LSE
1258586
7,048
65.0600
15:07:12
LSE
1258584
3,944
65.0600
15:07:12
LSE
1258582
3,108
65.0600
15:07:12
LSE
1258580
7,027
65.0600
15:07:12
LSE
1258578
5,365
65.0600
15:07:12
LSE
1258576
6,882
65.0700
15:07:53
LSE
1260304
7,189
65.0700
15:07:53
LSE
1260294
6,485
65.0700
15:07:53
LSE
1260296
171
65.0700
15:07:53

LSE
1260298
2,363
65.0700
15:07:53
LSE
1260300
4,475
65.0700
15:07:53
LSE
1260302
6,399
65.0500
15:08:23
LSE
1261503
5,962
65.0500
15:08:23
LSE
1261501
1,239
65.0900
15:08:54
LSE
1263383
5,122
65.0900
15:08:54
LSE
1263381
6,006
65.0900
15:08:54
LSE
1263379
4,504
65.0900
15:08:57
LSE
1263525
6,462
65.0900
15:08:57
LSE
1263527
6,276
65.0900
15:08:57
LSE

1263529
1,631
65.0900
15:08:57
LSE
1263531
7,302
65.0900
15:08:57
LSE
1263523
6,812
65.0800
15:09:33
LSE
1265050
1,466
65.0800
15:09:33
LSE
1265023
5,158
65.0800
15:09:33
LSE
1265021
6,542
65.0800
15:09:33
LSE
1265019
6,801
65.0500
15:10:13
LSE
1266902
6,597
65.0500
15:10:13
LSE
1266904
6,583
65.0500
15:10:13
LSE
1266906
2,004
65.0500
15:10:13
LSE
1266900

79
65.0500
15:10:13
LSE
1266898
4,278
65.0500
15:10:13
LSE
1266896
6,142
65.0500
15:10:13
LSE
1266894
2,762
65.1000
15:11:37
LSE
1270604
6,991
65.1000
15:11:37
LSE
1270602
5,878
65.1000
15:11:37
LSE
1270600
6,890
65.1000
15:11:37
LSE
1270598
3,847
65.1000
15:11:37
LSE
1270596
6,144
65.1000
15:11:37
LSE
1270594
6,542
65.1000
15:11:37
LSE
1270592
6,766

65.0900
15:11:38
LSE
1270627
7,084
65.0900
15:11:38
LSE
1270623
6,140
65.0900
15:11:38
LSE
1270625
5,966
65.0900
15:11:38
LSE
1270629
5,883
65.0800
15:12:05
LSE
1271828
5,519
65.1000
15:13:18
LSE
1274607
1,732
65.1000
15:13:18
LSE
1274595
6,344
65.1000
15:13:18
LSE
1274589
4,212
65.1000
15:13:18
LSE
1274591
17
65.1000
15:13:18
LSE
1274593
252
65.1000

15:13:18
LSE
1274601
5,851
65.1000
15:13:18
LSE
1274597
6,772
65.1000
15:13:18
LSE
1274599
200
65.1000
15:13:18
LSE
1274603
7,037
65.1000
15:13:18
LSE
1274605
7,208
65.1000
15:13:18
LSE
1274587
5,945
65.0800
15:13:20
LSE
1274671
5,942
65.0800
15:13:20
LSE
1274669
7,045
65.0400
15:13:30
LSE
1275239
7,037
65.0100
15:13:44
LSE
1276058
6,910
65.0100
15:13:44

LSE
1276056
755
65.0000
15:14:37
LSE
1278049
2,647
65.0000
15:14:37
LSE
1278047
6,439
65.0000
15:14:37
LSE
1278045
3,295
65.0000
15:14:37
LSE
1278043
6,107
65.0000
15:14:37
LSE
1278041
403
65.0000
15:14:37
LSE
1278039
1,244
65.0000
15:14:37
LSE
1278007
4,389
65.0000
15:14:37
LSE
1278009
2,591
65.0000
15:14:37
LSE
1278005
4,598
65.0000
15:14:37
LSE

1278003
6,127
65.0200
15:15:07
LSE
1279613
7,181
65.0200
15:15:07
LSE
1279611
6,846
65.0100
15:15:08
LSE
1279635
6,700
65.0000
15:15:10
LSE
1279733
6,596
64.9900
15:15:13
LSE
1279958
1,367
65.0400
15:15:51
LSE
1281447
6,192
65.0400
15:15:51
LSE
1281445
7,010
65.0400
15:15:51
LSE
1281443
5,045
65.0400
15:15:51
LSE
1281441
6,391
65.0000
15:16:03
LSE
1282037

6,697
65.0300
15:16:34
LSE
1283695
5,873
65.0200
15:16:41
LSE
1283970
5,571
65.0200
15:16:41
LSE
1283968
6,838
65.0200
15:16:41
LSE
1283974
816
65.0200
15:16:41
LSE
1283972
7,247
65.0400
15:17:10
LSE
1285229
6,704
65.0400
15:17:20
LSE
1285673
4,658
65.0400
15:17:20
LSE
1285671
6,651
65.0400
15:17:20
LSE
1285650
2,188
65.0400
15:17:20
LSE
1285652
3,934

65.0300
15:18:24
LSE
1288435
2,384
65.0300
15:18:24
LSE
1288433
6,172
65.0300
15:18:24
LSE
1288431
777
65.0300
15:18:24
LSE
1288429
5,365
65.0300
15:18:24
LSE
1288427
6,727
65.0500
15:19:13
LSE
1290857
6,737
65.0500
15:19:13
LSE
1290855
7,021
65.0500
15:19:13
LSE
1290853
1,127
65.0500
15:19:13
LSE
1290851
7,087
65.0500
15:19:13
LSE
1290843
3,062
65.0500

15:19:13
LSE
1290845
5,322
65.0500
15:19:13
LSE
1290847
6,757
65.0500
15:19:13
LSE
1290849
3,489
65.0500
15:19:13
LSE
1290841
6,228
65.0500
15:19:13
LSE
1290839
6,209
65.0400
15:19:27
LSE
1291488
7,219
65.0500
15:19:27
LSE
1291486
5,992
65.0500
15:19:27
LSE
1291484
6,670
65.0500
15:19:27
LSE
1291482
6,815
65.0500
15:19:27
LSE
1291480
7,195
64.9800
15:19:50

LSE
1292778
7,114
64.9800
15:19:50
LSE
1292776
2,343
64.9800
15:19:50
LSE
1292780
2,400
64.9800
15:19:53
LSE
1292870
267
65.0000
15:20:14
LSE
1293788
7,000
65.0000
15:20:14
LSE
1293786
5,920
65.0300
15:20:52
LSE
1295679
6,610
65.0200
15:21:05
LSE
1296006
5,115
65.0200
15:21:05
LSE
1296004
901
65.0200
15:21:05
LSE
1296002
2,517
65.0200
15:21:10
LSE

1296191
4,618
65.0200
15:21:10
LSE
1296193
6,780
65.0600
15:22:23
LSE
1299052
214
65.0600
15:22:23
LSE
1299050
10,700
65.1600
15:24:23
LSE
1304368
8,766
65.1600
15:24:23
LSE
1304366
8,984
65.1600
15:24:23
LSE
1304364
8,608
65.1600
15:24:23
LSE
1304362
9,444
65.1600
15:24:23
LSE
1304360
7,824
65.1600
15:24:23
LSE
1304358
7,010
65.1600
15:24:23
LSE
1304356

8,710
65.1600
15:24:23
LSE
1304354
6,004
65.0500
15:24:27
LSE
1304502
6,318
65.0600
15:24:27
LSE
1304500
9,156
65.1500
15:24:27
LSE
1304498
6,595
65.1500
15:24:27
LSE
1304496
7,270
65.1500
15:24:27
LSE
1304494
7,047
65.1500
15:24:27
LSE
1304486
6,360
65.1500
15:24:27
LSE
1304484
6,692
65.1500
15:24:27
LSE
1304490
6,352
65.1500
15:24:27
LSE
1304488
7,047

65.1500
15:24:27
LSE
1304492
6
65.0200
15:24:58
LSE
1305943
318
65.0200
15:24:59
LSE
1306189
6,013
65.0200
15:24:59
LSE
1306187
6,445
65.0200
15:25:01
LSE
1306299
5,948
65.0200
15:25:01
LSE
1306297
6,541
65.0200
15:25:01
LSE
1306301
6,419
65.0200
15:25:10
LSE
1306884
5,854
65.0200
15:25:45
LSE
1308765
6,771
65.0600
15:26:30
LSE
1310675
6,676
65.0500

15:26:30
LSE
1310669
6,801
65.0500
15:26:30
LSE
1310667
6,998
65.0500
15:26:30
LSE
1310673
6,276
65.0600
15:26:30
LSE
1310671
6,215
65.0600
15:26:30
LSE
1310663
5,878
65.0600
15:26:30
LSE
1310665
6,352
65.0200
15:26:51
LSE
1311451
7,008
65.0200
15:26:51
LSE
1311448
6,857
65.0200
15:26:51
LSE
1311441
5,856
65.0100
15:26:55
LSE
1311716
6,129
65.1300
15:29:21

LSE
1317644
7,444
65.1300
15:29:21
LSE
1317642
6,522
65.1300
15:29:21
LSE
1317638
2,628
65.1300
15:29:21
LSE
1317636
4,356
65.1300
15:29:21
LSE
1317634
6,313
65.1300
15:29:21
LSE
1317632
6,274
65.1300
15:29:21
LSE
1317606
6,369
65.1300
15:29:21
LSE
1317610
726
65.1300
15:29:21
LSE
1317608
7,063
65.1300
15:29:21
LSE
1317604
152
65.1300
15:29:21
LSE

1317602
7,000
65.1300
15:29:21
LSE
1317600
6,010
65.1100
15:29:30
LSE
1317997
5,933
65.1100
15:29:30
LSE
1317999
2,358
65.1100
15:29:52
LSE
1318891
7,706
65.1100
15:29:52
LSE
1318893
6,246
65.1100
15:29:52
LSE
1318889
6,710
65.1100
15:29:52
LSE
1318883
776
65.1100
15:29:52
LSE
1318881
6,195
65.1100
15:29:52
LSE
1318887
4,610
65.1100
15:29:52
LSE
1318885

741
65.1000
15:30:03
LSE
1319665
5,286
65.1000
15:30:03
LSE
1319663
4,414
65.1000
15:30:03
LSE
1319661
6,078
65.1000
15:30:03
LSE
1319659
1,705
65.1000
15:30:03
LSE
1319657
4,647
65.1000
15:30:03
LSE
1319655
4,264
65.1000
15:30:03
LSE
1319653
6,256
65.1000
15:30:03
LSE
1319651
4,871
65.0700
15:30:17
LSE
1320418
1,207
65.0700
15:30:17
LSE
1320416
4,229

65.0700
15:30:17
LSE
1320414
2,662
65.0700
15:30:17
LSE
1320407
6,981
65.0700
15:30:58
LSE
1322359
6,035
65.0700
15:30:58
LSE
1322357
6,148
65.0700
15:30:58
LSE
1322355
1,020
65.0700
15:30:58
LSE
1322353
6,751
65.0600
15:31:15
LSE
1323176
5,934
65.0600
15:31:15
LSE
1323178
6,994
65.0600
15:31:15
LSE
1323174
7,097
65.0600
15:31:15
LSE
1323172
6,507
65.0300

15:31:42
LSE
1324596
6,104
65.0200
15:31:55
LSE
1325206
6,202
65.0200
15:31:55
LSE
1325204
3,829
65.0700
15:33:14
LSE
1329765
6,544
65.0700
15:33:14
LSE
1329763
2,465
65.0700
15:33:25
LSE
1330188
5,064
65.0700
15:33:25
LSE
1330186
6,116
65.0700
15:33:25
LSE
1330184
6,269
65.0700
15:33:25
LSE
1330182
2,339
65.0700
15:33:25
LSE
1330174
3,026
65.0700
15:33:25

LSE
1330170
3,855
65.0700
15:33:25
LSE
1330172
957
65.0700
15:33:25
LSE
1330176
6,037
65.0700
15:33:25
LSE
1330178
5,951
65.0700
15:33:25
LSE
1330180
7,132
65.0600
15:33:27
LSE
1330248
6,209
65.0600
15:33:27
LSE
1330244
6,411
65.0600
15:33:27
LSE
1330246
5,238
65.0800
15:34:23
LSE
1333159
2,043
65.0800
15:34:23
LSE
1333161
2,526
65.0800
15:34:23
LSE

1333149
3,836
65.0800
15:34:23
LSE
1333143
2,043
65.0800
15:34:23
LSE
1333145
1,511
65.0800
15:34:23
LSE
1333147
6,232
65.0800
15:34:23
LSE
1333157
4,553
65.0800
15:34:23
LSE
1333151
6,489
65.0800
15:34:23
LSE
1333155
3,891
65.0800
15:34:23
LSE
1333153
1,431
65.0900
15:35:18
LSE
1335427
5,469
65.0900
15:35:18
LSE
1335425
1,531
65.0900
15:35:18
LSE
1335423

5,244
65.0900
15:35:18
LSE
1335421
3,490
65.0900
15:35:18
LSE
1335419
2,962
65.0900
15:35:18
LSE
1335417
4,038
65.0900
15:35:18
LSE
1335415
3,156
65.0900
15:35:18
LSE
1335413
6,752
65.0800
15:35:18
LSE
1335405
6,791
65.0800
15:35:18
LSE
1335403
6,186
65.0800
15:35:18
LSE
1335409
362
65.0800
15:35:18
LSE
1335407
885
65.0800
15:35:18
LSE
1335411
4,050

65.0900
15:35:18
LSE
1335401
2,389
65.0900
15:35:18
LSE
1335399
6,079
65.0900
15:35:18
LSE
1335397
285
65.0900
15:35:18
LSE
1335395
7,000
65.0900
15:35:18
LSE
1335393
2,541
65.0800
15:35:18
LSE
1335391
6,526
65.0800
15:35:18
LSE
1335389
6,179
65.0900
15:36:00
LSE
1337330
6,763
64.9800
15:36:37
LSE
1339105
7,121
64.9800
15:36:37
LSE
1339103
6,577
64.9800

15:36:37
LSE
1339107
5,975
64.9500
15:36:48
LSE
1339566
3,612
64.9900
15:38:09
LSE
1343293
3,611
64.9900
15:38:09
LSE
1343289
6,287
64.9900
15:38:09
LSE
1343295
6,917
64.9900
15:38:09
LSE
1343297
3,257
64.9900
15:38:09
LSE
1343291
3,810
64.9900
15:38:09
LSE
1343287
5,886
64.9900
15:38:09
LSE
1343285
1,556
64.9900
15:38:09
LSE
1343283
6,334
64.9900
15:38:09

LSE
1343281
5,443
64.9900
15:38:09
LSE
1343279
6,415
64.9900
15:38:09
LSE
1343277
6,427
64.9800
15:38:10
LSE
1343479
4,126
65.0100
15:39:12
LSE
1345886
3,536
65.0100
15:39:13
LSE
1345935
6,240
65.0100
15:39:13
LSE
1345923
1,081
65.0100
15:39:13
LSE
1345917
5,701
65.0100
15:39:13
LSE
1345919
6,695
65.0100
15:39:13
LSE
1345921
405
65.0100
15:39:13
LSE

1345929
6,157
65.0100
15:39:13
LSE
1345925
3,342
65.0100
15:39:13
LSE
1345933
3,518
65.0100
15:39:13
LSE
1345927
3,001
65.0100
15:39:13
LSE
1345931
2,829
65.0100
15:39:13
LSE
1345915
697
65.0000
15:40:04
LSE
1348297
7,100
65.0000
15:40:04
LSE
1348295
1,932
65.0000
15:40:07
LSE
1348452
5,427
65.0000
15:40:07
LSE
1348450
6,858
65.0000
15:40:15
LSE
1348823

6,092
65.0000
15:40:15
LSE
1348821
4,497
65.0000
15:40:15
LSE
1348819
933
65.0000
15:40:15
LSE
1348825
5,593
65.0000
15:40:15
LSE
1348827
60
65.0000
15:40:15
LSE
1348817
4,964
64.9900
15:41:03
LSE
1351270
1,940
64.9900
15:41:03
LSE
1351266
279
64.9900
15:41:03
LSE
1351268
2,713
64.9900
15:41:03
LSE
1351274
5,524
64.9900
15:41:03
LSE
1351272
3,655

64.9900
15:41:03
LSE
1351276
1,205
64.9900
15:41:03
LSE
1351278
7,209
64.9900
15:41:03
LSE
1351264
6,089
64.9900
15:41:03
LSE
1351262
6,580
64.9900
15:41:03
LSE
1351260
5,845
64.9900
15:41:03
LSE
1351258
2,109
65.0100
15:42:09
LSE
1353890
6,497
65.0100
15:42:31
LSE
1354740
7,044
65.0100
15:42:31
LSE
1354738
6,070
65.0100
15:42:31
LSE
1354736
5,103
65.0100

15:42:31
LSE
1354734
2,190
65.0100
15:42:31
LSE
1354732
6,437
65.0100
15:42:31
LSE
1354730
6,447
65.0100
15:42:31
LSE
1354728
6,142
65.0100
15:42:31
LSE
1354726
4,783
65.0100
15:42:31
LSE
1354724
4,431
65.0000
15:42:36
LSE
1354893
2,164
65.0000
15:42:36
LSE
1354891
6,627
65.0000
15:42:36
LSE
1354889
3,213
65.0100
15:43:27
LSE
1356963
6,692
65.0100
15:43:27

LSE
1356961
6,208
65.0100
15:43:27
LSE
1356959
7,272
65.0100
15:43:27
LSE
1356957
1,077
65.0100
15:43:35
LSE
1357407
1,011
65.0100
15:43:35
LSE
1357405
4,261
65.0100
15:43:35
LSE
1357403
758
65.0100
15:43:35
LSE
1357401
2,088
65.0100
15:43:35
LSE
1357398
1,987
65.0000
15:43:43
LSE
1357735
6,997
65.0000
15:43:43
LSE
1357733
6,489
65.0000
15:43:43
LSE

1357731
3,719
65.1500
15:45:20
LSE
1362051
1,990
65.1500
15:45:20
LSE
1362047
2,280
65.1500
15:45:20
LSE
1362049
6,258
65.1500
15:45:20
LSE
1362055
6,776
65.1500
15:45:20
LSE
1362053
8,563
65.1500
15:45:20
LSE
1362057
5,230
65.1500
15:45:20
LSE
1362045
7,237
65.1500
15:45:20
LSE
1362043
6,919
65.1500
15:45:20
LSE
1362041
7,679
65.1500
15:45:20
LSE
1362039

7,085
65.1400
15:45:27
LSE
1362319
7,285
65.1400
15:45:27
LSE
1362317
5,338
65.1400
15:45:27
LSE
1362315
1,829
65.1400
15:45:27
LSE
1362313
4,292
65.1300
15:45:28
LSE
1362374
1,664
65.1300
15:45:28
LSE
1362372
7,261
65.1200
15:45:57
LSE
1363443
5,898
65.1200
15:45:57
LSE
1363439
270
65.1200
15:45:57
LSE
1363437
6,940
65.1200
15:45:57
LSE
1363441
6,409

65.1000
15:46:10
LSE
1364097
6,336
65.1000
15:46:27
LSE
1364762
7,289
65.0900
15:46:49
LSE
1365590
6,942
65.0900
15:46:49
LSE
1365588
7,237
65.0900
15:46:49
LSE
1365586
7,091
65.0800
15:46:57
LSE
1365838
4,601
65.0800
15:46:57
LSE
1365834
2,129
65.0800
15:46:57
LSE
1365832
240
65.0900
15:46:57
LSE
1365827
6,249
65.0600
15:47:13
LSE
1366579
7,104
65.0600

15:47:22
LSE
1366991
6,414
65.0600
15:47:22
LSE
1366986
6,436
65.0400
15:48:13
LSE
1369009
2,140
65.0400
15:48:13
LSE
1368990
4,375
65.0400
15:48:13
LSE
1368988
7,100
65.0400
15:48:13
LSE
1368986
6,112
65.0600
15:49:02
LSE
1371123
5,884
65.0600
15:49:02
LSE
1371121
7,242
65.0600
15:49:02
LSE
1371119
5,959
65.0600
15:49:02
LSE
1371113
6,746
65.0600
15:49:02

LSE
1371111
6,651
65.0600
15:49:02
LSE
1371109
5,908
65.0400
15:49:29
LSE
1372241
6,047
65.0400
15:49:29
LSE
1372239
3,373
65.0600
15:50:05
LSE
1374009
2,879
65.0600
15:50:05
LSE
1374007
7,265
65.0600
15:50:05
LSE
1374005
6,945
65.0600
15:50:05
LSE
1374003
6,606
65.0600
15:50:05
LSE
1374001
6,986
65.0600
15:50:05
LSE
1373999
6,470
65.0500
15:50:10
LSE

1374254
6,576
65.0400
15:51:03
LSE
1376761
6,401
65.0400
15:51:03
LSE
1376763
6,389
65.0400
15:51:03
LSE
1376765
6,920
65.0400
15:51:03
LSE
1376767
7,175
65.0400
15:51:03
LSE
1376769
652
65.0400
15:51:03
LSE
1376771
6,813
65.0400
15:51:03
LSE
1376773
6,261
65.0400
15:51:03
LSE
1376775
6,490
65.0200
15:51:26
LSE
1377733
6,163
65.0200
15:51:26
LSE
1377731

133
65.0200
15:51:26
LSE
1377709
6,112
65.0300
15:52:06
LSE
1379427
7,051
65.0300
15:52:06
LSE
1379425
6,152
65.0300
15:52:06
LSE
1379423
6,648
65.0300
15:52:06
LSE
1379421
2,582
65.0300
15:52:48
LSE
1380645
4,240
65.0300
15:52:48
LSE
1380643
7,168
65.0400
15:52:48
LSE
1380634
6,914
65.0400
15:52:48
LSE
1380632
273
65.0400
15:52:48
LSE
1380630
5,962

65.0400
15:52:48
LSE
1380628
7,296
65.0400
15:52:48
LSE
1380626
5,993
65.0100
15:53:13
LSE
1381846
6,247
65.0100
15:53:13
LSE
1381844
7,265
65.0100
15:53:13
LSE
1381842
6,184
65.0100
15:53:13
LSE
1381840
6,616
65.0100
15:53:52
LSE
1383246
5,897
65.0100
15:53:52
LSE
1383248
6,851
65.0000
15:53:57
LSE
1383536
6,341
65.0000
15:53:57
LSE
1383534
536
64.9900

15:53:58
LSE
1383572
6,695
64.9900
15:53:58
LSE
1383570
25
64.9900
15:53:58
LSE
1383568
6,010
64.9700
15:54:07
LSE
1384117
6,695
64.9700
15:54:07
LSE
1384114
6,088
64.9700
15:54:08
LSE
1384119
7,223
64.9500
15:54:26
LSE
1384741
5,881
64.9600
15:54:58
LSE
1386033
6,954
64.9600
15:54:58
LSE
1386035
6,125
64.9600
15:54:58
LSE
1386031
403
64.9400
15:56:01

LSE
1388569
3,013
64.9900
15:57:07
LSE
1391242
3,937
64.9900
15:57:07
LSE
1391240
6,151
64.9900
15:57:07
LSE
1391238
4,421
64.9900
15:57:07
LSE
1391244
7,034
64.9900
15:57:07
LSE
1391236
5,178
64.9900
15:57:07
LSE
1391234
1,187
64.9900
15:57:07
LSE
1391197
6,318
64.9900
15:57:07
LSE
1391194
7,213
64.9900
15:57:07
LSE
1391191
7,556
64.9900
15:57:07
LSE

1391165
8,080
64.9900
15:57:07
LSE
1391163
8,978
64.9900
15:57:07
LSE
1391171
7,430
64.9900
15:57:07
LSE
1391167
7,436
64.9900
15:57:07
LSE
1391169
8,367
64.9900
15:57:07
LSE
1391161
5,459
64.9900
15:57:07
LSE
1391159
2,774
64.9900
15:57:07
LSE
1391157
8,253
64.9900
15:57:07
LSE
1391155
2,496
64.9900
15:57:57
LSE
1393094
240
64.9900
15:57:57
LSE
1393092

6,766
64.9900
15:57:57
LSE
1393096
4,373
64.9900
15:57:57
LSE
1393098
6,230
64.9900
15:58:23
LSE
1394358
5,798
64.9900
15:58:23
LSE
1394356
6,240
64.9900
15:58:23
LSE
1394362
6,181
64.9900
15:58:23
LSE
1394360
1,272
64.9900
15:58:23
LSE
1394364
6,688
64.9900
15:58:23
LSE
1394354
6,238
64.9900
15:58:23
LSE
1394352
6,272
64.9900
15:58:23
LSE
1394350
6,352

64.9900
15:58:23
LSE
1394348
6,248
64.9600
15:58:58
LSE
1395572
2,855
64.9600
15:58:58
LSE
1395570
4,412
64.9600
15:58:58
LSE
1395568
4,988
64.9600
15:58:58
LSE
1395566
1,625
64.9600
15:58:58
LSE
1395564
7,222
64.9600
15:58:58
LSE
1395562
7,028
64.9600
15:58:58
LSE
1395552
6,884
64.9600
15:58:58
LSE
1395550
6,448
64.9500
15:59:31
LSE
1397349
6,591
64.9500

15:59:31
LSE
1397347
7,047
64.9500
15:59:31
LSE
1397345
6,060
64.9300
16:00:10
LSE
1401113
6,386
64.9300
16:00:10
LSE
1401097
1,482
64.9300
16:00:10
LSE
1401099
5,761
64.9300
16:00:10
LSE
1401101
6,339
64.9300
16:00:10
LSE
1401103
2,927
64.9300
16:00:10
LSE
1401105
283
64.9300
16:00:10
LSE
1401107
54
64.9300
16:00:10
LSE
1401109
3,186
64.9300
16:00:10

LSE
1401111
53
64.9300
16:00:10
LSE
1401095
4,595
64.9300
16:00:10
LSE
1401093
2,382
64.9300
16:00:10
LSE
1401091
4,641
64.9300
16:00:10
LSE
1401089
5,834
64.9300
16:00:10
LSE
1401087
15
64.9300
16:00:10
LSE
1401076
6,211
64.9500
16:01:37
LSE
1406335
6,541
64.9400
16:01:41
LSE
1406637
7,047
64.9400
16:01:41
LSE
1406627
7,237
64.9400
16:01:41
LSE

1406623
247
64.9400
16:01:41
LSE
1406625
5,885
64.9400
16:01:41
LSE
1406635
6,857
64.9400
16:01:41
LSE
1406629
6,664
64.9400
16:01:41
LSE
1406631
7,218
64.9400
16:01:41
LSE
1406633
6,036
64.9300
16:02:00
LSE
1407357
6,160
64.9300
16:02:00
LSE
1407355
6,590
64.9200
16:02:07
LSE
1407667
6,388
64.9200
16:02:07
LSE
1407665
7,197
64.9200
16:02:07
LSE
1407663

6,471
64.9200
16:02:07
LSE
1407661
5,368
64.9200
16:02:07
LSE
1407659
795
64.9200
16:02:07
LSE
1407657
6,190
64.9000
16:02:14
LSE
1407981
5,908
64.9000
16:02:14
LSE
1407983
5,907
64.9200
16:03:15
LSE
1410835
7,301
64.9200
16:03:15
LSE
1410833
6,315
64.9200
16:03:15
LSE
1410831
7,208
64.9200
16:03:15
LSE
1410829
6,834
64.9200
16:03:15
LSE
1410827
6,602

64.9200
16:03:15
LSE
1410825
5,900
64.9200
16:03:15
LSE
1410823
5,930
64.9200
16:03:15
LSE
1410821
6,891
64.8900
16:04:14
LSE
1413626
6,793
64.8900
16:04:14
LSE
1413622
6,517
64.8900
16:04:14
LSE
1413624
6,896
64.8900
16:04:14
LSE
1413634
6,123
64.8900
16:04:14
LSE
1413628
3,780
64.8900
16:04:14
LSE
1413630
2,179
64.8900
16:04:14
LSE
1413632
5,273
64.8700

16:04:56
LSE
1415601
7,298
64.8700
16:04:56
LSE
1415599
1,913
64.8700
16:04:56
LSE
1415597
6,467
64.8700
16:04:56
LSE
1415595
6,888
64.8700
16:04:56
LSE
1415593
6,797
64.8700
16:04:56
LSE
1415591
5,945
64.8700
16:04:56
LSE
1415589
2,505
64.8600
16:05:10
LSE
1416360
2,374
64.8600
16:05:10
LSE
1416358
3,476
64.8600
16:05:10
LSE
1416356
6,541
64.8600
16:05:10

LSE
1416362
7,139
64.8600
16:05:10
LSE
1416364
4,484
64.8600
16:05:10
LSE
1416354
7,020
64.8400
16:05:17
LSE
1417075
92
64.8400
16:05:17
LSE
1417057
7,180
64.8300
16:05:57
LSE
1418693
6,462
64.8300
16:05:57
LSE
1418691
7,009
64.8300
16:05:57
LSE
1418689
1,364
64.8300
16:06:17
LSE
1419801
5,132
64.8300
16:06:17
LSE
1419799
6,166
64.8300
16:06:17
LSE

1419803
6,296
64.8300
16:06:17
LSE
1419805
6,721
64.8300
16:06:17
LSE
1419797
6,180
64.8200
16:06:18
LSE
1419852
265
64.8200
16:06:18
LSE
1419850
6,283
64.8200
16:06:18
LSE
1419848
4,272
64.8000
16:06:44
LSE
1421036
2,426
64.8000
16:06:44
LSE
1421034
2,228
64.7900
16:06:56
LSE
1421390
6,596
64.7900
16:06:56
LSE
1421386
6,343
64.7900
16:06:56
LSE
1421384

6,891
64.7900
16:06:56
LSE
1421388
6,780
64.7900
16:07:11
LSE
1422454
6,518
64.7900
16:07:11
LSE
1422330
4,071
64.7900
16:07:11
LSE
1422328
7,097
64.7900
16:07:11
LSE
1422332
3,092
64.7900
16:07:39
LSE
1423912
3,959
64.7900
16:07:39
LSE
1423910
7,057
64.7900
16:08:04
LSE
1425077
6,682
64.7900
16:08:04
LSE
1425073
5,910
64.7900
16:08:04
LSE
1425075
6,263

64.7900
16:08:04
LSE
1425071
6,557
64.7900
16:08:04
LSE
1425069
2,245
64.7800
16:08:05
LSE
1425143
3,640
64.7800
16:08:05
LSE
1425145
7,281
64.7600
16:08:11
LSE
1425397
2,409
64.7500
16:08:21
LSE
1425839
3,851
64.7500
16:08:21
LSE
1425837
6,495
64.7200
16:08:35
LSE
1426469
6,461
64.7200
16:08:35
LSE
1426467
6,848
64.7000
16:08:57
LSE
1427416
7,080
64.7000

16:08:57
LSE
1427414
6,067
64.7000
16:08:57
LSE
1427412
7,220
64.7000
16:08:57
LSE
1427410
5,896
64.6800
16:09:02
LSE
1427858
5,340
64.7000
16:10:19
LSE
1432134
3,488
64.7000
16:10:19
LSE
1432132
14,062
64.7000
16:10:19
LSE
1432130
10,204
64.6900
16:10:24
LSE
1432312
5,129
64.6900
16:10:24
LSE
1432310
7,000
64.7800
16:11:26
LSE
1435583
5,500
64.7800
16:11:26

LSE
1435581
7,000
64.7800
16:11:26
LSE
1435579
966
64.7900
16:11:30
LSE
1435832
6,001
64.7900
16:11:30
LSE
1435830
2,535
64.7900
16:11:30
LSE
1435827
558
64.7900
16:11:30
LSE
1435825
10,655
64.7900
16:11:30
LSE
1435823
3,821
64.7900
16:11:30
LSE
1435821
8,656
64.7900
16:11:30
LSE
1435819
9,032
64.7900
16:11:30
LSE
1435815
10,175
64.7900
16:11:30
LSE

1435813
5,500
64.7900
16:11:30
LSE
1435811
7,000
64.7900
16:11:30
LSE
1435809
7,904
64.7900
16:11:30
LSE
1435807
13,506
64.8000
16:11:39
LSE
1436283
877
64.8000
16:11:40
LSE
1436407
8,553
64.8000
16:11:40
LSE
1436411
1,184
64.8000
16:11:40
LSE
1436409
348
64.8000
16:11:52
LSE
1437175
304
64.8000
16:11:52
LSE
1437171
989
64.8000
16:11:52
LSE
1437169

5,850
64.8000
16:11:52
LSE
1437167
6,383
64.8000
16:11:52
LSE
1437165
11,294
64.8000
16:11:52
LSE
1437163
18,667
64.8000
16:11:52
LSE
1437161
3,768
64.8000
16:11:52
LSE
1437159
6,001
64.8000
16:11:52
LSE
1437173
8,445
64.8000
16:11:52
LSE
1437157
7,052
64.8000
16:11:52
LSE
1437155
24,000
64.9400
16:20:19
LSE
1466908
2,768
64.9400
16:20:19
LSE
1466906
24,000

64.9300
16:20:19
LSE
1466805
3,222
64.9300
16:20:19
LSE
1466803
12,162
64.9400
16:20:22
LSE
1467128
400
64.9400
16:20:22
LSE
1467126
8,573
64.9400
16:20:24
LSE
1467232
2,638
64.9400
16:20:24
LSE
1467230
5,905
64.9400
16:20:26
LSE
1467401
2,400
64.9300
16:20:29
LSE
1467555
3,200
64.9300
16:20:29
LSE
1467553
1,208
64.9300
16:20:34
LSE
1467854
9,226
64.9300

16:20:34
LSE
1467856
487
64.9300
16:20:34
LSE
1467852
3,211
64.9300
16:20:44
LSE
1468457
13,670
64.9300
16:20:44
LSE
1468455
15,786
64.9400
16:20:47
LSE
1468625
2,772
64.9400
16:20:47
LSE
1468623
7,000
64.9400
16:20:47
LSE
1468621
11,316
64.9400
16:20:47
LSE
1468619
1,419
64.9400
16:20:47
LSE
1468615
5,604
64.9200
16:20:47
LSE
1468579
7,023
64.9200
16:20:47

LSE
1468577
9,109
64.9400
16:21:14
LSE
1470732
6,193
64.9400
16:21:17
LSE
1470978
7,386
64.9400
16:21:39
LSE
1472224
2,743
64.9400
16:21:39
LSE
1472222
4,150
64.9400
16:21:39
LSE
1472220
3,577
64.9400
16:21:39
LSE
1472218
12,497
64.9400
16:21:39
LSE
1472206
949
64.9400
16:21:39
LSE
1472204
7,202
64.9300
16:21:51
LSE
1472801
8,255
64.9300
16:22:03
LSE

1473513
7,248
64.9400
16:22:03
LSE
1473510
6,651
64.9400
16:22:03
LSE
1473508
2,640
64.9400
16:22:03
LSE
1473502
2,665
64.9400
16:22:03
LSE
1473500
4,924
64.9400
16:22:03
LSE
1473504
7,000
64.9400
16:22:03
LSE
1473497
2,730
64.9400
16:22:03
LSE
1473495
5,388
64.9400
16:22:03
LSE
1473493
6,308
64.9400
16:22:23
LSE
1474742
2,768
65.0000
16:22:31
LSE
1475448

18,667
65.0000
16:22:31
LSE
1475446
2,200
65.0000
16:22:31
LSE
1475450
37,123
65.0000
16:22:31
LSE
1475444
7,183
64.9900
16:22:33
LSE
1475550
296
64.9800
16:22:39
LSE
1475765
6,779
64.9800
16:22:40
LSE
1475802
6,673
64.9800
16:22:40
LSE
1475800
6,352
64.9800
16:22:40
LSE
1475798
10,913
64.9700
16:22:46
LSE
1476116
2,732
64.9900
16:22:50
LSE
1476504
28,745

64.9900
16:22:50
LSE
1476502
6,438
64.9900
16:22:55
LSE
1476920
3,531
65.0000
16:22:55
LSE
1476879
3,283
65.0000
16:22:55
LSE
1476877
7,000
64.9900
16:23:08
LSE
1477633
2,774
64.9900
16:23:08
LSE
1477635
7,000
64.9900
16:23:08
LSE
1477631
5,201
64.9900
16:23:16
LSE
1478045
1,290
64.9900
16:23:16
LSE
1478043
6,799
64.9900
16:23:27
LSE
1478580
7,118
64.9800

16:23:31
LSE
1478764
31
64.9800
16:23:31
LSE
1478762
7,016
64.9800
16:23:31
LSE
1478756
890
64.9800
16:23:31
LSE
1478751
7,002
64.9800
16:23:31
LSE
1478745
2,257
64.9800
16:23:42
LSE
1479353
7,850
64.9800
16:23:42
LSE
1479357
8,003
64.9800
16:23:42
LSE
1479355
5,999
64.9600
16:23:55
LSE
1480054
1,827
64.9900
16:23:58
LSE
1480278
9,972
64.9900
16:23:58

LSE
1480276
14,185
64.9900
16:23:58
LSE
1480274
3,738
64.9900
16:23:58
LSE
1480272
4,729
64.9900
16:23:58
LSE
1480238
14,903
65.0000
16:23:59
LSE
1480330
6,706
65.0000
16:24:00
LSE
1480332
7,613
64.9900
16:24:05
LSE
1480730
1,035
64.9900
16:24:05
LSE
1480728
1,573
64.9900
16:24:05
LSE
1480726
6,288
64.9900
16:24:05
LSE
1480724
2,690
65.0000
16:24:05
LSE

1480698
2,536
65.0000
16:24:05
LSE
1480701
1,384
65.0000
16:24:05
LSE
1480703
589
65.0000
16:24:05
LSE
1480696
216
64.9800
16:24:09
LSE
1480927
5,677
64.9800
16:24:09
LSE
1480919
7,033
64.9700
16:24:24
LSE
1481702
6,241
64.9700
16:24:24
LSE
1481704
664
64.9700
16:24:24
LSE
1481697
2,811
64.9700
16:24:24
LSE
1481693
3,718
64.9700
16:24:24
LSE
1481695

2,254
64.9700
16:24:24
LSE
1481691
7,197
64.9600
16:24:36
LSE
1482723
4,413
64.9500
16:24:41
LSE
1483286
1,433
64.9500
16:24:41
LSE
1483284
13,475
64.9600
16:24:41
LSE
1483163
7,000
64.9600
16:24:41
LSE
1483161
6,503
64.9800
16:24:58
LSE
1484298
125
64.9800
16:24:58
LSE
1484296
8,294
64.9800
16:24:58
LSE
1484294
8,539
64.9800
16:24:58
LSE
1484292
5,815

64.9800
16:24:58
LSE
1484290
2,413
64.9800
16:25:01
LSE
1484434
9,404
64.9800
16:25:01
LSE
1484436
3,250
64.9900
16:25:07
LSE
1484663
1,472
65.0000
16:25:09
LSE
1484923
4,928
65.0000
16:25:09
LSE
1484921
3,515
64.9900
16:25:09
LSE
1484737
4,545
65.0000
16:25:12
LSE
1485107
5,521
65.0000
16:25:12
LSE
1485105
1,309
65.0000
16:25:13
LSE
1485145
4,545
65.0000

16:25:13
LSE
1485143
1,158
65.0000
16:25:13
LSE
1485135
5,935
64.9900
16:25:18
LSE
1485296
10,206
64.9900
16:25:18
LSE
1485292
4,483
64.9900
16:25:18
LSE
1485294
5,202
64.9800
16:25:21
LSE
1485448
2,097
64.9800
16:25:21
LSE
1485446
10,651
64.9800
16:25:21
LSE
1485444
11,683
64.9700
16:25:33
LSE
1485980
8,579
64.9700
16:25:40
LSE
1486447
2,472
64.9800
16:25:42

LSE
1486500
7,898
64.9800
16:25:42
LSE
1486498
4,928
64.9800
16:25:42
LSE
1486506
2,524
64.9800
16:25:42
LSE
1486502
2,570
64.9800
16:25:42
LSE
1486504
6,996
65.0000
16:25:45
LSE
1486697
8,200
64.9900
16:25:46
LSE
1486788
7,181
65.0000
16:25:48
LSE
1486930
1,545
65.0000
16:25:48
LSE
1486928
5,848
65.0000
16:25:49
LSE
1487001
6,505
65.0000
16:25:53
LSE

1487156
215
65.0000
16:25:53
LSE
1487144
7,806
65.0000
16:25:53
LSE
1487125
8,363
65.0000
16:25:53
LSE
1487123
5,288
64.9900
16:25:56
LSE
1487293
8,464
64.9900
16:25:56
LSE
1487295
1,652
64.9900
16:25:56
LSE
1487297
4,317
64.9900
16:25:56
LSE
1487299
6,019
64.9900
16:26:10
LSE
1488010
5,339
64.9900
16:26:10
LSE
1488008
2,475
64.9900
16:26:10
LSE
1488006

2,488
64.9900
16:26:10
LSE
1488004
7,697
64.9800
16:26:11
LSE
1488103
912
64.9800
16:26:11
LSE
1488101
6,194
64.9800
16:26:11
LSE
1488099
9,976
64.9800
16:26:18
LSE
1488428
231
64.9900
16:26:26
LSE
1488842
7,000
64.9900
16:26:26
LSE
1488840
6,618
64.9900
16:26:26
LSE
1488838
8,046
65.0000
16:26:26
LSE
1488774
7,000
65.0000
16:26:26
LSE
1488772
24,529

65.0000
16:26:26
LSE
1488770
40,860
65.0000
16:26:26
LSE
1488765
34,611
65.0000
16:26:26
LSE
1488763
93,101
65.0000
16:26:26
LSE
1488738
523
65.0000
16:26:26
LSE
1488740
6,899
65.0000
16:26:26
LSE
1488731
8,734
65.0000
16:26:28
LSE
1488924
28,467
65.0000
16:26:28
LSE
1488922
30,067
65.0000
16:26:28
LSE
1488920
14,455
65.0000
16:26:29
LSE
1488982
6,936
65.0000

16:26:29
LSE
1488951
3,307
64.9900
16:26:32
LSE
1489101
2,625
64.9900
16:26:32
LSE
1489099
6,411
64.9900
16:26:32
LSE
1489097
6,858
64.9900
16:26:32
LSE
1489095
6,599
64.9800
16:26:34
LSE
1489174
417
64.9800
16:26:34
LSE
1489164
5,906
64.9800
16:26:34
LSE
1489162
7,757
64.9800
16:26:34
LSE
1489160
8,858
64.9600
16:26:42
LSE
1489543
168
64.9600
16:26:42

LSE
1489541
12,226
64.9600
16:26:42
LSE
1489539
6,588
64.9700
16:26:42
LSE
1489495
7,939
64.9700
16:26:42
LSE
1489493
6,609
64.9500
16:26:46
LSE
1489683
811
64.9500
16:26:46
LSE
1489681
10,025
64.9500
16:26:46
LSE
1489678
3,949
64.9600
16:26:48
LSE
1489767
3,051
64.9600
16:26:48
LSE
1489765
6,973
64.9600
16:26:48
LSE
1489763
19,518
64.9900
16:26:53
LSE

1490102
11,874
64.9900
16:26:53
LSE
1490099
15,721
65.0000
16:26:55
LSE
1490300
29,109
65.0000
16:26:55
LSE
1490297
14,455
65.0000
16:26:55
LSE
1490295
14,303
65.0000
16:26:55
LSE
1490293

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

LLOYDS BANKING GROUP plc
(Registrant)

By: Douglas Radcliffe
Name: Douglas Radcliffe
Title: Group Investor Relations Director

Date: 25 April 2018